US20040014755A1 - Rho-kinase inhibitors - Google Patents
Rho-kinase inhibitors Download PDFInfo
- Publication number
- US20040014755A1 US20040014755A1 US10/339,393 US33939303A US2004014755A1 US 20040014755 A1 US20040014755 A1 US 20040014755A1 US 33939303 A US33939303 A US 33939303A US 2004014755 A1 US2004014755 A1 US 2004014755A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- halogen
- etoac
- compound according
- hplc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C*(C1)C1c1c(C)c(C=NC)cc(NC(C(C(C=C2)=C)=C2N=C(C)Nc2cc(C(C)(C)C)n[n]2C)=I)c1 Chemical compound C*(C1)C1c1c(C)c(C=NC)cc(NC(C(C(C=C2)=C)=C2N=C(C)Nc2cc(C(C)(C)C)n[n]2C)=I)c1 0.000 description 22
- KQKGFBSRIQEEOB-UHFFFAOYSA-N ClC1=CC=C(C2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 Chemical compound ClC1=CC=C(C2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 KQKGFBSRIQEEOB-UHFFFAOYSA-N 0.000 description 4
- JEKASZPHONLRDZ-UHFFFAOYSA-N [Ar]C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound [Ar]C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 JEKASZPHONLRDZ-UHFFFAOYSA-N 0.000 description 4
- UMIIABSEBQEFPL-UHFFFAOYSA-N C1=CC2=C(C=C1)SC(C1=NC3=C(C=CC=N3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2 Chemical compound C1=CC2=C(C=C1)SC(C1=NC3=C(C=CC=N3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2 UMIIABSEBQEFPL-UHFFFAOYSA-N 0.000 description 3
- SSQKYRNYYPJIDN-UHFFFAOYSA-N FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 SSQKYRNYYPJIDN-UHFFFAOYSA-N 0.000 description 3
- ZURYIRRFPLTYLB-UHFFFAOYSA-N [H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(OC)=C3)=NC3=C1C(C)=CO3)=C2 Chemical compound [H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(OC)=C3)=NC3=C1C(C)=CO3)=C2 ZURYIRRFPLTYLB-UHFFFAOYSA-N 0.000 description 3
- UJTKZWNRUPTHSB-UHFFFAOYSA-N BrC1=CC=C(N2CCOCC2)C=C1 Chemical compound BrC1=CC=C(N2CCOCC2)C=C1 UJTKZWNRUPTHSB-UHFFFAOYSA-N 0.000 description 2
- MXIIWZUVANLOQS-UHFFFAOYSA-N C.CN1CCCCC1.CN1N=NC2=C1C=CC=C2 Chemical compound C.CN1CCCCC1.CN1N=NC2=C1C=CC=C2 MXIIWZUVANLOQS-UHFFFAOYSA-N 0.000 description 2
- KQTXKBCQYMSBRK-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCO1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCO1)=N2 KQTXKBCQYMSBRK-UHFFFAOYSA-N 0.000 description 2
- IDVYIGNCBLVAEV-UHFFFAOYSA-N C1=CC2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1 Chemical compound C1=CC2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1 IDVYIGNCBLVAEV-UHFFFAOYSA-N 0.000 description 2
- RCNLKUWHGZSAEY-UHFFFAOYSA-N C1=CC2=NC=C(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1 Chemical compound C1=CC2=NC=C(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1 RCNLKUWHGZSAEY-UHFFFAOYSA-N 0.000 description 2
- IPQWKUMBZBLJHG-UHFFFAOYSA-N C1=CC=C(C2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1 Chemical compound C1=CC=C(C2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1 IPQWKUMBZBLJHG-UHFFFAOYSA-N 0.000 description 2
- FVEVZFAIMYRAFY-UHFFFAOYSA-N C1=CC=C(C2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound C1=CC=C(C2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 FVEVZFAIMYRAFY-UHFFFAOYSA-N 0.000 description 2
- VMVGFFVJOLJRMB-UHFFFAOYSA-N C1=CN=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CN=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 VMVGFFVJOLJRMB-UHFFFAOYSA-N 0.000 description 2
- RWNUWKZDSIHFOE-UHFFFAOYSA-N C1=CN=CC(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=C1 Chemical compound C1=CN=CC(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=C1 RWNUWKZDSIHFOE-UHFFFAOYSA-N 0.000 description 2
- IHIQYDQAUMJZLK-UHFFFAOYSA-N C1=COC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=COC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 IHIQYDQAUMJZLK-UHFFFAOYSA-N 0.000 description 2
- WCOQLHINPQSOJI-UHFFFAOYSA-N C=CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C=CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 WCOQLHINPQSOJI-UHFFFAOYSA-N 0.000 description 2
- ZNZJGIVVJZDMOO-UHFFFAOYSA-N CC1=CC(C)=NN1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CC1=CC(C)=NN1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 ZNZJGIVVJZDMOO-UHFFFAOYSA-N 0.000 description 2
- BLZKSRBAQDZAIX-UHFFFAOYSA-N CC1=CC2=C(C=CC=C2)S1 Chemical compound CC1=CC2=C(C=CC=C2)S1 BLZKSRBAQDZAIX-UHFFFAOYSA-N 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N CC1=CC=C(C(C)C)C=C1 Chemical compound CC1=CC=C(C(C)C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- ZYLPQYYLLRBVOK-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC=C2)N=C1 Chemical compound CC1=CC=C(C2=CC=CC=C2)N=C1 ZYLPQYYLLRBVOK-UHFFFAOYSA-N 0.000 description 2
- LONDBHTYIYKOCM-UHFFFAOYSA-N CC1=CC=CC(C2=CC=CN=C2)=C1 Chemical compound CC1=CC=CC(C2=CC=CN=C2)=C1 LONDBHTYIYKOCM-UHFFFAOYSA-N 0.000 description 2
- IYASLOPLXIQSIF-UHFFFAOYSA-N CC1=NC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 Chemical compound CC1=NC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 IYASLOPLXIQSIF-UHFFFAOYSA-N 0.000 description 2
- GFNVPUBIQQGKSL-UHFFFAOYSA-N CC1=NNC2=C1C=C(NC1=NC(C3=CC=CC(C4=CC=CC=C4)=C3)=NC3=C1SC=C3)C=C2 Chemical compound CC1=NNC2=C1C=C(NC1=NC(C3=CC=CC(C4=CC=CC=C4)=C3)=NC3=C1SC=C3)C=C2 GFNVPUBIQQGKSL-UHFFFAOYSA-N 0.000 description 2
- ZTERILKIUSLFNC-UHFFFAOYSA-N CCC(C)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CCC(C)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 ZTERILKIUSLFNC-UHFFFAOYSA-N 0.000 description 2
- HMVIELWIRQJXIP-UHFFFAOYSA-N CCC1=C(C2=CC=CC=C2)N=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)O1 Chemical compound CCC1=C(C2=CC=CC=C2)N=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)O1 HMVIELWIRQJXIP-UHFFFAOYSA-N 0.000 description 2
- SRNGZJVKXZDZOO-UHFFFAOYSA-N CCOC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound CCOC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 SRNGZJVKXZDZOO-UHFFFAOYSA-N 0.000 description 2
- CHLICZRVGGXEOD-UHFFFAOYSA-N COC1=CC=C(C)C=C1 Chemical compound COC1=CC=C(C)C=C1 CHLICZRVGGXEOD-UHFFFAOYSA-N 0.000 description 2
- NFQGQMBFMIIIOR-UHFFFAOYSA-N COC1=CC=C(C)C=N1 Chemical compound COC1=CC=C(C)C=N1 NFQGQMBFMIIIOR-UHFFFAOYSA-N 0.000 description 2
- XJONVSUBOVWLRE-UHFFFAOYSA-N COC1=CC=C(C2=CC=C(C)C=C2)C=C1CO Chemical compound COC1=CC=C(C2=CC=C(C)C=C2)C=C1CO XJONVSUBOVWLRE-UHFFFAOYSA-N 0.000 description 2
- ZKQNXPCLRCZANW-UHFFFAOYSA-N Cc1cc(CNc2nc(Nc3ccc4[nH]ncc4c3)c3[s]ccc3n2)cc(C)c1 Chemical compound Cc1cc(CNc2nc(Nc3ccc4[nH]ncc4c3)c3[s]ccc3n2)cc(C)c1 ZKQNXPCLRCZANW-UHFFFAOYSA-N 0.000 description 2
- BXVRFBZKYWYJMX-UHFFFAOYSA-N Cc1ccc(CNc2nc(Nc3ccc4[nH]ncc4c3)c3[s]ccc3n2)cc1 Chemical compound Cc1ccc(CNc2nc(Nc3ccc4[nH]ncc4c3)c3[s]ccc3n2)cc1 BXVRFBZKYWYJMX-UHFFFAOYSA-N 0.000 description 2
- GYQHQWLUSASIOK-UHFFFAOYSA-N FC(F)(F)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC(F)(F)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 GYQHQWLUSASIOK-UHFFFAOYSA-N 0.000 description 2
- ABKVVJMMIKHYGF-UHFFFAOYSA-N O=C(O)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound O=C(O)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 ABKVVJMMIKHYGF-UHFFFAOYSA-N 0.000 description 2
- WXMDFQBZMATQMY-UHFFFAOYSA-N OB(O)C1=CC2=C(C=CN=C2)S1 Chemical compound OB(O)C1=CC2=C(C=CN=C2)S1 WXMDFQBZMATQMY-UHFFFAOYSA-N 0.000 description 2
- WHDIUBHAKZDSJL-UHFFFAOYSA-N OB(O)C1=CC=C(N2CCOCC2)C=C1 Chemical compound OB(O)C1=CC=C(N2CCOCC2)C=C1 WHDIUBHAKZDSJL-UHFFFAOYSA-N 0.000 description 2
- MTGDUKHAVRDWDY-UHFFFAOYSA-N OC1CCC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)CC1 Chemical compound OC1CCC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)CC1 MTGDUKHAVRDWDY-UHFFFAOYSA-N 0.000 description 2
- FEWCHHMJNIOLJK-UHFFFAOYSA-N B.B.B.B.B.CC.CC.CC.CC.CC.CCCN.ClC1=NC([Ar])=NC=C1.NC(=O)CCNC(=O)[Ar].O=C(O)CCNC(=O)[Ar].O=P(Cl)(Cl)Cl.OC1=NC([Ar])=NC=C1 Chemical compound B.B.B.B.B.CC.CC.CC.CC.CC.CCCN.ClC1=NC([Ar])=NC=C1.NC(=O)CCNC(=O)[Ar].O=C(O)CCNC(=O)[Ar].O=P(Cl)(Cl)Cl.OC1=NC([Ar])=NC=C1 FEWCHHMJNIOLJK-UHFFFAOYSA-N 0.000 description 1
- FCDYQSLGMHZTMG-UHFFFAOYSA-N B.B.C.CC.CC.ClC1=NC([Ar])=NC=C1.N#CCCN=[N+]=[N-].O=P(Cl)(Cl)Cl Chemical compound B.B.C.CC.CC.ClC1=NC([Ar])=NC=C1.N#CCCN=[N+]=[N-].O=P(Cl)(Cl)Cl FCDYQSLGMHZTMG-UHFFFAOYSA-N 0.000 description 1
- LKPUVYBMIADJQZ-UHFFFAOYSA-N BrC1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2 Chemical compound BrC1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2 LKPUVYBMIADJQZ-UHFFFAOYSA-N 0.000 description 1
- SFKKNJPOCYOGFL-UHFFFAOYSA-N BrC1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCC(N3CCCCC3)CC1)=N2.C1=CC=C(C2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1.C1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1.O=C1NC2=C(C=CC=C2)N1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound BrC1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCC(N3CCCCC3)CC1)=N2.C1=CC=C(C2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1.C1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1.O=C1NC2=C(C=CC=C2)N1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 SFKKNJPOCYOGFL-UHFFFAOYSA-N 0.000 description 1
- NQIBPFSFCNXUFV-UHFFFAOYSA-N BrC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound BrC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 NQIBPFSFCNXUFV-UHFFFAOYSA-N 0.000 description 1
- NIIUNMPDGHIKSC-UHFFFAOYSA-N BrC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2.C1=CC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CN=C2C=C1.C1=CC=C(C2=NSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1.CC1=NN(C)C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C1=CC=C(F)C=C1 Chemical compound BrC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2.C1=CC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CN=C2C=C1.C1=CC=C(C2=NSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1.CC1=NN(C)C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C1=CC=C(F)C=C1 NIIUNMPDGHIKSC-UHFFFAOYSA-N 0.000 description 1
- WBCCOHBWOXCOOM-UHFFFAOYSA-N BrC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound BrC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 WBCCOHBWOXCOOM-UHFFFAOYSA-N 0.000 description 1
- WMPUCCQKOROYET-UHFFFAOYSA-N BrC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=CC2=C(C=C1)CN(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2.ClC1=CC=C(C2=CSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1.FC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound BrC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=CC2=C(C=C1)CN(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2.ClC1=CC=C(C2=CSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1.FC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 WMPUCCQKOROYET-UHFFFAOYSA-N 0.000 description 1
- KPNXDNUKSAMTMS-UHFFFAOYSA-N BrC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound BrC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 KPNXDNUKSAMTMS-UHFFFAOYSA-N 0.000 description 1
- HNOBQASSISWFKX-UHFFFAOYSA-N BrC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC(Br)=C1.CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC1 Chemical compound BrC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC(Br)=C1.CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC1 HNOBQASSISWFKX-UHFFFAOYSA-N 0.000 description 1
- FIQNOUDKPNFVSO-UHFFFAOYSA-N C(CC1)CC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 Chemical compound C(CC1)CC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 FIQNOUDKPNFVSO-UHFFFAOYSA-N 0.000 description 1
- MVSBUYCJZNDIFY-UHFFFAOYSA-N C(CC1)CCN1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 Chemical compound C(CC1)CCN1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 MVSBUYCJZNDIFY-UHFFFAOYSA-N 0.000 description 1
- SDWUAUFCCAKIOB-UHFFFAOYSA-N C(c1ccccc1)N(CC1)CCC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 Chemical compound C(c1ccccc1)N(CC1)CCC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 SDWUAUFCCAKIOB-UHFFFAOYSA-N 0.000 description 1
- GYRHNXAGXQMXGK-UHFFFAOYSA-N C1=CC(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=CN=C1 Chemical compound C1=CC(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=CN=C1 GYRHNXAGXQMXGK-UHFFFAOYSA-N 0.000 description 1
- TWMKGNRIJMWEJG-UHFFFAOYSA-N C1=CC(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=CN=C1.C1=CC=C(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=N2)C=C1.CC1=C(OC2=CN=CC=C2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=CN=C1.C1=CC=C(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=N2)C=C1.CC1=C(OC2=CN=CC=C2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 TWMKGNRIJMWEJG-UHFFFAOYSA-N 0.000 description 1
- VWNQPZVBCYENDD-UHFFFAOYSA-N C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1 Chemical compound C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1 VWNQPZVBCYENDD-UHFFFAOYSA-N 0.000 description 1
- JGPZOJIGZHIJJN-UHFFFAOYSA-N C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCOCC3)C=C1)=N2.C1=CN=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CCN(CC)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl Chemical compound C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCOCC3)C=C1)=N2.C1=CN=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CCN(CC)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl JGPZOJIGZHIJJN-UHFFFAOYSA-N 0.000 description 1
- IUNMKJBAOCXXRH-UHFFFAOYSA-N C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CN=CO2)=C1 Chemical compound C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CN=CO2)=C1 IUNMKJBAOCXXRH-UHFFFAOYSA-N 0.000 description 1
- FZZPWPPLAQRDTD-UHFFFAOYSA-N C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CN=CO2)=C1.C1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2.CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC=C1[N+](=O)[O-].COC1=CC(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)=CC=C1 Chemical compound C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CN=CO2)=C1.C1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2.CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC=C1[N+](=O)[O-].COC1=CC(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)=CC=C1 FZZPWPPLAQRDTD-UHFFFAOYSA-N 0.000 description 1
- QIHGDMHRBXJUQZ-UHFFFAOYSA-N C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1 Chemical compound C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1 QIHGDMHRBXJUQZ-UHFFFAOYSA-N 0.000 description 1
- CEIWBXPNGUTHAU-UHFFFAOYSA-N C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1.C1=CC2=C(C=C1)CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C2.C1=CC=C2C(=C1)CCCC2NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.COC1=CC=CC(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=N1.C1=CC2=C(C=C1)CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C2.C1=CC=C2C(=C1)CCCC2NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.COC1=CC=CC(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 CEIWBXPNGUTHAU-UHFFFAOYSA-N 0.000 description 1
- HSWYIFZAAWZRNH-UHFFFAOYSA-N C1=CC(SC2=CC=NC=C2)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC(SC2=CC=NC=C2)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 HSWYIFZAAWZRNH-UHFFFAOYSA-N 0.000 description 1
- UOJUWUZAPBMFEY-UHFFFAOYSA-N C1=CC(SC2=CC=NC=C2)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(OC3=CN=CC=N3)C=C1)=N2.C1=CN=CC(SC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)=C1 Chemical compound C1=CC(SC2=CC=NC=C2)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(OC3=CN=CC=N3)C=C1)=N2.C1=CN=CC(SC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)=C1 UOJUWUZAPBMFEY-UHFFFAOYSA-N 0.000 description 1
- MKXFLBWELQORLT-UHFFFAOYSA-N C1=CC2=C(C=C1)C=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2 Chemical compound C1=CC2=C(C=C1)C=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2 MKXFLBWELQORLT-UHFFFAOYSA-N 0.000 description 1
- NPIXQBAALXSYJE-UHFFFAOYSA-N C1=CC2=C(C=C1)C=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2.NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1.O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1.O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(O)=C3)=NC3=C1C(C)C=O3)=C2 Chemical compound C1=CC2=C(C=C1)C=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C=C2.NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1.O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1.O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(O)=C3)=NC3=C1C(C)C=O3)=C2 NPIXQBAALXSYJE-UHFFFAOYSA-N 0.000 description 1
- XWZGROYLNUBMRU-UHFFFAOYSA-N C1=CC2=C(C=C1)CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C2 Chemical compound C1=CC2=C(C=C1)CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)C2 XWZGROYLNUBMRU-UHFFFAOYSA-N 0.000 description 1
- UJHUEIUHXMUYRO-UHFFFAOYSA-N C1=CC2=C(C=C1)CN(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2 Chemical compound C1=CC2=C(C=C1)CN(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CC2 UJHUEIUHXMUYRO-UHFFFAOYSA-N 0.000 description 1
- YFUPYFKWAAYFAX-UHFFFAOYSA-N C1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CCC2 Chemical compound C1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CCC2 YFUPYFKWAAYFAX-UHFFFAOYSA-N 0.000 description 1
- QKWAHGAAYQJLLX-UHFFFAOYSA-N C1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CCC2.CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C2C=CC=CC2=N1.CCN1CCCC1CNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.NS(=O)(=O)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC2=C(C=C1)N(C1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)CCC2.CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C2C=CC=CC2=N1.CCN1CCCC1CNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.NS(=O)(=O)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 QKWAHGAAYQJLLX-UHFFFAOYSA-N 0.000 description 1
- CQKLJHZSVBFTPO-UHFFFAOYSA-N C1=CC2=C(C=C1)N(C1CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC1)N=N2 Chemical compound C1=CC2=C(C=C1)N(C1CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC1)N=N2 CQKLJHZSVBFTPO-UHFFFAOYSA-N 0.000 description 1
- DCPXQXJNVSBACU-UHFFFAOYSA-N C1=CC2=C(C=C1)N(C1CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC1)N=N2.COC1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound C1=CC2=C(C=C1)N(C1CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC1)N=N2.COC1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 DCPXQXJNVSBACU-UHFFFAOYSA-N 0.000 description 1
- NHUUQZVWYKDMPA-UHFFFAOYSA-N C1=CC2=C(C=C1)SC(C1=NC3=C(C=CC=N3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2.C1=CC=C(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)C=C1.C1=CSC(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)=C1.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(CC)=C3)=NC3=C1C(C)=CO3)=C2 Chemical compound C1=CC2=C(C=C1)SC(C1=NC3=C(C=CC=N3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2.C1=CC=C(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)C=C1.C1=CSC(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)=C1.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(CC)=C3)=NC3=C1C(C)=CO3)=C2 NHUUQZVWYKDMPA-UHFFFAOYSA-N 0.000 description 1
- MKYRMMMSZSVIGD-UHFFFAOYSA-N C1=CC2=C(C=CS2)C=N1 Chemical compound C1=CC2=C(C=CS2)C=N1 MKYRMMMSZSVIGD-UHFFFAOYSA-N 0.000 description 1
- JCUXXRZOCBSXEA-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(C1=CC=C(OCCN3CCOCC3)C=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(C1=CC=C(OCCN3CCOCC3)C=C1)=N2 JCUXXRZOCBSXEA-UHFFFAOYSA-N 0.000 description 1
- SUTHFXHBOGENNX-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(C1=CC=C(OCCN3CCOCC3)C=C1)=N2.C1=CC2=NC=C(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1.OC1=CC=C(C2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.[H]N(CC1=CC=C(C2=CC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=C2)C=C1)C1=CC=CC=N1.[H]N(CC1=CC=C(C2=NC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=N2)C=C1)C1=CC=CC=N1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(C1=CC=C(OCCN3CCOCC3)C=C1)=N2.C1=CC2=NC=C(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1.OC1=CC=C(C2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.[H]N(CC1=CC=C(C2=CC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=C2)C=C1)C1=CC=CC=N1.[H]N(CC1=CC=C(C2=NC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=N2)C=C1)C1=CC=CC=N1 SUTHFXHBOGENNX-UHFFFAOYSA-N 0.000 description 1
- JNUGTBANGQJXBV-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCC(N3CCCCC3)CC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCC(N3CCCCC3)CC1)=N2 JNUGTBANGQJXBV-UHFFFAOYSA-N 0.000 description 1
- CBYVMSYVPVBCBU-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCCC3CCCCC31)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCCC3CCCCC31)=N2 CBYVMSYVPVBCBU-UHFFFAOYSA-N 0.000 description 1
- FDMVOVJNPPCQHS-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCCC3CCCCC31)=N2.C1=CC=C(C2=NC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=NC=C2)C=C1.C1=CC=C2C=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=CC2=C1.FC1=CC2=C(C=C1)N/C=C\2CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(N1CCCC3CCCCC31)=N2.C1=CC=C(C2=NC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=NC=C2)C=C1.C1=CC=C2C=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=CC2=C1.FC1=CC2=C(C=C1)N/C=C\2CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 FDMVOVJNPPCQHS-UHFFFAOYSA-N 0.000 description 1
- ZIHQQENZZLYBIH-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3C=NC=N3)C=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3C=NC=N3)C=C1)=N2 ZIHQQENZZLYBIH-UHFFFAOYSA-N 0.000 description 1
- ZIWUELIXUCMXNG-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3C=NC=N3)C=C1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C3NC=NC3=C1)=N2.FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C(F)(F)F)=C1.FC1=CC(F)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3C=NC=N3)C=C1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C3NC=NC3=C1)=N2.FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C(F)(F)F)=C1.FC1=CC(F)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 ZIWUELIXUCMXNG-UHFFFAOYSA-N 0.000 description 1
- IMTDSNDLBFJQEW-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCCCC3)C=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCCCC3)C=C1)=N2 IMTDSNDLBFJQEW-UHFFFAOYSA-N 0.000 description 1
- VIRSHBOPSKNRAX-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCCCC3)C=C1)=N2.CC1CN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC(C)O1.CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C(C)(C)C)=N1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCCCC3)C=C1)=N2.CC1CN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC(C)O1.CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C(C)(C)C)=N1 VIRSHBOPSKNRAX-UHFFFAOYSA-N 0.000 description 1
- LPFDOSZJNVVLNZ-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCOCC3)C=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(N3CCOCC3)C=C1)=N2 LPFDOSZJNVVLNZ-UHFFFAOYSA-N 0.000 description 1
- FKNQZWLLZHZXPI-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(OC3=CN=CC=N3)C=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C(OC3=CN=CC=N3)C=C1)=N2 FKNQZWLLZHZXPI-UHFFFAOYSA-N 0.000 description 1
- DBHMDKCFPNGMLS-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C3NC=NC3=C1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1=CC=C3NC=NC3=C1)=N2 DBHMDKCFPNGMLS-UHFFFAOYSA-N 0.000 description 1
- YLPOTUCWHWNTTQ-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCC1)=N2 YLPOTUCWHWNTTQ-UHFFFAOYSA-N 0.000 description 1
- FDVSDWZSEDVFRT-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCCN1CCOCC1)=N2.FC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.OCCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCCN1CCOCC1)=N2.FC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.OCCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 FDVSDWZSEDVFRT-UHFFFAOYSA-N 0.000 description 1
- XZVAHRAFAODYJZ-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCC1)=N2 XZVAHRAFAODYJZ-UHFFFAOYSA-N 0.000 description 1
- DKOXUQZDUKQDKE-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCCC1)=N2.C=CCC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C(=O)O.C=CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCCC1)=N2.C=CCC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C(=O)O.C=CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 DKOXUQZDUKQDKE-UHFFFAOYSA-N 0.000 description 1
- XIAABYZPOQNCMK-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCCC1)=N2 XIAABYZPOQNCMK-UHFFFAOYSA-N 0.000 description 1
- NXAPLVDTZWKJSE-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCO1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NN1CCCCC1)=N2.C1=CC=C(CN2CCC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NC1CCCCC1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCO1)=N2.C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NN1CCCCC1)=N2.C1=CC=C(CN2CCC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 NXAPLVDTZWKJSE-UHFFFAOYSA-N 0.000 description 1
- QNOJDNFVZVNESL-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCC1CCCCC1)=N2 QNOJDNFVZVNESL-UHFFFAOYSA-N 0.000 description 1
- XSIVZELDUJDWSX-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCCN1CCOCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCCN1CCOCC1)=N2 XSIVZELDUJDWSX-UHFFFAOYSA-N 0.000 description 1
- QDCQTIYQCMXEGM-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCN1CCOCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCN1CCOCC1)=N2 QDCQTIYQCMXEGM-UHFFFAOYSA-N 0.000 description 1
- KERAZDRIXGRNGA-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCN1CCOCC1)=N2.C1=CC=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=COC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NCCN1CCOCC1)=N2.C1=CC=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=COC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 KERAZDRIXGRNGA-UHFFFAOYSA-N 0.000 description 1
- XOGDWKCZTPHMCC-UHFFFAOYSA-N C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NN1CCCCC1)=N2 Chemical compound C1=CC2=C(S1)C(NC1=CC3=C(C=C1)NN=C3)=NC(NN1CCCCC1)=N2 XOGDWKCZTPHMCC-UHFFFAOYSA-N 0.000 description 1
- IKEZOZKYBHSDAU-UHFFFAOYSA-N C1=CC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CN=C2C=C1 Chemical compound C1=CC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CN=C2C=C1 IKEZOZKYBHSDAU-UHFFFAOYSA-N 0.000 description 1
- QEKTXUOUPVHBEX-UHFFFAOYSA-N C1=CC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1 Chemical compound C1=CC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=C2C=C1 QEKTXUOUPVHBEX-UHFFFAOYSA-N 0.000 description 1
- QAGCBTSHBXBENJ-UHFFFAOYSA-N C1=CC2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1 Chemical compound C1=CC2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1 QAGCBTSHBXBENJ-UHFFFAOYSA-N 0.000 description 1
- KJSDEZJYBJFTQW-UHFFFAOYSA-N C1=CC2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1.C1=CC=C(C2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1.C1=CSC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC(Cl)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1.C1=CC=C(C2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1.C1=CSC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC(Cl)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 KJSDEZJYBJFTQW-UHFFFAOYSA-N 0.000 description 1
- PJNKOTNMGSKMDF-UHFFFAOYSA-N C1=CC2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C.CCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2C=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C.CCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 PJNKOTNMGSKMDF-UHFFFAOYSA-N 0.000 description 1
- NQMKDGVZZJHHSN-UHFFFAOYSA-N C1=CC2=CN=CC=C2C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC2=CN=CC=C2C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 NQMKDGVZZJHHSN-UHFFFAOYSA-N 0.000 description 1
- DARRGGQVCDUDHC-UHFFFAOYSA-N C1=CC2=CN=CC=C2C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.C1=CN=C2C=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC2=C1.COC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CC2=CN=CC=C2C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.C1=CN=C2C=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC2=C1.COC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 DARRGGQVCDUDHC-UHFFFAOYSA-N 0.000 description 1
- ZOWIAAHMEMSWQS-UHFFFAOYSA-N C1=CC=C(C2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1 Chemical compound C1=CC=C(C2=CC=CC(CNC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1 ZOWIAAHMEMSWQS-UHFFFAOYSA-N 0.000 description 1
- UXTNNARPUJOMTG-UHFFFAOYSA-N C1=CC=C(C2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1.C1=CC=C(COC2=CC=CN=C2NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.ClC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+](O)C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(C2=CC=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=C2)C=C1.C1=CC=C(COC2=CC=CN=C2NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.ClC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+](O)C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 UXTNNARPUJOMTG-UHFFFAOYSA-N 0.000 description 1
- RULFELWNBPWZCH-UHFFFAOYSA-N C1=CC=C(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)C=C1 Chemical compound C1=CC=C(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)C=C1 RULFELWNBPWZCH-UHFFFAOYSA-N 0.000 description 1
- VBSKEAITLVMUQG-UHFFFAOYSA-N C1=CC=C(C2=NC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=NC=C2)C=C1 Chemical compound C1=CC=C(C2=NC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=NC=C2)C=C1 VBSKEAITLVMUQG-UHFFFAOYSA-N 0.000 description 1
- RBRQYFXELSVZBZ-UHFFFAOYSA-N C1=CC=C(C2=NSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1 Chemical compound C1=CC=C(C2=NSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1 RBRQYFXELSVZBZ-UHFFFAOYSA-N 0.000 description 1
- OZLCAJTZVYOASM-UHFFFAOYSA-N C1=CC=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 OZLCAJTZVYOASM-UHFFFAOYSA-N 0.000 description 1
- ZLLZPSBYGRUTGX-UHFFFAOYSA-N C1=CC=C(CN2CCC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound C1=CC=C(CN2CCC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 ZLLZPSBYGRUTGX-UHFFFAOYSA-N 0.000 description 1
- QBJOVGQDIDGKQX-UHFFFAOYSA-N C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 QBJOVGQDIDGKQX-UHFFFAOYSA-N 0.000 description 1
- QXUFVASYIVIXSV-UHFFFAOYSA-N C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.CC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.CC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.ClC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 QXUFVASYIVIXSV-UHFFFAOYSA-N 0.000 description 1
- BAIWWKYDHOXDSP-UHFFFAOYSA-N C1=CC=C(COC2=CC=CN=C2NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(COC2=CC=CN=C2NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 BAIWWKYDHOXDSP-UHFFFAOYSA-N 0.000 description 1
- FAYMSHHQDAXTTQ-UHFFFAOYSA-N C1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound C1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 FAYMSHHQDAXTTQ-UHFFFAOYSA-N 0.000 description 1
- NLXUAIQRVUSLDA-UHFFFAOYSA-N C1=CC=C(OC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)C=C1 Chemical compound C1=CC=C(OC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)C=C1 NLXUAIQRVUSLDA-UHFFFAOYSA-N 0.000 description 1
- UMXYIJYPXKXYMP-UHFFFAOYSA-N C1=CC=C(OC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)C=C1.C1=CN=CC(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=C1.COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(OC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)C=C1.C1=CN=CC(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)=C1.COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 UMXYIJYPXKXYMP-UHFFFAOYSA-N 0.000 description 1
- LMBZWBONVKZWHO-UHFFFAOYSA-N C1=CC=C(OCCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CC=C(OCCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 LMBZWBONVKZWHO-UHFFFAOYSA-N 0.000 description 1
- ZOAVMURARHNLRU-UHFFFAOYSA-N C1=CC=C(OCCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=CC(C)=NN1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CCC(C)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound C1=CC=C(OCCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=CC(C)=NN1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CCC(C)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 ZOAVMURARHNLRU-UHFFFAOYSA-N 0.000 description 1
- QRBMUNDOCCEZPZ-UHFFFAOYSA-N C1=CC=C(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=N2)C=C1 Chemical compound C1=CC=C(SC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=N2)C=C1 QRBMUNDOCCEZPZ-UHFFFAOYSA-N 0.000 description 1
- UZMHVOPBVHRESE-UHFFFAOYSA-N C1=CC=C2C(=C1)CCCC2NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C1=CC=C2C(=C1)CCCC2NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 UZMHVOPBVHRESE-UHFFFAOYSA-N 0.000 description 1
- AYVGHSUYXZNEHT-UHFFFAOYSA-N C1=CC=C2C=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=CC2=C1 Chemical compound C1=CC=C2C=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)N=CC2=C1 AYVGHSUYXZNEHT-UHFFFAOYSA-N 0.000 description 1
- JZNJTTNDMBGBQZ-UHFFFAOYSA-N C1=CN(C2CCN(C3=CC=C(NC4=NC5=C(SC=C5)C(NC5=CC6=C(C=C5)NN=C6)=N4)C=C3)CC2)C=C1 Chemical compound C1=CN(C2CCN(C3=CC=C(NC4=NC5=C(SC=C5)C(NC5=CC6=C(C=C5)NN=C6)=N4)C=C3)CC2)C=C1 JZNJTTNDMBGBQZ-UHFFFAOYSA-N 0.000 description 1
- DMVIOJXVRHRINI-UHFFFAOYSA-N C1=CN(C2CCN(C3=CC=C(NC4=NC5=C(SC=C5)C(NC5=CC6=C(C=C5)NN=C6)=N4)C=C3)CC2)C=C1.CC1CCCCC1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.ClC1=CC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 Chemical compound C1=CN(C2CCN(C3=CC=C(NC4=NC5=C(SC=C5)C(NC5=CC6=C(C=C5)NN=C6)=N4)C=C3)CC2)C=C1.CC1CCCCC1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.ClC1=CC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 DMVIOJXVRHRINI-UHFFFAOYSA-N 0.000 description 1
- WAZXEQMZULJSMP-UHFFFAOYSA-N C1=CN=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.ClC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+]([O-])C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 Chemical compound C1=CN=C(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.ClC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+]([O-])C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 WAZXEQMZULJSMP-UHFFFAOYSA-N 0.000 description 1
- KOQANVSOBLEXMO-UHFFFAOYSA-N C1=CN=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CN=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 KOQANVSOBLEXMO-UHFFFAOYSA-N 0.000 description 1
- PYDLMEYMWCOYPG-UHFFFAOYSA-N C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 PYDLMEYMWCOYPG-UHFFFAOYSA-N 0.000 description 1
- QIKQVAZJTHATHX-UHFFFAOYSA-N C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=CN=C2C=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C2=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1.ClC1=NC=CC=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.C1=CN=C2C=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C2=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1.ClC1=NC=CC=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 QIKQVAZJTHATHX-UHFFFAOYSA-N 0.000 description 1
- IGHDTKAIZNKMKW-UHFFFAOYSA-N C1=CN=C2C=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC2=C1 Chemical compound C1=CN=C2C=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC2=C1 IGHDTKAIZNKMKW-UHFFFAOYSA-N 0.000 description 1
- QXQIULWVJALNPJ-UHFFFAOYSA-N C1=CN=C2C=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C2=C1 Chemical compound C1=CN=C2C=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C2=C1 QXQIULWVJALNPJ-UHFFFAOYSA-N 0.000 description 1
- JWIWNHHPWFYUJV-UHFFFAOYSA-N C1=CN=C2N=C(C3=CC4=C(C=CC=C4)S3)N=C(NC3=CC4=C(C=C3)NN=C4)C2=C1.CC1=NNC2=C1C=C(NC1=NC(C3=CC=CC(C4=CC=CC=C4)=C3)=NC3=C1SC=C3)C=C2 Chemical compound C1=CN=C2N=C(C3=CC4=C(C=CC=C4)S3)N=C(NC3=CC4=C(C=C3)NN=C4)C2=C1.CC1=NNC2=C1C=C(NC1=NC(C3=CC=CC(C4=CC=CC=C4)=C3)=NC3=C1SC=C3)C=C2 JWIWNHHPWFYUJV-UHFFFAOYSA-N 0.000 description 1
- QOYSEFFOZHXBNE-UHFFFAOYSA-N C1=CN=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CN=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 QOYSEFFOZHXBNE-UHFFFAOYSA-N 0.000 description 1
- UDNWKFWVIGUBSU-UHFFFAOYSA-N C1=CN=CC(SC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)=C1 Chemical compound C1=CN=CC(SC2=CC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=CC=C2)=C1 UDNWKFWVIGUBSU-UHFFFAOYSA-N 0.000 description 1
- INILMQFHMXZLGJ-UHFFFAOYSA-N C1=CSC(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)=C1 Chemical compound C1=CSC(C2=CSC3=C2C(NC2=CC4=C(C=C2)NN=C4)=NC=N3)=C1 INILMQFHMXZLGJ-UHFFFAOYSA-N 0.000 description 1
- ZJPFELWHADKZLK-UHFFFAOYSA-N C1=CSC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound C1=CSC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 ZJPFELWHADKZLK-UHFFFAOYSA-N 0.000 description 1
- XNZGSFFSQQJYQT-UHFFFAOYSA-N C1c2ccccc2CC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 Chemical compound C1c2ccccc2CC1Nc1nc(Nc2ccc3N[I]=Cc3c2)c2[s]ccc2n1 XNZGSFFSQQJYQT-UHFFFAOYSA-N 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N C=CC1=CC=C(C)C=C1 Chemical compound C=CC1=CC=C(C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- AGHNIKMPJPSAGP-UHFFFAOYSA-N C=CC1=CC=C(C)C=C1.CC1=CC(F)=CC(F)=C1.CC1=CC2=C(C=CC=C2)S1.CC1=CC=C(C(=O)N2CCOCC2)S1.CC1=CC=C(C)C=C1.CC1=CC=C(C2=CC3=C(C=CN=C3)S2)C=C1.CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C2=CC=CC=C2)N=C1.CC1=CC=C(C2=CC=CC=C2)N=C1.CC1=CC=C(C2=CC=NC=C2)C=C1.CC1=CC=C(F)C(C2=CC=CC=C2)=C1.CC1=CC=C(F)C=C1.CC1=CC=C(N2CCNCC2)C=C1.CC1=CC=C(N2CCOCC2)C=C1.CC1=CC=CC(C)=C1.CC1=CC=CC(F)=C1.CC1=CC=CC(OC(F)(F)F)=C1.CC1=CC=CC=C1.CCC1=CC=C(C)C=C1.CCOC1=CC(C)=CC=C1.COC1=CC(C)=CC=C1.COC1=CC=C(C)C=C1.COC1=CC=C(C)C=N1 Chemical compound C=CC1=CC=C(C)C=C1.CC1=CC(F)=CC(F)=C1.CC1=CC2=C(C=CC=C2)S1.CC1=CC=C(C(=O)N2CCOCC2)S1.CC1=CC=C(C)C=C1.CC1=CC=C(C2=CC3=C(C=CN=C3)S2)C=C1.CC1=CC=C(C2=CC=CC=C2)C=C1.CC1=CC=C(C2=CC=CC=C2)N=C1.CC1=CC=C(C2=CC=CC=C2)N=C1.CC1=CC=C(C2=CC=NC=C2)C=C1.CC1=CC=C(F)C(C2=CC=CC=C2)=C1.CC1=CC=C(F)C=C1.CC1=CC=C(N2CCNCC2)C=C1.CC1=CC=C(N2CCOCC2)C=C1.CC1=CC=CC(C)=C1.CC1=CC=CC(F)=C1.CC1=CC=CC(OC(F)(F)F)=C1.CC1=CC=CC=C1.CCC1=CC=C(C)C=C1.CCOC1=CC(C)=CC=C1.COC1=CC(C)=CC=C1.COC1=CC=C(C)C=C1.COC1=CC=C(C)C=N1 AGHNIKMPJPSAGP-UHFFFAOYSA-N 0.000 description 1
- XXJLGOQYSDDNDK-UHFFFAOYSA-N C=CCC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C(=O)O Chemical compound C=CCC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C(=O)O XXJLGOQYSDDNDK-UHFFFAOYSA-N 0.000 description 1
- PYDDBTLSGBIRBR-UHFFFAOYSA-N CC(=O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 Chemical compound CC(=O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 PYDDBTLSGBIRBR-UHFFFAOYSA-N 0.000 description 1
- GNIQQKORSMFYPE-UHFFFAOYSA-N CC(=O)C1=CC=C(C2=CC=C(C)C=C2)C=C1 Chemical compound CC(=O)C1=CC=C(C2=CC=C(C)C=C2)C=C1 GNIQQKORSMFYPE-UHFFFAOYSA-N 0.000 description 1
- UBYHQVOLGNDPTL-UHFFFAOYSA-N CC(=O)N1CCC2=C1C=CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2 Chemical compound CC(=O)N1CCC2=C1C=CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2 UBYHQVOLGNDPTL-UHFFFAOYSA-N 0.000 description 1
- HSTAWSZUXOEPSG-UHFFFAOYSA-N CC(=O)N1CCC2=C1C=CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2.CN1N=C(C2=CC=CS2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.COC1=CC=C2N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)SC2=N1 Chemical compound CC(=O)N1CCC2=C1C=CC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=C2.CN1N=C(C2=CC=CS2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.COC1=CC=C2N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)SC2=N1 HSTAWSZUXOEPSG-UHFFFAOYSA-N 0.000 description 1
- IEBHYKHHIAJQOK-UHFFFAOYSA-N CC(=O)NC1=CC=C(C2=CC=C(C)C=C2)C=C1 Chemical compound CC(=O)NC1=CC=C(C2=CC=C(C)C=C2)C=C1 IEBHYKHHIAJQOK-UHFFFAOYSA-N 0.000 description 1
- QLCNJFGDGYRFPQ-UHFFFAOYSA-N CC(=O)NC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1C(F)(F)F Chemical compound CC(=O)NC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1C(F)(F)F QLCNJFGDGYRFPQ-UHFFFAOYSA-N 0.000 description 1
- CRYWKOXFFOCIQK-UHFFFAOYSA-N CC(=O)NC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1C(F)(F)F.CCN(C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1)C(C)C.FC(F)(F)C1=CC=NN1C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CC(=O)NC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1C(F)(F)F.CCN(C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1)C(C)C.FC(F)(F)C1=CC=NN1C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 CRYWKOXFFOCIQK-UHFFFAOYSA-N 0.000 description 1
- ZZJRROKWGWYLBN-UHFFFAOYSA-N CC(C)(C)C1=C(C#N)SC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1 Chemical compound CC(C)(C)C1=C(C#N)SC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1 ZZJRROKWGWYLBN-UHFFFAOYSA-N 0.000 description 1
- YLVAYZGZKQSQEE-UHFFFAOYSA-N CC(C)(C)C1=C(C#N)SC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1.CCC1=C(C2=CC=CC=C2)N=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)O1.FC1=CC2=C(N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)S2)C(F)=C1 Chemical compound CC(C)(C)C1=C(C#N)SC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1.CCC1=C(C2=CC=CC=C2)N=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)O1.FC1=CC2=C(N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)S2)C(F)=C1 YLVAYZGZKQSQEE-UHFFFAOYSA-N 0.000 description 1
- GWURPOYXXCTONE-UHFFFAOYSA-N CC(C)(C)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CC(C)(C)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 GWURPOYXXCTONE-UHFFFAOYSA-N 0.000 description 1
- SHAMWVCDDZFIEL-UHFFFAOYSA-N CC(C)(C)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=CC(C)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC(C)(C)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.CC1=CC(C)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 SHAMWVCDDZFIEL-UHFFFAOYSA-N 0.000 description 1
- NRKBPWBFTAVJCA-UHFFFAOYSA-N CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=C(F)C=C1 Chemical compound CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=C(F)C=C1 NRKBPWBFTAVJCA-UHFFFAOYSA-N 0.000 description 1
- AQRCFAQUSISAMK-UHFFFAOYSA-N CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=C(F)C=C1.FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C(F)C=C1.FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=C(F)C=C1.FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C(F)C=C1.FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 AQRCFAQUSISAMK-UHFFFAOYSA-N 0.000 description 1
- SMUDINOOORDNBZ-UHFFFAOYSA-N CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=CC=C1 Chemical compound CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=CC=C1 SMUDINOOORDNBZ-UHFFFAOYSA-N 0.000 description 1
- WLWXNIPRLXZHMU-UHFFFAOYSA-N CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=CC=C1.CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl.CCOC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.FC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound CC(NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1)C1=CC=CC=C1.CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl.CCOC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.FC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 WLWXNIPRLXZHMU-UHFFFAOYSA-N 0.000 description 1
- NXOYDBQUTWVUSZ-UHFFFAOYSA-N CC.CC.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC=C3)=NC3=C1C=CO3)=C2 Chemical compound CC.CC.[H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC=C3)=NC3=C1C=CO3)=C2 NXOYDBQUTWVUSZ-UHFFFAOYSA-N 0.000 description 1
- BBCNOFQJHPPMRP-UHFFFAOYSA-N CC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound CC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 BBCNOFQJHPPMRP-UHFFFAOYSA-N 0.000 description 1
- LHWACWFLWKKDPI-UHFFFAOYSA-N CC1=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC(Br)=C1 Chemical compound CC1=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC(Br)=C1 LHWACWFLWKKDPI-UHFFFAOYSA-N 0.000 description 1
- XZFNOQPCZWRESB-UHFFFAOYSA-N CC1=C(OC2=CN=CC=C2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC1=C(OC2=CN=CC=C2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 XZFNOQPCZWRESB-UHFFFAOYSA-N 0.000 description 1
- VJYXZJGDFJJDGF-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC=C1 Chemical compound CC1=CC(C(F)(F)F)=CC=C1 VJYXZJGDFJJDGF-UHFFFAOYSA-N 0.000 description 1
- LNNBCDGBBKYJQW-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC=C1.CC1=CC(C2=CC=CS2)=CC=C1.CC1=CC(C2=CC=NC=C2)=CC=C1.CC1=CC(CO)=CC=C1.CC1=CC=C(C(C)(C)C)C=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(CO)C=C1.CC1=CC=C(N2CCCCC2)C=C1 Chemical compound CC1=CC(C(F)(F)F)=CC=C1.CC1=CC(C2=CC=CS2)=CC=C1.CC1=CC(C2=CC=NC=C2)=CC=C1.CC1=CC(CO)=CC=C1.CC1=CC=C(C(C)(C)C)C=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(C(C)C)C=C1.CC1=CC=C(CO)C=C1.CC1=CC=C(N2CCCCC2)C=C1 LNNBCDGBBKYJQW-UHFFFAOYSA-N 0.000 description 1
- AFOCNRSNOSLFHZ-UHFFFAOYSA-N CC1=CC(C)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC1=CC(C)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 AFOCNRSNOSLFHZ-UHFFFAOYSA-N 0.000 description 1
- BOCLRFOJQFQHDM-UHFFFAOYSA-N CC1=CC(C)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.N#CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=C(O)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC1=CC(C)=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.N#CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=C(O)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 BOCLRFOJQFQHDM-UHFFFAOYSA-N 0.000 description 1
- NPDIDUXTRAITDE-UHFFFAOYSA-N CC1=CC(C2=CC=CC=C2)=CC=C1 Chemical compound CC1=CC(C2=CC=CC=C2)=CC=C1 NPDIDUXTRAITDE-UHFFFAOYSA-N 0.000 description 1
- ZIEYQXYJGHFGFB-UHFFFAOYSA-N CC1=CC(C2=CC=CC=C2)=CC=C1.CC1=CC=C(C2=CC=C(Cl)C=C2)C=C1.CC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1.CC1=CC=C(C2=CC=C(F)C=C2)C=C1.CC1=CC=C(C2=CC=CC(Cl)=C2)C=C1.CC1=CC=C(C2=CC=CC([N+](=O)[O-])=C2)C=C1.CC1=CC=C(C2=CC=CC=C2Cl)C=C1.CC1=CC=C(C2=CC=CC=C2F)C=C1.CC1=CC=C(C2=CC=CC=N2)C=C1.CC1=CC=C(C2=CN=CC=C2)C=C1.CC1=CC=C(Cl)C=C1.CC1=CC=CC(Cl)=C1.COC1=CC=C(C2=CC=C(C)C=C2)C=C1.COC1=CC=C(C2=CC=C(C)C=C2)C=C1F Chemical compound CC1=CC(C2=CC=CC=C2)=CC=C1.CC1=CC=C(C2=CC=C(Cl)C=C2)C=C1.CC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1.CC1=CC=C(C2=CC=C(F)C=C2)C=C1.CC1=CC=C(C2=CC=CC(Cl)=C2)C=C1.CC1=CC=C(C2=CC=CC([N+](=O)[O-])=C2)C=C1.CC1=CC=C(C2=CC=CC=C2Cl)C=C1.CC1=CC=C(C2=CC=CC=C2F)C=C1.CC1=CC=C(C2=CC=CC=N2)C=C1.CC1=CC=C(C2=CN=CC=C2)C=C1.CC1=CC=C(Cl)C=C1.CC1=CC=CC(Cl)=C1.COC1=CC=C(C2=CC=C(C)C=C2)C=C1.COC1=CC=C(C2=CC=C(C)C=C2)C=C1F ZIEYQXYJGHFGFB-UHFFFAOYSA-N 0.000 description 1
- SMKMXVCNNASZEB-UHFFFAOYSA-N CC1=CC(C2=CC=CS2)=CC=C1 Chemical compound CC1=CC(C2=CC=CS2)=CC=C1 SMKMXVCNNASZEB-UHFFFAOYSA-N 0.000 description 1
- IWRUAXOGIJVROI-UHFFFAOYSA-N CC1=CC(C2=CC=NC=C2)=CC=C1 Chemical compound CC1=CC(C2=CC=NC=C2)=CC=C1 IWRUAXOGIJVROI-UHFFFAOYSA-N 0.000 description 1
- JJCKHVUTVOPLBV-UHFFFAOYSA-N CC1=CC(CO)=CC=C1 Chemical compound CC1=CC(CO)=CC=C1 JJCKHVUTVOPLBV-UHFFFAOYSA-N 0.000 description 1
- YISYUYYETHYYMD-UHFFFAOYSA-N CC1=CC(F)=CC(F)=C1 Chemical compound CC1=CC(F)=CC(F)=C1 YISYUYYETHYYMD-UHFFFAOYSA-N 0.000 description 1
- AIKOPSMZPOGMSJ-UHFFFAOYSA-N CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C2C=CC=CC2=N1 Chemical compound CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C2C=CC=CC2=N1 AIKOPSMZPOGMSJ-UHFFFAOYSA-N 0.000 description 1
- AUTFAAZFCCPDHP-UHFFFAOYSA-N CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC=C1[N+](=O)[O-] Chemical compound CC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC=C1[N+](=O)[O-] AUTFAAZFCCPDHP-UHFFFAOYSA-N 0.000 description 1
- PMMOKWBXWLBRPD-UHFFFAOYSA-N CC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound CC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 PMMOKWBXWLBRPD-UHFFFAOYSA-N 0.000 description 1
- XHIPXDDGMZRSLF-UHFFFAOYSA-N CC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2.CN1C2=CC=CC=C2N=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CN1N=C(C2=CC=CC=C2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.ClC1=CC2=C(C=C1)OC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=N2 Chemical compound CC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2.CN1C2=CC=CC=C2N=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CN1N=C(C2=CC=CC=C2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.ClC1=CC2=C(C=C1)OC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=N2 XHIPXDDGMZRSLF-UHFFFAOYSA-N 0.000 description 1
- VFRHJBKHEQZRJM-UHFFFAOYSA-N CC1=CC=C(C(=O)N2CCOCC2)S1 Chemical compound CC1=CC=C(C(=O)N2CCOCC2)S1 VFRHJBKHEQZRJM-UHFFFAOYSA-N 0.000 description 1
- QCWXDVFBZVHKLV-UHFFFAOYSA-N CC1=CC=C(C(C)(C)C)C=C1 Chemical compound CC1=CC=C(C(C)(C)C)C=C1 QCWXDVFBZVHKLV-UHFFFAOYSA-N 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N CC1=CC=C(C)C=C1 Chemical compound CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- SXVMLOJQVHAHHZ-UHFFFAOYSA-N CC1=CC=C(C2=CC3=C(C=CN=C3)S2)C=C1 Chemical compound CC1=CC=C(C2=CC3=C(C=CN=C3)S2)C=C1 SXVMLOJQVHAHHZ-UHFFFAOYSA-N 0.000 description 1
- QAOZLQJWOHCEOV-UHFFFAOYSA-N CC1=CC=C(C2=CC=C(C)C([N+](=O)[O-])=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=C(C)C([N+](=O)[O-])=C2)C=C1 QAOZLQJWOHCEOV-UHFFFAOYSA-N 0.000 description 1
- XYOKCUNCQZYSPK-UHFFFAOYSA-N CC1=CC=C(C2=CC=C(Cl)C=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=C(Cl)C=C2)C=C1 XYOKCUNCQZYSPK-UHFFFAOYSA-N 0.000 description 1
- BBBFSPBYVBEIJU-UHFFFAOYSA-N CC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1 Chemical compound CC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1 BBBFSPBYVBEIJU-UHFFFAOYSA-N 0.000 description 1
- JSBJQQZPQJIGFJ-UHFFFAOYSA-N CC1=CC=C(C2=CC=C(F)C=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=C(F)C=C2)C=C1 JSBJQQZPQJIGFJ-UHFFFAOYSA-N 0.000 description 1
- XAIDWOFGGNDTPE-UHFFFAOYSA-N CC1=CC=C(C2=CC=C([N+](=O)[O-])C=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=C([N+](=O)[O-])C=C2)C=C1 XAIDWOFGGNDTPE-UHFFFAOYSA-N 0.000 description 1
- WAEKCHUPDOGQJY-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC(Cl)=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=CC(Cl)=C2)C=C1 WAEKCHUPDOGQJY-UHFFFAOYSA-N 0.000 description 1
- VXPLSDQTIWIHJH-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC([N+](=O)[O-])=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=CC([N+](=O)[O-])=C2)C=C1 VXPLSDQTIWIHJH-UHFFFAOYSA-N 0.000 description 1
- JTZVTVSSLYYVAM-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC3=C2C=CC=C3)C=C1 Chemical compound CC1=CC=C(C2=CC=CC3=C2C=CC=C3)C=C1 JTZVTVSSLYYVAM-UHFFFAOYSA-N 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=CC=C2)C=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- LZQKARVGXYAKEN-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC=C2Cl)C=C1 Chemical compound CC1=CC=C(C2=CC=CC=C2Cl)C=C1 LZQKARVGXYAKEN-UHFFFAOYSA-N 0.000 description 1
- UZRWCXBSPNFXAK-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC=C2F)C=C1 Chemical compound CC1=CC=C(C2=CC=CC=C2F)C=C1 UZRWCXBSPNFXAK-UHFFFAOYSA-N 0.000 description 1
- KJNZQKYSNAQLEO-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC=N2)C=C1 Chemical compound CC1=CC=C(C2=CC=CC=N2)C=C1 KJNZQKYSNAQLEO-UHFFFAOYSA-N 0.000 description 1
- DKFPQCUHILRPNN-UHFFFAOYSA-N CC1=CC=C(C2=CC=CS2)C=C1 Chemical compound CC1=CC=C(C2=CC=CS2)C=C1 DKFPQCUHILRPNN-UHFFFAOYSA-N 0.000 description 1
- MRAIVJPPOXSJNG-UHFFFAOYSA-N CC1=CC=C(C2=CC=NC=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=NC=C2)C=C1 MRAIVJPPOXSJNG-UHFFFAOYSA-N 0.000 description 1
- KUZNURGIXXKBEJ-UHFFFAOYSA-N CC1=CC=C(C2=CN=CC=C2)C=C1 Chemical compound CC1=CC=C(C2=CN=CC=C2)C=C1 KUZNURGIXXKBEJ-UHFFFAOYSA-N 0.000 description 1
- ZKYPCPPLWHALNY-UHFFFAOYSA-N CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl Chemical compound CC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl ZKYPCPPLWHALNY-UHFFFAOYSA-N 0.000 description 1
- KMTDMTZBNYGUNX-UHFFFAOYSA-N CC1=CC=C(CO)C=C1 Chemical compound CC1=CC=C(CO)C=C1 KMTDMTZBNYGUNX-UHFFFAOYSA-N 0.000 description 1
- NPDACUSDTOMAMK-UHFFFAOYSA-N CC1=CC=C(Cl)C=C1 Chemical compound CC1=CC=C(Cl)C=C1 NPDACUSDTOMAMK-UHFFFAOYSA-N 0.000 description 1
- LOXSAAXJGAQNJU-UHFFFAOYSA-N CC1=CC=C(F)C(C2=CC=CC=C2)=C1 Chemical compound CC1=CC=C(F)C(C2=CC=CC=C2)=C1 LOXSAAXJGAQNJU-UHFFFAOYSA-N 0.000 description 1
- WRWPPGUCZBJXKX-UHFFFAOYSA-N CC1=CC=C(F)C=C1 Chemical compound CC1=CC=C(F)C=C1 WRWPPGUCZBJXKX-UHFFFAOYSA-N 0.000 description 1
- SEKVDGJLBQJSTO-UHFFFAOYSA-N CC1=CC=C(N2CCCCC2)C=C1 Chemical compound CC1=CC=C(N2CCCCC2)C=C1 SEKVDGJLBQJSTO-UHFFFAOYSA-N 0.000 description 1
- ONEYFZXGNFNRJH-UHFFFAOYSA-N CC1=CC=C(N2CCNCC2)C=C1 Chemical compound CC1=CC=C(N2CCNCC2)C=C1 ONEYFZXGNFNRJH-UHFFFAOYSA-N 0.000 description 1
- OLAFVASCPJETBP-UHFFFAOYSA-N CC1=CC=C(N2CCOCC2)C=C1 Chemical compound CC1=CC=C(N2CCOCC2)C=C1 OLAFVASCPJETBP-UHFFFAOYSA-N 0.000 description 1
- MBEXEYJTRNLJBT-UHFFFAOYSA-N CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 MBEXEYJTRNLJBT-UHFFFAOYSA-N 0.000 description 1
- VHUDPMKBQFCVGJ-UHFFFAOYSA-N CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1OC.OCCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1OC.OCCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 VHUDPMKBQFCVGJ-UHFFFAOYSA-N 0.000 description 1
- IVSZLXZYQVIEFR-UHFFFAOYSA-N CC1=CC=CC(C)=C1 Chemical compound CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 1
- QDHTXXOHGMXWDR-UHFFFAOYSA-N CC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 QDHTXXOHGMXWDR-UHFFFAOYSA-N 0.000 description 1
- OSOUNOBYRMOXQQ-UHFFFAOYSA-N CC1=CC=CC(Cl)=C1 Chemical compound CC1=CC=CC(Cl)=C1 OSOUNOBYRMOXQQ-UHFFFAOYSA-N 0.000 description 1
- BTQZKHUEUDPRST-UHFFFAOYSA-N CC1=CC=CC(F)=C1 Chemical compound CC1=CC=CC(F)=C1 BTQZKHUEUDPRST-UHFFFAOYSA-N 0.000 description 1
- WPBXTCORBJRRIM-UHFFFAOYSA-N CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 WPBXTCORBJRRIM-UHFFFAOYSA-N 0.000 description 1
- BVTQIWAXRJLDQW-UHFFFAOYSA-N CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C Chemical compound CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C BVTQIWAXRJLDQW-UHFFFAOYSA-N 0.000 description 1
- XTVBUDBKLBBUBT-UHFFFAOYSA-N CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1 Chemical compound CC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=N1 XTVBUDBKLBBUBT-UHFFFAOYSA-N 0.000 description 1
- WRNXOOXIPSTAGJ-UHFFFAOYSA-N CC1=CC=CC(OC(F)(F)F)=C1 Chemical compound CC1=CC=CC(OC(F)(F)F)=C1 WRNXOOXIPSTAGJ-UHFFFAOYSA-N 0.000 description 1
- GGXKQILBNJUKSH-UHFFFAOYSA-N CC1=CC=CC2=C1C1=C(C=CC=C1)O2 Chemical compound CC1=CC=CC2=C1C1=C(C=CC=C1)O2 GGXKQILBNJUKSH-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N CC1=CC=CC=C1 Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- AEFCHOMXJJCVJW-UHFFFAOYSA-N CC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 Chemical compound CC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 AEFCHOMXJJCVJW-UHFFFAOYSA-N 0.000 description 1
- GHGJRQUDLXQODE-UHFFFAOYSA-N CC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1.CN1N=C(C(C)(C)C)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CN1N=C(C2CC2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.FC(F)(F)C1=NN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 Chemical compound CC1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1.CN1N=C(C(C)(C)C)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.CN1N=C(C2CC2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1.FC(F)(F)C1=NN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 GHGJRQUDLXQODE-UHFFFAOYSA-N 0.000 description 1
- IPEZLDLJNUPTMI-UHFFFAOYSA-N CC1=COC(N)=C1C#N Chemical compound CC1=COC(N)=C1C#N IPEZLDLJNUPTMI-UHFFFAOYSA-N 0.000 description 1
- VBVWRIUMKXPHKC-UHFFFAOYSA-N CC1=NC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1.COC1=C(OC)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CC1=NC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1.COC1=C(OC)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 VBVWRIUMKXPHKC-UHFFFAOYSA-N 0.000 description 1
- MWYWRISDPFGRJI-UHFFFAOYSA-N CC1=NN(C)C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C1=CC=C(F)C=C1 Chemical compound CC1=NN(C)C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1C1=CC=C(F)C=C1 MWYWRISDPFGRJI-UHFFFAOYSA-N 0.000 description 1
- HQMYDRGGBUKAKP-UHFFFAOYSA-N CC1=NNC2=C1C=C(N)C=C2 Chemical compound CC1=NNC2=C1C=C(N)C=C2 HQMYDRGGBUKAKP-UHFFFAOYSA-N 0.000 description 1
- LROBQAZPUIRMFF-UHFFFAOYSA-N CC1=NNC2=C1C=C(NC1=NC(Cl)=NC3=C1SC=C3)C=C2 Chemical compound CC1=NNC2=C1C=C(NC1=NC(Cl)=NC3=C1SC=C3)C=C2 LROBQAZPUIRMFF-UHFFFAOYSA-N 0.000 description 1
- ZGDNJFXKELMVLS-UHFFFAOYSA-N CC1=NNC2=C1C=C([N+](=O)[O-])C=C2 Chemical compound CC1=NNC2=C1C=C([N+](=O)[O-])C=C2 ZGDNJFXKELMVLS-UHFFFAOYSA-N 0.000 description 1
- LXBJRGMQQLEDOS-UHFFFAOYSA-N CC1CCCCC1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CC1CCCCC1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 LXBJRGMQQLEDOS-UHFFFAOYSA-N 0.000 description 1
- XPTAXIJFLRVNCG-UHFFFAOYSA-N CC1CN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC(C)O1 Chemical compound CC1CN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC(C)O1 XPTAXIJFLRVNCG-UHFFFAOYSA-N 0.000 description 1
- JRLPEMVDPFPYPJ-UHFFFAOYSA-N CCC1=CC=C(C)C=C1 Chemical compound CCC1=CC=C(C)C=C1 JRLPEMVDPFPYPJ-UHFFFAOYSA-N 0.000 description 1
- NHPDPRQIKQLPDJ-UHFFFAOYSA-N CCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 NHPDPRQIKQLPDJ-UHFFFAOYSA-N 0.000 description 1
- OCYLAWOZDBUXPT-UHFFFAOYSA-N CCN(C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1)C(C)C Chemical compound CCN(C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1)C(C)C OCYLAWOZDBUXPT-UHFFFAOYSA-N 0.000 description 1
- SNTATNAVBOJYNO-UHFFFAOYSA-N CCN(CC)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl Chemical compound CCN(CC)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1Cl SNTATNAVBOJYNO-UHFFFAOYSA-N 0.000 description 1
- INHUETIDDHYTSJ-UHFFFAOYSA-N CCN1CCCC1CNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CCN1CCCC1CNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 INHUETIDDHYTSJ-UHFFFAOYSA-N 0.000 description 1
- UALKQROXOHJHFG-UHFFFAOYSA-N CCOC1=CC(C)=CC=C1 Chemical compound CCOC1=CC(C)=CC=C1 UALKQROXOHJHFG-UHFFFAOYSA-N 0.000 description 1
- MSESMLWUYPLOPX-UHFFFAOYSA-N CCOC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CCOC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 MSESMLWUYPLOPX-UHFFFAOYSA-N 0.000 description 1
- UEWVXVSAFDBVAF-UHFFFAOYSA-N CCOC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.OCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound CCOC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1.OCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 UEWVXVSAFDBVAF-UHFFFAOYSA-N 0.000 description 1
- RDNDORVEMOWCHU-UHFFFAOYSA-N CN(C)C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 Chemical compound CN(C)C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 RDNDORVEMOWCHU-UHFFFAOYSA-N 0.000 description 1
- WPFPDGUSKZUCPV-UHFFFAOYSA-N CN(C)C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1.COC1=C(O)C=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)OC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.OC1CCC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)CC1 Chemical compound CN(C)C1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1.COC1=C(O)C=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC(F)(F)OC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.OC1CCC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)CC1 WPFPDGUSKZUCPV-UHFFFAOYSA-N 0.000 description 1
- PZTNKUBGTDUTFJ-UHFFFAOYSA-N CN1C2=CC=CC=C2N=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CN1C2=CC=CC=C2N=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 PZTNKUBGTDUTFJ-UHFFFAOYSA-N 0.000 description 1
- NDIONECNVSHGQJ-UHFFFAOYSA-N CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC1 Chemical compound CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)CC1 NDIONECNVSHGQJ-UHFFFAOYSA-N 0.000 description 1
- CEOJLFHUKHJSPL-UHFFFAOYSA-N CN1N=C(C(C)(C)C)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CN1N=C(C(C)(C)C)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 CEOJLFHUKHJSPL-UHFFFAOYSA-N 0.000 description 1
- LGDDCHFLNXAATA-UHFFFAOYSA-N CN1N=C(C2=CC=CC=C2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CN1N=C(C2=CC=CC=C2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 LGDDCHFLNXAATA-UHFFFAOYSA-N 0.000 description 1
- ZXUGSCWLYNXNTO-UHFFFAOYSA-N CN1N=C(C2=CC=CS2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CN1N=C(C2=CC=CS2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 ZXUGSCWLYNXNTO-UHFFFAOYSA-N 0.000 description 1
- LWJZDPHZRDBVQW-UHFFFAOYSA-N CN1N=C(C2CC2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound CN1N=C(C2CC2)C=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 LWJZDPHZRDBVQW-UHFFFAOYSA-N 0.000 description 1
- NQXDAWUZEFVGJN-UHFFFAOYSA-N COC(CCCC1=CSC=C1)OC Chemical compound COC(CCCC1=CSC=C1)OC NQXDAWUZEFVGJN-UHFFFAOYSA-N 0.000 description 1
- SZJMVVOLKZAPCJ-UHFFFAOYSA-N COC(CNCC1=CSC=C1)OC Chemical compound COC(CNCC1=CSC=C1)OC SZJMVVOLKZAPCJ-UHFFFAOYSA-N 0.000 description 1
- LDRKJRJZNPFAGB-UHFFFAOYSA-N COC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound COC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 LDRKJRJZNPFAGB-UHFFFAOYSA-N 0.000 description 1
- GCILBUUASGQXAX-UHFFFAOYSA-N COC1=C(O)C=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound COC1=C(O)C=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 GCILBUUASGQXAX-UHFFFAOYSA-N 0.000 description 1
- QTGFIKPKZATJSC-UHFFFAOYSA-N COC1=C(OC)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound COC1=C(OC)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 QTGFIKPKZATJSC-UHFFFAOYSA-N 0.000 description 1
- OSIGJGFTADMDOB-UHFFFAOYSA-N COC1=CC(C)=CC=C1 Chemical compound COC1=CC(C)=CC=C1 OSIGJGFTADMDOB-UHFFFAOYSA-N 0.000 description 1
- DESOLECJXURASU-UHFFFAOYSA-N COC1=CC(C2=NC3=C(C(C)=CO3)C(Cl)=N2)=CC=C1 Chemical compound COC1=CC(C2=NC3=C(C(C)=CO3)C(Cl)=N2)=CC=C1 DESOLECJXURASU-UHFFFAOYSA-N 0.000 description 1
- LHQRMHPMPXGWOC-UHFFFAOYSA-N COC1=CC(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)=CC=C1 Chemical compound COC1=CC(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)=CC=C1 LHQRMHPMPXGWOC-UHFFFAOYSA-N 0.000 description 1
- VPCRPOHXUAVIAS-UHFFFAOYSA-N COC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CC=CC=C2)=C1.CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=NC=CC=C2)=N1.ClC1=C(N2CCOCC2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound COC1=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C2=CC=CC=C2)=C1.CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=NC=CC=C2)=N1.ClC1=C(N2CCOCC2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 VPCRPOHXUAVIAS-UHFFFAOYSA-N 0.000 description 1
- PFAKVKDJVNXTHH-UHFFFAOYSA-N COC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound COC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 PFAKVKDJVNXTHH-UHFFFAOYSA-N 0.000 description 1
- QYZQYRZOOMNZFU-UHFFFAOYSA-N COC1=CC=C(C2=CC=C(C)C=C2)C(OC)=C1 Chemical compound COC1=CC=C(C2=CC=C(C)C=C2)C(OC)=C1 QYZQYRZOOMNZFU-UHFFFAOYSA-N 0.000 description 1
- ASKBXZKXIBPNRA-UHFFFAOYSA-N COC1=CC=C(C2=CC=C(C)C=C2)C=C1 Chemical compound COC1=CC=C(C2=CC=C(C)C=C2)C=C1 ASKBXZKXIBPNRA-UHFFFAOYSA-N 0.000 description 1
- YCZRVSWTOURVPF-UHFFFAOYSA-N COC1=CC=C(C2=CC=C(C)C=C2)C=C1F Chemical compound COC1=CC=C(C2=CC=C(C)C=C2)C=C1F YCZRVSWTOURVPF-UHFFFAOYSA-N 0.000 description 1
- OUTCYYYAEXRMSX-UHFFFAOYSA-N COC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound COC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 OUTCYYYAEXRMSX-UHFFFAOYSA-N 0.000 description 1
- UKJITNXLJTWKSO-UHFFFAOYSA-N COC1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 Chemical compound COC1=CC=C(N2CCN(C3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)CC2)C=C1 UKJITNXLJTWKSO-UHFFFAOYSA-N 0.000 description 1
- NHWARZRBHBWEMO-UHFFFAOYSA-N COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 NHWARZRBHBWEMO-UHFFFAOYSA-N 0.000 description 1
- DULNUXJCAKPXPN-UHFFFAOYSA-N COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1OC Chemical compound COC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1OC DULNUXJCAKPXPN-UHFFFAOYSA-N 0.000 description 1
- GJLJFKDTYCSJHJ-UHFFFAOYSA-N COC1=CC=C(OC)C(C2=CC=C(C)C=C2)=C1 Chemical compound COC1=CC=C(OC)C(C2=CC=C(C)C=C2)=C1 GJLJFKDTYCSJHJ-UHFFFAOYSA-N 0.000 description 1
- DFMSRYYRUVCEIA-UHFFFAOYSA-N COC1=CC=C2N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)SC2=N1 Chemical compound COC1=CC=C2N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)SC2=N1 DFMSRYYRUVCEIA-UHFFFAOYSA-N 0.000 description 1
- XTZJTWMCKGRTEH-UHFFFAOYSA-N COC1=CC=CC(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound COC1=CC=CC(CCNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 XTZJTWMCKGRTEH-UHFFFAOYSA-N 0.000 description 1
- MOGLXQSRGNEDDA-UHFFFAOYSA-N COC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound COC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 MOGLXQSRGNEDDA-UHFFFAOYSA-N 0.000 description 1
- VNEDXWYHPUQYCK-UHFFFAOYSA-N COC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=CC=CC=C2)=C1 Chemical compound COC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=CC=CC=C2)=C1 VNEDXWYHPUQYCK-UHFFFAOYSA-N 0.000 description 1
- HYTDLRLCVTXBIB-UHFFFAOYSA-N COC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound COC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 HYTDLRLCVTXBIB-UHFFFAOYSA-N 0.000 description 1
- GQBOWWOZQUDQTM-UHFFFAOYSA-N COc1cc(CCNc2nc(Nc3ccc4N[I]=Cc4c3)c3[s]ccc3n2)ccc1 Chemical compound COc1cc(CCNc2nc(Nc3ccc4N[I]=Cc4c3)c3[s]ccc3n2)ccc1 GQBOWWOZQUDQTM-UHFFFAOYSA-N 0.000 description 1
- DKIPYGFGYOTLFI-UHFFFAOYSA-N CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C(C)(C)C)=N1 Chemical compound CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C(C)(C)C)=N1 DKIPYGFGYOTLFI-UHFFFAOYSA-N 0.000 description 1
- HDNBODDGYMYCOS-UHFFFAOYSA-N CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=NC=CC=C2)=N1 Chemical compound CSC1=NC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=NC(C2=NC=CC=C2)=N1 HDNBODDGYMYCOS-UHFFFAOYSA-N 0.000 description 1
- GDXQXKYVDFJNSQ-UHFFFAOYSA-N C[n]1nc(C2CC2)cc1NC([I]=C1Nc2ccc3[nH]ncc3c2)=Nc2c1[s]cc2 Chemical compound C[n]1nc(C2CC2)cc1NC([I]=C1Nc2ccc3[nH]ncc3c2)=Nc2c1[s]cc2 GDXQXKYVDFJNSQ-UHFFFAOYSA-N 0.000 description 1
- PBHKWIHPJIOQFN-UHFFFAOYSA-N ClC1=C(N2CCOCC2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound ClC1=C(N2CCOCC2)C=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 PBHKWIHPJIOQFN-UHFFFAOYSA-N 0.000 description 1
- HCUBASBTMMZUPU-UHFFFAOYSA-N ClC1=CC(Cl)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound ClC1=CC(Cl)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 HCUBASBTMMZUPU-UHFFFAOYSA-N 0.000 description 1
- WWEJIZIKCFFVTL-UHFFFAOYSA-N ClC1=CC2=C(C=C1)OC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=N2 Chemical compound ClC1=CC2=C(C=C1)OC(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)=N2 WWEJIZIKCFFVTL-UHFFFAOYSA-N 0.000 description 1
- JWPXLGSRPNFADF-UHFFFAOYSA-N ClC1=CC=C(C2=CSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1 Chemical compound ClC1=CC=C(C2=CSC(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)=N2)C=C1 JWPXLGSRPNFADF-UHFFFAOYSA-N 0.000 description 1
- XWQXNHLJOWNXDN-UHFFFAOYSA-N ClC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound ClC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 XWQXNHLJOWNXDN-UHFFFAOYSA-N 0.000 description 1
- OPBUMIBJXVBSRN-UHFFFAOYSA-N ClC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound ClC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 OPBUMIBJXVBSRN-UHFFFAOYSA-N 0.000 description 1
- URFQABJIYGLVSI-UHFFFAOYSA-N ClC1=CC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 Chemical compound ClC1=CC=C(OC2=CC=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)C=C2)C=C1 URFQABJIYGLVSI-UHFFFAOYSA-N 0.000 description 1
- NFEVBKOAOVYROZ-UHFFFAOYSA-N ClC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound ClC1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 NFEVBKOAOVYROZ-UHFFFAOYSA-N 0.000 description 1
- VIILLCLNVSHWEG-UHFFFAOYSA-N ClC1=NC(/C2=C/C3=C(C=CC=C3)S2)=NC2=NC=CC=C12 Chemical compound ClC1=NC(/C2=C/C3=C(C=CC=C3)S2)=NC2=NC=CC=C12 VIILLCLNVSHWEG-UHFFFAOYSA-N 0.000 description 1
- KTUSZYRIKRSQDY-UHFFFAOYSA-N ClC1=NC(C2=CN=C3C=CC=CC3=N2)=NC2=C1SC=C2 Chemical compound ClC1=NC(C2=CN=C3C=CC=CC3=N2)=NC2=C1SC=C2 KTUSZYRIKRSQDY-UHFFFAOYSA-N 0.000 description 1
- AQECFYPZMBRCIA-UHFFFAOYSA-N ClC1=NC2=C(SC=C2)C(Cl)=N1 Chemical compound ClC1=NC2=C(SC=C2)C(Cl)=N1 AQECFYPZMBRCIA-UHFFFAOYSA-N 0.000 description 1
- JXBQZJFEMKROTK-UHFFFAOYSA-N ClC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound ClC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 JXBQZJFEMKROTK-UHFFFAOYSA-N 0.000 description 1
- XVEVLTZRLLPLLH-UHFFFAOYSA-N ClC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound ClC1=NC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 XVEVLTZRLLPLLH-UHFFFAOYSA-N 0.000 description 1
- IKAPCBKKDJHLHH-UHFFFAOYSA-N ClC1=NC=CC=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound ClC1=NC=CC=C1NC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 IKAPCBKKDJHLHH-UHFFFAOYSA-N 0.000 description 1
- GBZFNIMKWXDXTP-UHFFFAOYSA-N FC(F)(F)C1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound FC(F)(F)C1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 GBZFNIMKWXDXTP-UHFFFAOYSA-N 0.000 description 1
- YPEBOWSSDQWOTD-UHFFFAOYSA-N FC(F)(F)C1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.FC(F)(F)OC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=C(F)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+]([O-])C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC(F)(F)C1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1.FC(F)(F)OC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.FC1=C(F)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1.O=[N+]([O-])C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 YPEBOWSSDQWOTD-UHFFFAOYSA-N 0.000 description 1
- DRYWXGZGAKQGAA-UHFFFAOYSA-N FC(F)(F)C1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound FC(F)(F)C1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 DRYWXGZGAKQGAA-UHFFFAOYSA-N 0.000 description 1
- DEBUATKNJBXSKE-UHFFFAOYSA-N FC(F)(F)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound FC(F)(F)C1=CC=CC(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 DEBUATKNJBXSKE-UHFFFAOYSA-N 0.000 description 1
- MXSNODXSWLCMJB-UHFFFAOYSA-N FC(F)(F)C1=CC=NN1C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC(F)(F)C1=CC=NN1C1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 MXSNODXSWLCMJB-UHFFFAOYSA-N 0.000 description 1
- QGCYMEQUNBTFOP-UHFFFAOYSA-N FC(F)(F)C1=NN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 Chemical compound FC(F)(F)C1=NN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)S1 QGCYMEQUNBTFOP-UHFFFAOYSA-N 0.000 description 1
- NXZBGEWMDHHQGY-UHFFFAOYSA-N FC(F)(F)OC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC(F)(F)OC1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 NXZBGEWMDHHQGY-UHFFFAOYSA-N 0.000 description 1
- ZSQFMCLZDUVPAM-UHFFFAOYSA-N FC(F)(F)OC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC(F)(F)OC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 ZSQFMCLZDUVPAM-UHFFFAOYSA-N 0.000 description 1
- PIKBLFGLUAZKRQ-UHFFFAOYSA-N FC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 Chemical compound FC1=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=CC=C1 PIKBLFGLUAZKRQ-UHFFFAOYSA-N 0.000 description 1
- JFADRESJYCVGDY-UHFFFAOYSA-N FC1=C(F)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC1=C(F)C=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 JFADRESJYCVGDY-UHFFFAOYSA-N 0.000 description 1
- OSABSBVBDNJCIG-UHFFFAOYSA-N FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C(F)C=C1 Chemical compound FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C(F)C=C1 OSABSBVBDNJCIG-UHFFFAOYSA-N 0.000 description 1
- BEUHDYITCIXINS-UHFFFAOYSA-N FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C(F)(F)F)=C1 Chemical compound FC1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC(C(F)(F)F)=C1 BEUHDYITCIXINS-UHFFFAOYSA-N 0.000 description 1
- WRBDHRTTXPRHSH-UHFFFAOYSA-N FC1=CC(F)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound FC1=CC(F)=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 WRBDHRTTXPRHSH-UHFFFAOYSA-N 0.000 description 1
- MBSHRYLEVKPRLA-UHFFFAOYSA-N FC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 Chemical compound FC1=CC2=C(C=C1)N=C(NC1=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N1)S2 MBSHRYLEVKPRLA-UHFFFAOYSA-N 0.000 description 1
- ARBLOBGESCQWQP-UHFFFAOYSA-N FC1=CC2=C(C=C1)NC=C2CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound FC1=CC2=C(C=C1)NC=C2CCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 ARBLOBGESCQWQP-UHFFFAOYSA-N 0.000 description 1
- FMDJMRBYYXWLGR-UHFFFAOYSA-N FC1=CC2=C(N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)S2)C(F)=C1 Chemical compound FC1=CC2=C(N=C(NC3=NC4=C(SC=C4)C(NC4=CC5=C(C=C4)NN=C5)=N3)S2)C(F)=C1 FMDJMRBYYXWLGR-UHFFFAOYSA-N 0.000 description 1
- DAOWKVRWFJBYAQ-UHFFFAOYSA-N FC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound FC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 DAOWKVRWFJBYAQ-UHFFFAOYSA-N 0.000 description 1
- FBCJAZLWFTWOEY-UHFFFAOYSA-N FC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 Chemical compound FC1=CC=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=C1 FBCJAZLWFTWOEY-UHFFFAOYSA-N 0.000 description 1
- OUCMHFQMVMZWGQ-UHFFFAOYSA-N N#CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound N#CC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 OUCMHFQMVMZWGQ-UHFFFAOYSA-N 0.000 description 1
- VRJPEHZUCRVBSK-UHFFFAOYSA-N NC(=O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 Chemical compound NC(=O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 VRJPEHZUCRVBSK-UHFFFAOYSA-N 0.000 description 1
- FHCNTCINOXNXLI-UHFFFAOYSA-N NC(=O)C1=CC=CN=C1NC(=O)/C1=C/C2=C(C=CC=C2)S1 Chemical compound NC(=O)C1=CC=CN=C1NC(=O)/C1=C/C2=C(C=CC=C2)S1 FHCNTCINOXNXLI-UHFFFAOYSA-N 0.000 description 1
- UURQINISCFSPEH-UHFFFAOYSA-N NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3[SH]=CCC3=N2)=CC=C1 Chemical compound NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3[SH]=CCC3=N2)=CC=C1 UURQINISCFSPEH-UHFFFAOYSA-N 0.000 description 1
- YCBXIRPRDFBICG-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound NS(=O)(=O)C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 YCBXIRPRDFBICG-UHFFFAOYSA-N 0.000 description 1
- QPZWDCOQFBHSQT-UHFFFAOYSA-N Nc1cc(-c(nc2Nc3ccc4[nH]ncc4c3)nc3c2S=CC3)ccc1 Chemical compound Nc1cc(-c(nc2Nc3ccc4[nH]ncc4c3)nc3c2S=CC3)ccc1 QPZWDCOQFBHSQT-UHFFFAOYSA-N 0.000 description 1
- YKOKRQGCMCXUNG-UHFFFAOYSA-N O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1 Chemical compound O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3SC=CC3=N2)=CC=C1)C1=CC=NC=C1 YKOKRQGCMCXUNG-UHFFFAOYSA-N 0.000 description 1
- VFRMWDQEHAOULM-UHFFFAOYSA-N O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3[SH]=CCC3=N2)=CC=C1)C1=CC=NC=C1 Chemical compound O=C(NC1=CC(C2=NC(NC3=CC4=C(C=C3)NN=C4)=C3[SH]=CCC3=N2)=CC=C1)C1=CC=NC=C1 VFRMWDQEHAOULM-UHFFFAOYSA-N 0.000 description 1
- FPBBRCDRXSTXDL-UHFFFAOYSA-N O=C(O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 Chemical compound O=C(O)C1=C(NC(=O)C2=CN=C3C=CC=CC3=N2)C=CS1 FPBBRCDRXSTXDL-UHFFFAOYSA-N 0.000 description 1
- AYJXFQZSODZYKJ-UHFFFAOYSA-N O=C(O)C1=CC=CN=C1NC(=O)/C1=C/C2=C(C=CC=C2)S1 Chemical compound O=C(O)C1=CC=CN=C1NC(=O)/C1=C/C2=C(C=CC=C2)S1 AYJXFQZSODZYKJ-UHFFFAOYSA-N 0.000 description 1
- WPPLAJADAQYNPQ-UHFFFAOYSA-N O=C1NC2=C(C=CC=C2)N1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound O=C1NC2=C(C=CC=C2)N1C1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 WPPLAJADAQYNPQ-UHFFFAOYSA-N 0.000 description 1
- DBVZIPOGYQOMSV-UHFFFAOYSA-N O=[N+]([O-])C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 Chemical compound O=[N+]([O-])C1=CC(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)=CC=C1 DBVZIPOGYQOMSV-UHFFFAOYSA-N 0.000 description 1
- NRXZSBZRFZUJMA-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound O=[N+]([O-])C1=CC=C(CNC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 NRXZSBZRFZUJMA-UHFFFAOYSA-N 0.000 description 1
- FDJPTGFKWCIKOP-UHFFFAOYSA-N O=[N+]([O-])C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound O=[N+]([O-])C1=CN=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 FDJPTGFKWCIKOP-UHFFFAOYSA-N 0.000 description 1
- PVCSELWCLKDKAH-UHFFFAOYSA-N OC1=NC(/C2=C/C3=C(C=CC=C3)S2)=NC2=NC=CC=C12 Chemical compound OC1=NC(/C2=C/C3=C(C=CC=C3)S2)=NC2=NC=CC=C12 PVCSELWCLKDKAH-UHFFFAOYSA-N 0.000 description 1
- HNMBNHDWYBJZSZ-UHFFFAOYSA-N OC1=NC(C2=CN=C3C=CC=CC3=N2)=NC2=C1SC=C2 Chemical compound OC1=NC(C2=CN=C3C=CC=CC3=N2)=NC2=C1SC=C2 HNMBNHDWYBJZSZ-UHFFFAOYSA-N 0.000 description 1
- FKOXFLCICMLKKI-UHFFFAOYSA-N OC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound OC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 FKOXFLCICMLKKI-UHFFFAOYSA-N 0.000 description 1
- IOMJPWLUIGLVHV-UHFFFAOYSA-N OCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound OCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 IOMJPWLUIGLVHV-UHFFFAOYSA-N 0.000 description 1
- ZMZKBMVSPVYPQG-UHFFFAOYSA-N OCCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 Chemical compound OCCC1=CC=C(NC2=NC3=C(SC=C3)C(NC3=CC4=C(C=C3)NN=C4)=N2)C=C1 ZMZKBMVSPVYPQG-UHFFFAOYSA-N 0.000 description 1
- BPISCNPRTUYEGN-UHFFFAOYSA-N OCCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 Chemical compound OCCNC1=NC2=C(SC=C2)C(NC2=CC3=C(C=C2)NN=C3)=N1 BPISCNPRTUYEGN-UHFFFAOYSA-N 0.000 description 1
- FHQIDGWZDOKKDI-UHFFFAOYSA-N [H]N(CC1=CC=C(B(O)O)C=C1)C1=CC=CC=C1 Chemical compound [H]N(CC1=CC=C(B(O)O)C=C1)C1=CC=CC=C1 FHQIDGWZDOKKDI-UHFFFAOYSA-N 0.000 description 1
- NTVJHRKYOWMSDE-UHFFFAOYSA-N [H]N(CC1=CC=C(C2=CC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=C2)C=C1)C1=CC=CC=N1 Chemical compound [H]N(CC1=CC=C(C2=CC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=C2)C=C1)C1=CC=CC=N1 NTVJHRKYOWMSDE-UHFFFAOYSA-N 0.000 description 1
- LSJCLEMNBKGNIA-UHFFFAOYSA-N [H]N(CC1=CC=C(C2=NC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=N2)C=C1)C1=CC=CC=N1 Chemical compound [H]N(CC1=CC=C(C2=NC3=C(SC=C3)C(N([H])C3=CC4=C(C=C3)N([H])N=C4)=N2)C=C1)C1=CC=CC=N1 LSJCLEMNBKGNIA-UHFFFAOYSA-N 0.000 description 1
- RRZPPHRGDCRYJQ-UHFFFAOYSA-N [H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(O)=C3)=NC3=C1C(C)=CO3)=C2 Chemical compound [H]N1N=CC2=C1C=CC(N([H])C1=NC(C3=CC=CC(O)=C3)=NC3=C1C(C)=CO3)=C2 RRZPPHRGDCRYJQ-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N c1n[nH]c2ccccc12 Chemical compound c1n[nH]c2ccccc12 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
- the pathology of a number of human and animal diseases including hypertension, erectile dysfunction, coronary cerebral circulatory impairments, neurodegenerative disorders and cancer can be linked directly to changes in the actin cytoskeleton. These diseases pose a serious unmet medical need.
- the actin cytoskeleton is composed of a meshwork of actin filaments and actin-binding proteins found in all eukaryotic cells. In smooth muscle cells the assembly and disassembly of the actin cytoskeleton is the primary motor force responsible for smooth muscle contraction and relaxation.
- Rho Ras superfamily of GTPases. This subset currently consists of RhoA through E and RhoG (refereed to collectively as Rho), Rac 1 and 2, Cdc42Hs and G25K and TC10 isoforms (Mackay, et al. J Biol Chem 1998, 273, 20685).
- Rho RhoA
- RhoG RhoG
- Cdc42Hs Cdc42Hs
- G25K G25K
- TC10 TC10 isoforms
- Rho proteins controls the formation of actin stress fibers, thick bundles of actin filaments, and the clustering of integrins at focal adhesion complexes.
- Rac proteins control the formation of lamellopodia or membrane ruffles on the cell surface and Cdc42 controls filopodia formation.
- This family of proteins plays a critical part in the control of key cellular functions including cell movement, axonal guidance, cytokinesis, and changes in cell morphology, shape and polarity.
- Rho proteins can control different biological responses.
- Rho proteins are responsible for the calcium sensitization during smooth muscle contraction.
- the Rho GTPases are responsible for the cellular responses to agonist such as lysophosphatidic acid (LPA), thrombin and thromboxane A 2 (Fukata, et al. Trends Pharcol Sci 2001, 22, 32).
- LPA lysophosphatidic acid
- thrombin thrombin
- thromboxane A 2 thromboxane A 2
- Agonist response is coupled through heterotrimeric G proteins G alpha12 or G alpha13 (Goetzl, et al. Cancer Res 1999, 59, 4732; Buhl, et al. J Biol Chem 1995, 270, 24631) though other receptors maybe involved.
- Rho GTPases Upon activation Rho GTPases activate a number of downstream effectors including PIP5-kinase, Rhothekin, Rhophilin, PKN and Rho kinase isoforms ROCK-1/ROKbeta and ROCK-1/ROKalpha (Mackay and Hall J Biol Chem 1998, 273, 20685; Aspenstrom Curr Opin Cell Biol 1999, 11, 95; Amano, et al. Exp Cell Res 2000, 261, 44).
- Rho kinase was identified as a RhoA interacting protein isolated from bovine brain (Matsui, et al. Embo J 1996, 15, 2208). It is a member of the myotonic dystrophy family of protein kinase and contains a serine/threonine kinase domain at the amino terminus, a coiled-coil domain in the central region and a Rho interaction domain at the carboxy terminus (Amano, et al. Exp Cell Res 2000, 261, 44). Its kinase activity is enhanced upon binding to GTP-bound RhoA and when introduced into cells, it can reproduce many of the activities of activated RhoA.
- Rho kinase mediates calcium sensitization and smooth muscle contraction and inhibition of Rho kinase blocks 5-HT and phenylephrine agonist induced muscle contraction.
- Rho kinase When introduced into non-smooth muscle cells, Rho kinase induces stress fiber formation and is required for the cellular transformation mediated by RhoA (Sahai, et al. Curr Biol 1999 9 136).
- Rho kinase regulates a number of downstream proteins through phosphorylation, including myosin light chain (Somlyo, et al. J Physiol (Lond) 2000, 522 Pt 2, 177), the myosin light chain phosphatase binding subunit (Fukata, et al. J Cell Biol 1998, 141, 409) and LIM-kinase 2 ( Sumi, et al. J Bio Chem 2001, 276, 670).
- Rho kinase inhibitors for the treatment of human diseases.
- Several patents have appeared claiming (+)-trans-4-(1-aminoethyl)- 1 -(pyridin-4-ylaminocarbonyl)cyclohexane dihydrochloride monohydrate (WO-00078351, WO-00057913) and substituted isoquinolinesulfonyl (EP-00187371) compounds as Rho kinase inhibitors with activity in animal models.
- cardiovascular diseases such as hypertension (Uehata, et al.
- Rho kinase activity has benefits for controlling cerebral vasospasms and ischemia following subarachnoid hemorrhage ( Pharma Japan 199, 1470, 16).
- Rho Kinase inhibitors are useful as Rho Kinase inhibitors and thus have utilities in the treatment of hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, neuronal degeneration, spinal cord injury, cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases, thrombotic disorders, asthma, glaucoma and osteoporosis.
- the compounds of the invention are useful to treat erectile dysfunction, i.e., erectile dysfunction mediated by Rho-kinase.
- Erectile dysfunction can be defined as an inability to obtain or sustain an erection adequate for intercourse, WO 94/28902, U.S. Pat. No. 6,103,765 and U.S. Pat. No. 6,124,461.
- X is —(CH 2 ) x —, —O—(CH 2 ) n —, —S—(CH 2 ) n —, —NR 7 —CO—(CH 2 ) n —, —NR 7 —SO 2 —(CH 2 ) n —, —NR 7 —(CH 2 ) n —, or —(O)C—NR 7 —,
- each n is an integer which is independently 0, 1, 2 or 3,
- a and c are each independently —CR 5 ⁇ , —N ⁇ , or —NR 6 —, wherein one of a or c is —NR 6 —, and b is —CR 5 ⁇ or —N ⁇ ;
- A is H, halogen, —CO—OR 8 , —CO—R 8 , cyano, —OR 8 , —NR 8 R 9 , —CO—NR 8 R 9 , —NR 8 —CO—R 9 , —NR 8 —CO—OR 9 , —NR 8 —SO 2 —R 9 , —SR 8 , —SO 2 —R 8 , —SO 2 —NR 8 R 9 , NR 8 —CO—NHR 9 , or
- A is a 3-20 atom, preferably 5-15 atom, cyclic or polycyclic moiety, e.g., containing 1-4 rings, which optionally contain 1-3 N, O or S atoms per ring, and may optionally be aryl or heteroaryl.
- A may optionally be substituted up to 3 times by (i) C 1 -C 10 alkyl or C 2 -C 10 -alkenyl, each optionally substituted with halogen up to perhalo; (ii) C 3 -C 10 cycloalkyl; (iii) optionally substituted aryl; (iv) optionally substituted heteroaryl; (v) halogen; (vi) —CO—OR 8 ; (vii) —CO—R 8 ; (viii) cyano; (ix) —OR 8 , (x) —NR 8 R 13 ; (xi) nitro; (xii) —CO—NR 8 R 9 ; (xiii) —C 1 -C 10 -alkyl-NR 8 R 9 ; (xiv) —NR 8 —CO—R 12 ; (xv) —NR 8 —CO—OR 9 ; (xvi) —NR 8 —SO 2 —R 9 ;
- Ring B represents a fused 5- or 6-membered heterocyclic ring containing 1-2 O, N, and/or S atoms and 1-5 C atoms.
- R 1 , and R 6 -R 11 are each independently H and C 1-6 alkyl
- R 2 -R 5 are each independently (i) C 1-10 alkyl or C 2-10 -alkenyl each optionally substituted by amino, N-lower alkylamino, N,N-dilower alkylamino, N-lower alkanoylamino, hydroxy, cyano, —COOR 10 , —COR 14 , —OCOR 14 , —OR 10 , C 5-10 -heteroaryl, C 5-10 -heteroaryloxy, C 5-10 -heteroaryl-C 1-10 -alkoxy, or halogen up to perhalo; (ii) C 3 -C 10 cycloalkyl, in which 1-3 carbon atoms are optionally independently replaced by O, N or S; (iii) C 3-10 -cycloalkenyl; (iv) partially unsaturated C 5-10 -heterocyclyl; (v) aryl; (vi) heteroaryl; (vii)
- R 12 is H, C 1-6 -alkyl or C 5-10 -aryl
- R 13 is H, C 1-6 -alkyl or C 1-6 -alkoxy
- R 14 is lower alkyl or phenyl
- R 15 is lower alkyl, halogen, amino, N-lower alkyl amino, N,N-dilower alkylamino N-lower alkanoylamino, OH, CN, COOR 10 , —COR 14 or —OCOR 14 ;
- R 16 is hydrogen, C 1-6 -alkyl optionally substituted by halogen, up to perhalo, or C 5-10 -heteroaryl;
- —X-A is not CH 3 when B represents a thieno[3,2b]fused ring, and b and c are —CR 5 ⁇ , and a is NH;
- A is not phenyl when X is NH, B forms an imidazo fused ring, and -a-b-c- is —CR 5 ⁇ N—NR 6 — or —NR 6 ⁇ N—CR 5 —.
- suitable aryl or heteroaryl groups include, but are not limited to, 5-12 carbon-atom aromatic rings or ring systems containing 1-3 rings, at least one of which is aromatic, in which one or more, e.g., 1-4 carbon atoms in one or more of the rings can be replaced by oxygen, nitrogen or sulfur atoms.
- Each ring typically has 3-7 atoms.
- aryl or heteroaryl can be 2- or 3-furyl, 2- or 3-thienyl, 2- or 4-triazinyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or 5-yl, 1,2,4-triazol-1-, -3- or B5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-thiadiazol-2- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-thiadiazol-2- or
- Preferred moieties A include cyclohexyl; or C 5-12 -aryl or C 5-12 -heteroaryl each independently optionally substituted up to three times by (i) C 1 -C 10 -alkyl or C 2-10 -alkenyl each optionally substituted with halogen up to perhalo; (ii) C 3 -C 10 cycloalkyl; (iii) C 5-12 -aryl optionally substituted by 1-3 halogen atoms; (iv) C 5-12 -heteroaryl; (v) halogen; (vi) —CO—OR 8 ; (vii) —CO—R 8 ; (viii) cyano; (ix) —OR 8 ; (x) —NR 8 R 13 ; (xi) nitro; (xii) —CO—NR 8 R 9 ; (xiii) —C 1-10 -alkyl-NR 8 R 9 ; (xiv) ——
- moieties A include phenyl, pyridyl, pyrimidinyl, oxazolyl, furyl, thienyl, pyrrolyl, imidazolyl, isoxazolyl and pyrazinyl, each independently substituted up to three times by halogen, C 1-10 -alkyl, C 1-10 -alkoxyphenyl, naphthyl, —OR 10 ,
- each Z independently is halogen, hydroxy, hydroxy-C 1-10 -alkyl, —CN, —NO 2 , C 1-10 -alkoxycarboxyl, —NR 10 —CO—R 11 , or —NR 10 —CO—OR 11 , as well as OR 10 , y is 0-3, more preferably 1-3, and R 4 is as described above.
- Preferred moieties A additionally include
- R 15 is H; phenyl optionally substituted by C 1-10 -alkyl, C 1-10 -alkoxy, C 1-10 -alkylcarboxyl, or halogen; benzyl; pyrimidyl or pyridyl; and R 16 is H, phenyl, —COOR 10 ,
- Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, sulphonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicyclic acid, phenylacetic acid, and mandelic acid.
- basic salts of inorganic and organic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, sulphonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicyclic
- pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li + , Na + or K + ), alkaline earth cations (e.g., Mg + , Ca + or Ba + ), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations, such as those arising from protonation or peralkylation of triethylamine, N,N-diethylamine, N,N-dicyclohexylamine, pyridine, N,N-dimethylaminopyridine (DMAP), 1,4-diazabiclo[2.2.2]octane (DABCO), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
- a number of the compounds of Formula I possess asymmetric carbons and can therefore exist in racemic and optically active forms. Methods of separation of enantiomeric and diastereomeric mixtures are well known to one skilled in the art.
- the present invention encompasses any isolated racemic or optically active form of compounds described in Formula I which possess Rho-kinase inhibitory activity.
- the invention also includes pharmaceutical compositions including a compound of Formula I, and a physiologically acceptable carrier.
- the invention moreover encompasses treating indications mediated by Rho-kinase, by administering a compound of Formula I, or a pharmaceutical composition containing a compound of Formula I.
- cardiovascular diseases such as hypertension, artherosclerosis, restenosis and cerebral ischemia, or vasospasm central nervous system disorders such as neuronal degeneration and spinal cord injury, erectile dysfunction, e.g., in patients who do not have satisfactory response to PDE-5 inhibitors, and cancer (e.g., tumor growth) mediated by Rho-kinase, by administering, e.g., to a host in need thereof, of an effective amount of a compound of Formula I.
- Cancers and tumors mediated by Rho-kinase include cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
- a number of the compounds of Formula I possess asymmetric carbons and can therefore exist in racemic and optically active forms. Methods of separation of enantiomeric and diastereomeric mixtures are well known to one skilled in the art.
- the present invention encompasses any isolated racemic or optically active form of compounds described in Formula I which possess Rho-kinase inhibitory activity.
- the invention also includes pharmaceutical compositions including a compound of Formula I, and a physiologically acceptable carrier.
- the invention moreover encompasses treating indications mediated by Rho-kinase, by administering a compound of Formula I, or a pharmaceutical composition containing a compound of Formula I.
- cardiovascular diseases such as hypertension, artherosclerosis, restenosis and cerebral ischemia, or vasospasm central nervous system disorders such as neuronal degeneration and spinal cord injury, erectile dysfunction, e.g., in patients who do not have satisfactory response to PDE-5 inhibitors, and cancer (e.g., tumor growth) mediated by Rho-kinase, by administering, e.g., to a host in need thereof, of an effective amount of a compound of Formula I.
- Cancers and tumors mediated by Rho-kinase include cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
- the compounds may be administered orally, topically, parenterally, by inhalation or spray, vaginally, rectally or sublingually in dosage unit formulations.
- administration by injection includes intravenous, intraarticular, intramuscular, subcutaneous and parenteral injections, as well as use of infusion techniques.
- Dermal administration may include topical application or transdermal administration.
- One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and if desired other active ingredients.
- compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions.
- Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- These compounds may also be prepared in solid, rapidly released form.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions containing the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions may also be used.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl, or n-propyl p-hydroxybenzoate
- coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
- flavoring agents for example ethyl, or n-propyl p-hydroxybenzoate
- sweetening agents such as sucrose or saccharin.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., sodium EDTA
- suspending agent e.g., sodium EDTA
- preservatives e.g., sodium EDTA, sodium sulfate, sodium bicarbonate
- the compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Compounds of the invention may also be administrated transdermally using methods known to those skilled in the art (see, for example: Chien; “Transdermal Controlled Systemic Medications”; Marcel Dekker, Inc.; 1987. Lipp et al. WO94/04157 Mar. 3, 1994).
- a solution or suspension of a compound of Formula I in a suitable volatile solvent optionally containing penetration enhancing agents can be combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms.
- a solution or suspension of a compound of Formula I may be formulated into a lotion or salve.
- Suitable solvents for processing transdermal delivery systems are known to those skilled in the art, and include lower alcohols such as ethanol or isopropyl alcohol, lower ketones such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotrifluoroethane, or trichlorofluoroethane.
- Suitable solvents may also include mixtures of one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar ethers, lower hydrocarbons, halogenated hydrocarbons.
- Suitable penetration enhancing materials for transdermal delivery system include, for example, monohydroxy or polyhydroxy alcohols such as ethanol, propylene glycol or benzyl alcohol, saturated or unsaturated C 8 -C 18 fatty alcohols such as lauryl alcohol or cetyl alcohol, saturated or unsaturated C 8 -C 18 fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tertbutyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid or palmitic acid, or diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons such as diisopropyl adipate, diisobutyl adipate,
- Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl isosorbid and diethyleneglycol monoethyl ether.
- Suitable penetration enhancing formulations may also include mixtures of one or more materials selected from monohydroxy or polyhydroxy alcohols, saturated or unsaturated C 8 -C 18 fatty alcohols, saturated or unsaturated C 8 -C 18 fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated discarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.
- Suitable binding materials for transdermal delivery systems include polyacrylates, silicones, polyurethanes, block polymers, styrenebutadiene copolymers, and natural and synthetic rubbers.
- Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix.
- compositions of the invention may also be in the form of oil-in-water emulsions.
- the oil phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example, gum acacia or gum tragacanth, naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- the compounds may also be administered in the form of suppositories for rectal or vaginal administration of the drug.
- compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature or vaginal temperature and will therfore melt in the rectum or vagina to release the drug.
- suitable non-irritating excipient include cocoa butter and polyethylene glycols.
- the present pharmaceutical compositions may take any form which is suitable for administration to the penis either via injection into the corpora cavernosa or transurethral administration, or topically applied to the urethral meatus.
- the pharmaceutical composition is suitably in the form of a saline solution.
- the pharmaceutical composition is in a form suitable for transurethral administration, and in this case the composition is typically in the form of a solution, an ointment, or a suppository.
- the pharmaceutical composition is administered 1 to 50 minutes, preferably 10 to 20 minutes, prior to the time of commencing sexual intercourse.
- the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily dosage for administration by injection including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily vaginal dosage regime will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily topical dosage regimen will preferably be from 0.01 to 200 mg administered between one to four times daily.
- the transdermal concentration will preferably be that required to maintain a daily dose is of from 0.1 to 200 mg/Kg.
- the daily inhalation dosage regimen will preferably be from 0.01 to 10 mg/Kg of total body weight.
- the optimal course of treatment i.e., the mode of treatment and the daily number of doses of a compound of Formula I or a pharmaceutically acceptable salt thereof given for a defined number of days, can be ascertained by those skilled in the art using conventional treatment tests.
- the present compounds and compositions exhibit Rho-kinase inhibitory activity, and are thus useful to treat the indications listed above, e.g., indications mediated by Rho-kinase.
- indications mediated by Rho-kinase is meant diseases or conditions whose progression proceeds, at least in part, via the Rho pathway.
- Rho-kinase inhibitory activity e.g., ROCK-1 inhibition
- ROCK-1 inhibition can be evaluated as follows:
- the kinase domain of human ROCK-1, amino acids 27-530, is isolated as a glutathione S-transferase fusion protein from Sf9 insect cells.
- the protein is partially purified by glutathione Sepharose 4B (Pharmacia Biotech, Piscataway, N.J.) affinity purification.
- Reactions is carried out in 96-well plates in a total volume of 100 uL containing 50 mM N-[2-Hydoryethyl]piperaxine-N′-[2-ethanesulfonic acid] pH 7.5, 5 mM MgCl 2 , 1 mM dithiothreitol, 6 ⁇ M ATP, 0.2 ⁇ Ci [ 33 P]ATP (NEN, Boston, Mass.), 1 ⁇ g myelin basic protein and 0.1 ⁇ g ROCK-1. Test compounds are dissolved in 100% dimethylsulfoxide, diluted to the appropriated concentration and added to the reaction. The final concentration of dimethylsulfoxide did not exceed 0.5%. The reaction is run for one hour at room temperature.
- the reaction is stopped with the addition of 7 mL of 1 N HCL, transferred to P30 membranes and the amount of [ 33 P]ATP, as counts per minute (c.p.m.) incorporated into the substrate, myelin basic protein, is read in a BetaPlate Reader (Packard Instrument Co., Meriden, Conn.). (All reagents were purchased from Sigma Chemical Co., St. Louis, Mo. unless stated otherwise.) Percentage inhibition is measured by the amount of incorporation of radioactivity in the presence of the test compound when compared to the amount of incorporation in the absence of the test compound.
- Inhibitory activity can also be evaluated by measurement of stress fiber formation, performed essentially as described by Ridley, A. J., and A. Hall, Cell 70:389-399 (1992).
- Human fibrosarcoma HT1080 (CCL-121, American Type Culture Collection, Manassas, Va.) cells are plated on 22 ⁇ 22 mm #1 glass cover slips in six-well tissue culture plates (Costar) at 2.5 ⁇ 10 4 cells/well in Delbeco's modified Eagle's Medium (DMEM, Gibco) supplemented with 10% fetal calf serum. Cells are maintained in a humidified, 5% CO 2 atmosphere at 37° C.
- DMEM Delbeco's modified Eagle's Medium
- test compounds are dissolved in 100% dimethylsulfoxide, diluted to the appropriated concentration and added to the culture medium 60 minutes prior to the induction of stress fiber formation. The final concentration of dimethylsulfoxide did not exceed 0.25%.
- Stress fiber formation is induced by the addition of lysophosphatidic acid (1-oleoyl-2-hydroxy-sn-glycerol-3-phosphate, Avanti Polar-Lipids, Alabaster, Ala.) to 10 ⁇ M final concentration in Delbeco's modified Eagle's Medium containing 0.1% fatty acid free bovine serum albumin for 15 minutes at 37° C.
- Cells are fixed with 4% paraformaldeyhde (Poly Scientific, Bay Shore, N.J.) in phosphate buffered saline (PBS) for 15 minutes. Cells are then washed 3 times in PBS and them permeabilized using a solution containing 40 mM piperazine-N-N′bis[2-ethanesulfonic acid], 50 mM N-[2-hydoryethyl]piperaxine-N′-[2-ethanesulfonic acid], 0.1% Triton X-100, 75 mM NaCl, mM MgCl 2 , 0.5 mM EGTA, pH 7.2 for 2 minutes at room temperature.
- PBS phosphate buffered saline
- the cells are washed 3 times for 5 minutes each in PBS and then actin stress fibers are stained using 10 units/mL rhodamine phalloidin (Molecular Probes, Eugene, Oreg.) in PBS for 60 minutes at room temperature.
- the cells are washed 3 times with PBS and the cover slips mounted on glass microscope slides.
- the percentage of stress fiber positive cells on each slide was determined visually using a Nikon Labphoto-2 microscope. At least 100 cells were counted per slide and experiments were done in duplicate. Percentage inhibition is measured by counting the number of stress fiber positive cells in the presence of the test compound when compared to the number of stress fiber positive cells in the absence of the test compound.
- the compounds of the invention can be made according to routine, conventional chemical methods, and/or as disclosed below, from starting materials which are either commercially available or produceable according to routine, conventional chemical methods. General methods for the preparation of the compounds are given below, and the preparation of representative compounds is specifically illustrated in the Examples.
- a mixture of compound 3 and a phenol, N-substituted amine, or N-substituted aniline (A-X—H. where X is O or NR 8 ) is heated to 140° C. for 2 hours. The mixture is cooled to room temperature and is treated with ether to form precipitate or purified by silica gel column chromatography. The precipitate is filtered, washed with ether several times, and is dried under high vacuum to provide product.
- a heterocyclic aminoester of Formula 6 is acylated with an aromatic acid chloride or anhydride, in a base such as pyridine.
- the amide ester product is converted to the amide acid of Formula 7 by hydrolysis, or if R′′ is methyl, by action of boron tribromide.
- Conversion of the acid to the amide of Formula 8 is accomplished by reaction of 7 with ammonia in the presence of catalysts such as DMAP and EDC. Cyclization to 9 may be carried out by heating the diamide 8 in the presence of a base such as sodium hydroxide.
- the chloro intermediate of Formula 10 is formed by treatment of 9 with a chlorinating agent such as phosphorous oxychloride.
- a cyanoheterocyclic amine of Formula 10 may be directly converted to compounds of Formula 4 by heating with a Vilsmeier reagent, prepared in situ by treatment of an aromatic N,N-dimethyl amide with a phosphorous oxychloride or oxalyl chloride and the like.
- Step 1 Preparation of 2,3-dichlorothieno[3,2-d]pyrimidine
- Step 2 Preparation of 4-(N-5-aminoindazole)-2-chloro-thieno[3,2-d]pyrimidine
- Step 3 Preparation of 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]-pyrimidin-4-amine
- N-BOC protected boronic acid used in step 3 BOC group was removed by TFA in CH 2 CL 2 at rt. Purified by silica gel column chromatography (gradient, EtOAc in hexanes from 10% to 75%); (45 mg, 19% yield); LCMS m/z 528 (M+M)+).
- Step 2 Preparation of N-(1H-indazol-5-yl)-N-(5- ⁇ 4-[(2-pyridinylamino)methyl]-phenyl ⁇ -1-benzothien-7-yl)amine
- Step 1 Preparation of methyl 3-[(2-guinoxalinylcarbonyl)amino]-2-thiophenecarboxylate
- Step 2 Preparation of 3-[(2-guinoxalinylcarbonyl)amino]-2-thiophenecarboxylic acid
- Step 3 Preparation of N-[2-(aminocarbonyl)-3-thienyl]-2-quinoxalinecarboxamide
- Step 6 Preparation of N-(1H-indazol-5-yl)-2-(2-quinoxalinyl)thieno[3,2-d]-pyrimidin-4-amine
- Step 2 Preparation of 4-chloro-2-(3-methoxyphenyl)-5-methylfuro[2,3-d]-pyrimidine
- the Vilsmeier Reagent was prepared by stirring of 3-methoxy-N,N-dimethylbenzamide (1.17 g, 7.9 mmol) and POCl 3 (3.0 g, 19.7 mmol) at 0° C. for 30 minutes. To this reagent was added 2-amino-4-methyl-3-furonitrile (1.0 g, 6.6 mmol) and dry dichloroethane (5.0 ml). The reaction mixture was heated to 40° C. and stirred at this temperature for 18 h. The mixture was then poured into ice water. After adjusting the pH of the solution to 9 via treatment with NaHCO 3 solution, the solution was extracted with dichloromethane. The organic layer was then dried and concentrated.
- Step 1 Preparation of 2-(3-aminophenyl)-N-(1H-indazol-5-yl)thieno[3,2-d]-pyrimidin-4-amine
- Step 2 Preparation of 2-(3-aminophenyl)-N-(1H-indazol-5-yl)thieno[3,2-d]-pyrimidin-4-amine
- Step 4 Preparation of 2-(1,1′-biphenyl-3-yl)-N-(3-methyl-1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine
- step 3 A procedure analogous for that of Example 1, step 3 was followed.
- a mixture of the step 3 product (0.4 g, 1.3 mmol), 3-phenylphenylboronic acid, (0.3 g, 1.5 mmol) and sodium bicarbonate (0.33 g, 3.9 mmol) in DME/H 2 O (3/1, 56 mL) was flushed with Ar for 1 h, and Pd(dppf)Cl 2 was added.
- the solution was heated to reflux for 48 h at 100° C.
- the crude product was purified by silica gel chromatography to afford a white solid (0.35 g, 65%).
- R 0.2 (EtOAc/hexane, 1/1).
- Step 1 Preparation of 2-[(1-benzothien-2-ylcarbonyl)amino]nicotinic acid
- Step 2 Preparation of 2-[(1-benzothien-2-ylcarbonyl)amino]nicotinamide
- Step 4 Preparation of 2-(1-benzothien-2-yl)-4-chloropyrido[2,3-d]pyrimidine
- Step 5 Preparation of N-[2-(1-benzothien-2-yl)pyrido[2,3-d]pyrimidin-4-yl]-N-(1H-indazol-5-yl)amine
- Step 2 Preparation of N-(2,2-dimethoxyethyl)-4-methyl-N-(3-thienylmethyl)-benzenesulfonamide
Abstract
Description
- The present invention relates to compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.
- The pathology of a number of human and animal diseases including hypertension, erectile dysfunction, coronary cerebral circulatory impairments, neurodegenerative disorders and cancer can be linked directly to changes in the actin cytoskeleton. These diseases pose a serious unmet medical need. The actin cytoskeleton is composed of a meshwork of actin filaments and actin-binding proteins found in all eukaryotic cells. In smooth muscle cells the assembly and disassembly of the actin cytoskeleton is the primary motor force responsible for smooth muscle contraction and relaxation. In non-muscle cells, dynamic rearrangements of the actin cytoskeleton are responsible for regulating cell morphology, cell motility, actin stress fiber formation, cell adhesion and specialized cellular functions such as neurite retraction, phagocytosis or cytokinesis (Van Aelst, et al.Genes Dev 1997, 11, 2295).
- The actin cytoskeleton is controlled by a family of proteins that are a subset of the Ras superfamily of GTPases. This subset currently consists of RhoA through E and RhoG (refereed to collectively as Rho), Rac 1 and 2, Cdc42Hs and G25K and TC10 isoforms (Mackay, et al.J Biol Chem 1998, 273, 20685). These proteins are GTP (guanine nucleotide triphosphate) binding proteins with intrinsic GTPase activity. They act as molecular switches and cycles between inactive GDP (guanine nucleotide diphosphate) bound and active GTP bound states. Using biochemical and genetic manipulations, it has been possible to assign functions to each family member. Upon activation the Rho proteins controls the formation of actin stress fibers, thick bundles of actin filaments, and the clustering of integrins at focal adhesion complexes. When activated the Rac proteins control the formation of lamellopodia or membrane ruffles on the cell surface and Cdc42 controls filopodia formation. Together this family of proteins plays a critical part in the control of key cellular functions including cell movement, axonal guidance, cytokinesis, and changes in cell morphology, shape and polarity.
- Depending on the cell type and the activating receptor, the Rho proteins can control different biological responses. In smooth muscle cells, Rho proteins are responsible for the calcium sensitization during smooth muscle contraction. In non-smooth muscle cells the Rho GTPases are responsible for the cellular responses to agonist such as lysophosphatidic acid (LPA), thrombin and thromboxane A2 (Fukata, et al. Trends Pharcol Sci 2001, 22, 32). Agonist response is coupled through heterotrimeric G proteins Galpha12 or Galpha13 (Goetzl, et al. Cancer Res 1999, 59, 4732; Buhl, et al. J Biol Chem 1995, 270, 24631) though other receptors maybe involved. Upon activation Rho GTPases activate a number of downstream effectors including PIP5-kinase, Rhothekin, Rhophilin, PKN and Rho kinase isoforms ROCK-1/ROKbeta and ROCK-1/ROKalpha (Mackay and Hall J Biol Chem 1998, 273, 20685; Aspenstrom Curr Opin Cell Biol 1999, 11, 95; Amano, et al. Exp Cell Res 2000, 261, 44).
- Rho kinase was identified as a RhoA interacting protein isolated from bovine brain (Matsui, et al.Embo J 1996, 15, 2208). It is a member of the myotonic dystrophy family of protein kinase and contains a serine/threonine kinase domain at the amino terminus, a coiled-coil domain in the central region and a Rho interaction domain at the carboxy terminus (Amano, et al. Exp Cell Res 2000, 261, 44). Its kinase activity is enhanced upon binding to GTP-bound RhoA and when introduced into cells, it can reproduce many of the activities of activated RhoA. In smooth muscle cells Rho kinase mediates calcium sensitization and smooth muscle contraction and inhibition of Rho kinase blocks 5-HT and phenylephrine agonist induced muscle contraction. When introduced into non-smooth muscle cells, Rho kinase induces stress fiber formation and is required for the cellular transformation mediated by RhoA (Sahai, et al. Curr Biol 1999 9 136). Rho kinase regulates a number of downstream proteins through phosphorylation, including myosin light chain (Somlyo, et al. J Physiol (Lond) 2000, 522 Pt 2, 177), the myosin light chain phosphatase binding subunit (Fukata, et al. J Cell Biol 1998, 141, 409) and LIM-kinase 2 ( Sumi, et al. J Bio Chem 2001, 276, 670).
- Inhibition of Rho kinase activity in animal models has demonstrated a number of benefits of Rho kinase inhibitors for the treatment of human diseases. Several patents have appeared claiming (+)-trans-4-(1-aminoethyl)- 1 -(pyridin-4-ylaminocarbonyl)cyclohexane dihydrochloride monohydrate (WO-00078351, WO-00057913) and substituted isoquinolinesulfonyl (EP-00187371) compounds as Rho kinase inhibitors with activity in animal models. These include models of cardiovascular diseases such as hypertension (Uehata, et al.Nature 1997, 389, 990), atherosclerosis (Retzer, et al. FEBS Lett 2000, 466, 70), restenosis (Eto, et al. Am J Physiol Heart Circ Physiol 2000, 278, H1744; Negoro, et al. Biochem Biophys Res Commun 1999, 262, 211), cerebral ischemia (Uehata, et al. Nature 1997, 389, 990; Seasholtz, et al. Circ Res 1999, 84, 1186; Hitomi, et al. Life Sci 2000, 67, 1929; Yamamoto, et al. J Cardiovasc Pharmacol 2000, 35, 203), cerebral vasospasm (Sato, et al. Circ Res 2000, 87, 195; Kim, et al. Neurosurgery 2000, 46, 440), penile erectile dysfunction (Chitaley, et al. Nat Med 2001, 7, 119), central nervous system disorders such as neuronal degeneration and spinal cord injury (Hara, et al. J Neurosurg 2000, 93, 94; Toshima, et al. Stroke 2000, 31, 2245) and in neoplasias where inhibition of Rho kinase has been shown to inhibit tumor cell growth and metastasis (Itoh, et al. Nat Med 1999, 5, 221; Somlyo, et al. Biochem Biophys Res Commun 2000, 269, 652), angiogenesis (Uchida, et al. Biochem Biophys Res Commun 2000, 269, 633; Gingras, et al. Biochem J2000, 348 Pt 2, 273), arterial thrombotic disorders such as platelet aggregation (Klages, et al. J Cell Biol 1999, 144, 745; Retzer, et al. Cell Signal 2000, 12, 645) and leukocyte aggregation (Kawaguchi, et al. Eur J Pharmacol 2000, 403, 203; Sanchez-Madrid, et al. Embo J 1999, 18, 501), asthma (Setoguchi, et al. Br J Pharmacol 2001, 132, 111; Nakahara, et al. Eur J Pharmacol 2000, 389, 103), regulation of intraoccular pressure (Honjo, et al. Invest Ophthalmol Vis Sci 2001, 42, 137) and bone resorption (Chellaiah, et al. J Biol Chem 2000, 275, 11993; Zhang, et al. J Cell Sci 1995, 108, 2285).
- The inhibition of Rho kinase activity in patients has benefits for controlling cerebral vasospasms and ischemia following subarachnoid hemorrhage (Pharma Japan 199, 1470, 16).
- The compounds and their derivatives presented in this invention are useful as Rho Kinase inhibitors and thus have utilities in the treatment of hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, neuronal degeneration, spinal cord injury, cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases, thrombotic disorders, asthma, glaucoma and osteoporosis.
- In addition, the compounds of the invention are useful to treat erectile dysfunction, i.e., erectile dysfunction mediated by Rho-kinase. Erectile dysfunction can be defined as an inability to obtain or sustain an erection adequate for intercourse, WO 94/28902, U.S. Pat. No. 6,103,765 and U.S. Pat. No. 6,124,461.
-
- wherein
- X is —(CH2)x—, —O—(CH2)n—, —S—(CH2)n—, —NR7—CO—(CH2)n—, —NR7—SO2—(CH2)n —, —NR 7—(CH2)n—, or —(O)C—NR7—,
- each n is an integer which is independently 0, 1, 2 or 3,
- x is 0-3
- p is 0-3
- a and c are each independently —CR5═, —N═, or —NR6—, wherein one of a or c is —NR6—, and b is —CR5═ or —N═;
- A is H, halogen, —CO—OR8, —CO—R8, cyano, —OR8, —NR8R9, —CO—NR8R9, —NR8—CO—R9, —NR8—CO—OR9, —NR8—SO2—R9, —SR8, —SO2—R8, —SO2—NR8R9, NR8—CO—NHR9, or
- A is a 3-20 atom, preferably 5-15 atom, cyclic or polycyclic moiety, e.g., containing 1-4 rings, which optionally contain 1-3 N, O or S atoms per ring, and may optionally be aryl or heteroaryl. A may optionally be substituted up to 3 times by (i) C1-C10 alkyl or C2-C10-alkenyl, each optionally substituted with halogen up to perhalo; (ii) C3-C10 cycloalkyl; (iii) optionally substituted aryl; (iv) optionally substituted heteroaryl; (v) halogen; (vi) —CO—OR8; (vii) —CO—R8; (viii) cyano; (ix) —OR8, (x) —NR8R13; (xi) nitro; (xii) —CO—NR8R9; (xiii) —C1-C10-alkyl-NR8R9; (xiv) —NR8—CO—R12; (xv) —NR8—CO—OR9; (xvi) —NR8—SO2—R9;
- (xvii) —SR8; (xviii) —SO2—R8; (xix) —SO2—NR8R9; or (xx) NR8—CO—NHR9;
- Ring B represents a fused 5- or 6-membered heterocyclic ring containing 1-2 O, N, and/or S atoms and 1-5 C atoms.
- R1, and R6-R11 are each independently H and C1-6 alkyl,
- R2-R5 are each independently (i) C1-10 alkyl or C2-10-alkenyl each optionally substituted by amino, N-lower alkylamino, N,N-dilower alkylamino, N-lower alkanoylamino, hydroxy, cyano, —COOR10, —COR14, —OCOR14, —OR10, C5-10-heteroaryl, C5-10-heteroaryloxy, C5-10-heteroaryl-C1-10-alkoxy, or halogen up to perhalo; (ii) C3-C10 cycloalkyl, in which 1-3 carbon atoms are optionally independently replaced by O, N or S; (iii) C3-10-cycloalkenyl; (iv) partially unsaturated C5-10-heterocyclyl; (v) aryl; (vi) heteroaryl; (vii) halogen; (viii) —CO—OR10; (ix) —OCOR10; (X) —OCO2R10; (xi) —CHO; (xii) cyano; (xiii) —OR16; (xiv) —NR10R15; (xv) nitro; (xvi) —CO—NR10R11; (xvii) —NR10—CO—R12; (xviii) —NR10—CO—OR11; (xix) —NR10—SO2—R12; (xx) —SR16; (xxi) —SOR16; (xxii) —SO2—R16; (xxiii) —SO2—NR10R11; (xxiv) NR10—CO—NHR11; (xxv) amidino; (xxvi) guanidino; (xxvii) sulfo; (xxviii) —B(OH)2; (xxix) —OCON(R10)2; or (xxx) —NR10CON(R10)2;
- R12 is H, C1-6-alkyl or C5-10-aryl,
- R13 is H, C1-6-alkyl or C1-6-alkoxy,
- R14 is lower alkyl or phenyl;
- R15 is lower alkyl, halogen, amino, N-lower alkyl amino, N,N-dilower alkylamino N-lower alkanoylamino, OH, CN, COOR10, —COR14 or —OCOR14;
- R16 is hydrogen, C1-6-alkyl optionally substituted by halogen, up to perhalo, or C5-10-heteroaryl; and
- with the provisos that A is not hydrogen when x is 0;
- —X-A is not CH3 when B represents a thieno[3,2b]fused ring, and b and c are —CR5═, and a is NH;
- and A is not phenyl when X is NH, B forms an imidazo fused ring, and -a-b-c- is —CR5═N—NR6— or —NR6═N—CR5—.
- In formula I, suitable aryl or heteroaryl groups, e.g., for A, include, but are not limited to, 5-12 carbon-atom aromatic rings or ring systems containing 1-3 rings, at least one of which is aromatic, in which one or more, e.g., 1-4 carbon atoms in one or more of the rings can be replaced by oxygen, nitrogen or sulfur atoms. Each ring typically has 3-7 atoms. For example, aryl or heteroaryl can be 2- or 3-furyl, 2- or 3-thienyl, 2- or 4-triazinyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or 5-yl, 1,2,4-triazol-1-, -3- or B5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-thiadiazol-2- or 5-yl, 1,2,4-oxadiazol-3- or 5-yl, 1,3,4-thiadiazol-2- or 5-yl, 1,3,4-thiadiazol-3- or 5-yl, 1,2,3-thiadiazol-4- or 5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4-4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5- 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5- 6- or 7-benzisoxazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 4-, 5-, 6- or 7-benz-1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-isoquinolinyl, 1-, 2-, 3-, 4- or 9-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl, or 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, or additionally optionally substituted phenyl, 2- or 3-thienyl, 1,3,4-thiadiazolyl, 3-pyrryl, 3-pyrazolyl, 2-thiazolyl or 5-thiazolyl, etc.
- Preferred moieties A include cyclohexyl; or C5-12-aryl or C5-12-heteroaryl each independently optionally substituted up to three times by (i) C1-C10-alkyl or C2-10-alkenyl each optionally substituted with halogen up to perhalo; (ii) C3-C10 cycloalkyl; (iii) C5-12-aryl optionally substituted by 1-3 halogen atoms; (iv) C5-12-heteroaryl; (v) halogen; (vi) —CO—OR8; (vii) —CO—R8; (viii) cyano; (ix) —OR8; (x) —NR8R13; (xi) nitro; (xii) —CO—NR8R9; (xiii) —C1-10-alkyl-NR8R9; (xiv) —NR8—CO—R12; (xv) —NR8—CO—OR9; (xvi) —NR8—SO2—R9; (xvii) —SR8; (xviii) —SO2—R8; (xix) —SO2—NR8R9, or (xx) NR8—CO—NHR9.
-
- wherein each Z independently is halogen, hydroxy, hydroxy-C1-10-alkyl, —CN, —NO2, C1-10-alkoxycarboxyl, —NR10—CO—R11, or —NR10—CO—OR11, as well as OR10, y is 0-3, more preferably 1-3, and R4 is as described above.
-
-
- The present invention is also directed to pharmaceutically acceptable salts of formula I. Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, sulphonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicyclic acid, phenylacetic acid, and mandelic acid. In addition, pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li+, Na+ or K+), alkaline earth cations (e.g., Mg+, Ca+ or Ba+), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations, such as those arising from protonation or peralkylation of triethylamine, N,N-diethylamine, N,N-dicyclohexylamine, pyridine, N,N-dimethylaminopyridine (DMAP), 1,4-diazabiclo[2.2.2]octane (DABCO), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
- A number of the compounds of Formula I possess asymmetric carbons and can therefore exist in racemic and optically active forms. Methods of separation of enantiomeric and diastereomeric mixtures are well known to one skilled in the art. The present invention encompasses any isolated racemic or optically active form of compounds described in Formula I which possess Rho-kinase inhibitory activity.
- The invention also includes pharmaceutical compositions including a compound of Formula I, and a physiologically acceptable carrier.
- The invention moreover encompasses treating indications mediated by Rho-kinase, by administering a compound of Formula I, or a pharmaceutical composition containing a compound of Formula I. Thus, the invention encompasses treating cardiovascular diseases such as hypertension, artherosclerosis, restenosis and cerebral ischemia, or vasospasm central nervous system disorders such as neuronal degeneration and spinal cord injury, erectile dysfunction, e.g., in patients who do not have satisfactory response to PDE-5 inhibitors, and cancer (e.g., tumor growth) mediated by Rho-kinase, by administering, e.g., to a host in need thereof, of an effective amount of a compound of Formula I. Cancers and tumors mediated by Rho-kinase include cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
- A number of the compounds of Formula I possess asymmetric carbons and can therefore exist in racemic and optically active forms. Methods of separation of enantiomeric and diastereomeric mixtures are well known to one skilled in the art. The present invention encompasses any isolated racemic or optically active form of compounds described in Formula I which possess Rho-kinase inhibitory activity.
- The invention also includes pharmaceutical compositions including a compound of Formula I, and a physiologically acceptable carrier.
- The invention moreover encompasses treating indications mediated by Rho-kinase, by administering a compound of Formula I, or a pharmaceutical composition containing a compound of Formula I. Thus, the invention encompasses treating cardiovascular diseases such as hypertension, artherosclerosis, restenosis and cerebral ischemia, or vasospasm central nervous system disorders such as neuronal degeneration and spinal cord injury, erectile dysfunction, e.g., in patients who do not have satisfactory response to PDE-5 inhibitors, and cancer (e.g., tumor growth) mediated by Rho-kinase, by administering, e.g., to a host in need thereof, of an effective amount of a compound of Formula I. Cancers and tumors mediated by Rho-kinase include cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
- The compounds may be administered orally, topically, parenterally, by inhalation or spray, vaginally, rectally or sublingually in dosage unit formulations. The term ‘administration by injection’ includes intravenous, intraarticular, intramuscular, subcutaneous and parenteral injections, as well as use of infusion techniques. Dermal administration may include topical application or transdermal administration. One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and if desired other active ingredients.
- Compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. These compounds may also be prepared in solid, rapidly released form.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions containing the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions may also be used. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.
- The compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Compounds of the invention may also be administrated transdermally using methods known to those skilled in the art (see, for example: Chien; “Transdermal Controlled Systemic Medications”; Marcel Dekker, Inc.; 1987. Lipp et al. WO94/04157 Mar. 3, 1994). For example, a solution or suspension of a compound of Formula I in a suitable volatile solvent optionally containing penetration enhancing agents can be combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms. In addition, on treatment with emulsifying agents and water, a solution or suspension of a compound of Formula I may be formulated into a lotion or salve.
- Suitable solvents for processing transdermal delivery systems are known to those skilled in the art, and include lower alcohols such as ethanol or isopropyl alcohol, lower ketones such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotrifluoroethane, or trichlorofluoroethane. Suitable solvents may also include mixtures of one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar ethers, lower hydrocarbons, halogenated hydrocarbons.
- Suitable penetration enhancing materials for transdermal delivery system are known to those skilled in the art, and include, for example, monohydroxy or polyhydroxy alcohols such as ethanol, propylene glycol or benzyl alcohol, saturated or unsaturated C8-C18 fatty alcohols such as lauryl alcohol or cetyl alcohol, saturated or unsaturated C8-C18 fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tertbutyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid or palmitic acid, or diesters of saturated or unsaturated dicarboxylic acids with a total of up to 24 carbons such as diisopropyl adipate, diisobutyl adipate, diisopropyl sebacate, diisopropyl maleate, or diisopropyl fumarate. Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl isosorbid and diethyleneglycol monoethyl ether. Suitable penetration enhancing formulations may also include mixtures of one or more materials selected from monohydroxy or polyhydroxy alcohols, saturated or unsaturated C8-C18 fatty alcohols, saturated or unsaturated C8-C18 fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated discarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.
- Suitable binding materials for transdermal delivery systems are known to those skilled in the art and include polyacrylates, silicones, polyurethanes, block polymers, styrenebutadiene copolymers, and natural and synthetic rubbers. Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix.
- Pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oil phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example, gum acacia or gum tragacanth, naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- The compounds may also be administered in the form of suppositories for rectal or vaginal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature or vaginal temperature and will therfore melt in the rectum or vagina to release the drug. Such materials include cocoa butter and polyethylene glycols.
- Moreover, for treatment of erectile dysfunction, the present pharmaceutical compositions may take any form which is suitable for administration to the penis either via injection into the corpora cavernosa or transurethral administration, or topically applied to the urethral meatus. In the case of injection into the corpora cavernosa, the pharmaceutical composition is suitably in the form of a saline solution. Preferably, the pharmaceutical composition is in a form suitable for transurethral administration, and in this case the composition is typically in the form of a solution, an ointment, or a suppository. Typically, the pharmaceutical composition is administered 1 to 50 minutes, preferably 10 to 20 minutes, prior to the time of commencing sexual intercourse.
- For all regimens of use disclosed herein for compounds of Formula I, the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily vaginal dosage regime will preferably be from 0.01 to 200 mg/Kg of total body weight. The daily topical dosage regimen will preferably be from 0.01 to 200 mg administered between one to four times daily. The transdermal concentration will preferably be that required to maintain a daily dose is of from 0.1 to 200 mg/Kg. The daily inhalation dosage regimen will preferably be from 0.01 to 10 mg/Kg of total body weight.
- It will be appreciated by those skilled in the art that the particular method of administration will depend on a variety of factors, all of which are considered routinely when administering therapeutics. It will also be understood, however, that the specific dose level for any given patient will depend upon a variety of factors, including, the activity of the specific compound employed, the age of the patient, the body weight of the patient, the general health of the patient, the gender of the patient, the diet of the patient, time of administration, route of administration, rate of excretion, drug combinations, and the severity of the condition undergoing therapy. It will be further appreciated by one skilled in the art that the optimal course of treatment, i.e., the mode of treatment and the daily number of doses of a compound of Formula I or a pharmaceutically acceptable salt thereof given for a defined number of days, can be ascertained by those skilled in the art using conventional treatment tests.
- The present compounds and compositions exhibit Rho-kinase inhibitory activity, and are thus useful to treat the indications listed above, e.g., indications mediated by Rho-kinase. By indications mediated by Rho-kinase is meant diseases or conditions whose progression proceeds, at least in part, via the Rho pathway.
- Rho-kinase inhibitory activity, e.g., ROCK-1 inhibition, can be evaluated as follows:
- The kinase domain of human ROCK-1, amino acids 27-530, is isolated as a glutathione S-transferase fusion protein from Sf9 insect cells. The protein is partially purified by glutathione Sepharose 4B (Pharmacia Biotech, Piscataway, N.J.) affinity purification. Reactions is carried out in 96-well plates in a total volume of 100 uL containing 50 mM N-[2-Hydoryethyl]piperaxine-N′-[2-ethanesulfonic acid] pH 7.5, 5 mM MgCl2, 1 mM dithiothreitol, 6 μM ATP, 0.2 μCi [33P]ATP (NEN, Boston, Mass.), 1 μg myelin basic protein and 0.1 μg ROCK-1. Test compounds are dissolved in 100% dimethylsulfoxide, diluted to the appropriated concentration and added to the reaction. The final concentration of dimethylsulfoxide did not exceed 0.5%. The reaction is run for one hour at room temperature. The reaction is stopped with the addition of 7 mL of 1 N HCL, transferred to P30 membranes and the amount of [33P]ATP, as counts per minute (c.p.m.) incorporated into the substrate, myelin basic protein, is read in a BetaPlate Reader (Packard Instrument Co., Meriden, Conn.). (All reagents were purchased from Sigma Chemical Co., St. Louis, Mo. unless stated otherwise.) Percentage inhibition is measured by the amount of incorporation of radioactivity in the presence of the test compound when compared to the amount of incorporation in the absence of the test compound.
- Inhibitory activity can also be evaluated by measurement of stress fiber formation, performed essentially as described by Ridley, A. J., and A. Hall, Cell 70:389-399 (1992). Human fibrosarcoma HT1080 (CCL-121, American Type Culture Collection, Manassas, Va.) cells are plated on 22×22 mm #1 glass cover slips in six-well tissue culture plates (Costar) at 2.5×104 cells/well in Delbeco's modified Eagle's Medium (DMEM, Gibco) supplemented with 10% fetal calf serum. Cells are maintained in a humidified, 5% CO2 atmosphere at 37° C. After 24 hours the culture medium is removed and replaced with medium without 10% fetal calf serum and the cells cultured for an additional 48 hours. Test compounds are dissolved in 100% dimethylsulfoxide, diluted to the appropriated concentration and added to the culture medium 60 minutes prior to the induction of stress fiber formation. The final concentration of dimethylsulfoxide did not exceed 0.25%. Stress fiber formation is induced by the addition of lysophosphatidic acid (1-oleoyl-2-hydroxy-sn-glycerol-3-phosphate, Avanti Polar-Lipids, Alabaster, Ala.) to 10 μM final concentration in Delbeco's modified Eagle's Medium containing 0.1% fatty acid free bovine serum albumin for 15 minutes at 37° C. Cells are fixed with 4% paraformaldeyhde (Poly Scientific, Bay Shore, N.J.) in phosphate buffered saline (PBS) for 15 minutes. Cells are then washed 3 times in PBS and them permeabilized using a solution containing 40 mM piperazine-N-N′bis[2-ethanesulfonic acid], 50 mM N-[2-hydoryethyl]piperaxine-N′-[2-ethanesulfonic acid], 0.1% Triton X-100, 75 mM NaCl, mM MgCl2, 0.5 mM EGTA, pH 7.2 for 2 minutes at room temperature. The cells are washed 3 times for 5 minutes each in PBS and then actin stress fibers are stained using 10 units/mL rhodamine phalloidin (Molecular Probes, Eugene, Oreg.) in PBS for 60 minutes at room temperature. The cells are washed 3 times with PBS and the cover slips mounted on glass microscope slides. The percentage of stress fiber positive cells on each slide was determined visually using a Nikon Labphoto-2 microscope. At least 100 cells were counted per slide and experiments were done in duplicate. Percentage inhibition is measured by counting the number of stress fiber positive cells in the presence of the test compound when compared to the number of stress fiber positive cells in the absence of the test compound.
- Using the above protocols, all of the compounds as disclosed herein are determined to have Rho-kinase inhibitory activity.
- The compounds of the invention can be made according to routine, conventional chemical methods, and/or as disclosed below, from starting materials which are either commercially available or produceable according to routine, conventional chemical methods. General methods for the preparation of the compounds are given below, and the preparation of representative compounds is specifically illustrated in the Examples.
- Abbreviations and Acronyms
- When the following abbreviations are used herein, they have the following meaning:
Ac2O acetic anhydride anhy anhydrous n-BuOH n-butanol t-BuOH t-butanol CD3OD methanol-d4 Celite ® diatomaceous earth filter agent, ® Celite Corp. CH2Cl2 methylene chloride CI-MS chemical ionization mass spectroscopy conc concentrated dec decomposition DME dimethoxyethane DMF N,N-dimethylformamide DMSO dimethylsulfoxide ELSD evaporative light scattering detector EtOAc ethyl acetate EtOH ethanol (100%) Et2O diethyl ether Et3N triethylamine HPLC ES- high performance liquid chromatography-electrospray mass MS spectroscopy NMM 4-methylmorpholine Ph3P triphenylphosphine Pd(dppf) [1,1'-bis(diphenylphosphino)ferrocene] Cl2 dichloropalladium(II) Pd(PPh3)4 tetrakis(triphenylphosphine)palladium(0) Pd(OAc)2 palladium acetate P(O)Cl3 phosphorous oxychloride RT retention time (HPLC0 rt room temperature THF tetrahydrofuran TFA trifluoroacetic acid TLC thin layer chromatography -
-
-
-
- A heterocyclic aminoester of Formula 6 is acylated with an aromatic acid chloride or anhydride, in a base such as pyridine. The amide ester product is converted to the amide acid of Formula 7 by hydrolysis, or if R″ is methyl, by action of boron tribromide. Conversion of the acid to the amide of Formula 8 is accomplished by reaction of 7 with ammonia in the presence of catalysts such as DMAP and EDC. Cyclization to 9 may be carried out by heating the diamide 8 in the presence of a base such as sodium hydroxide. The chloro intermediate of Formula 10 is formed by treatment of 9 with a chlorinating agent such as phosphorous oxychloride.
- A cyanoheterocyclic amine of Formula 10 may be directly converted to compounds of Formula 4 by heating with a Vilsmeier reagent, prepared in situ by treatment of an aromatic N,N-dimethyl amide with a phosphorous oxychloride or oxalyl chloride and the like.
- Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
- In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius; and, unless otherwise indicated, all parts and percentages are by weight.
- The entire disclosure of all applications, patents and publications, cited above or below, and of corresponding U.S. Provisional Application Serial No. 60/277,974, filed Mar. 23, 2001, U.S. Provisional Application No. 60/315,341 filed Aug. 29, 2001, U.S. Provisional Application Serial No. 60/315,338 filed Aug. 29, 2001, and U.S. Provisional Application No. 60/346,628, filed Jan. 10, 2002 are hereby incorporated by reference.
-
-
- A solution of thienoyleneurea (6.0 g) and N,N-dimethylaniline (2.9 mL) in phosphorus oxychloride (35 mL) was heated at 125° C. (oil bath) for 22 h under argon. The solution cooled to 50° C. and was poured into cold water (0° C., 8.0 mL) while vigorously stirring. The precipitate was filtered, washed with water, and dissolved in EtOAc. The organic solution was filtered, washed with water, and the organic phase was dried over MgSO4, filtered and concentrated to afford a yellow precipitate (4.5 g, 61% yield).
-
- A mixture of the compound for step 1 (4.0 g, 19.5 mmol), 5-aminoindazole (3.2 g, 23.4 mmol), and potassium acetate (2.5 g, 25.4 mmol) in THF/water (100 mL/50 mL) was stirred rt overnight. The THF was removed under reduced pressure and the residue was partitioned between EtOAc and water. The organic phase was washed with aqueous NH4Cl, dried over MgSO4, filtered. The filtrate was poured onto a silica gel column and eluted with EtOAc. The solvent was concentrated by rotary evaporation and a gray precipitate was obtained (3.9 g, 65% yield). Rf=0.28 (EtOAc/hexanes, 1/1).
-
- A mixture of the compound from step 2 (6.9 g, 23 mmol), 5-chlorothienyl boronic acid (3.7 g, 23 mmol) and sodium bicarbonate (5.8 g, 69 mmol) in DME/H2O (3/1, 300 mL) was flushed with Ar for 1 h. Pd(dppf)Cl2 (1.8 g, 2.3 mmol) was added and the mixture was heated to reflux for 48 h. The solvent was removed by rotary evaporation and the crude product was purified by silica gel chromatography to afford of yellow solid (3.5 g, 40% yield). Rf=0.20 (EtOAc/hexane, 1/1). 1H NMR (methanol-d4) δ8.05 (s, 1H), 8.00 (s, 1H), 7.89 (d, 1H, J=3 Hz), 7.68-7.59 (m, 2H), 7.50 (d, 1H, J=3 Hz), 7.29 (1H, d, J=3 Hz), 6.95 (d, 1H, J=3 Hz).
- Using an procedure analogous to that described for example 1 and reacting 4-(N-5-aminoindazole)-2-chlorothieno[3,2-d]pyrimidine and the appropriate boronic acid or ester, the compounds described in Table 1 below were prepared.
TABLE 1 Ex. No. Ar1 Note 2 1 3 2 4 3 5 4 6 5 7 6 8 7 9 8 10 9 11 10 12 11 13 12 14 13 15 14 16 15 17 16 18 17 19 18 20 19 21 20 22 21 23 22 24 23 25 24 26 25 27 26 28 27 29 28 30 29 31 30 32 31 33 32 34 33 35 34 36 35 37 36 38 37 39 38 40 39 41 40 42 41 43 42 44 43 45 44 46 45 47 46 48 47 49 48 50 49 51 50 52 51 53 52 54 53 55 54 56 55 57 56 58 57 - 1) HPLC/MS: (M+H)+ m/z 378.4. Rf=0.39 (50% EtOAc/Hex). 1H NMR (DMSO): δ13.1 (s, 1H), 9.8 (s, 1H), 8.3-8.4 (m, 2H), 8.2 (d, J=5.7 Hz, 1H), 8.1 (s, 2H), 7.5-7.7 (m, 5H)
- 2) HPLC/MS: (M+H)+ m/z 421.4. Rf=0.25 (50% EtOAc/Hex). 1H NMR (CD3OD): δ8.7 (m, 1H), 8.4 (d, J=8.4 Hz, 2H), 8.2-8.3 (m, 7H), 7.6-7.7 (m, 4H)
- 3) HPLC/MS: (M+H)+ m/z 450.4. Rf=0.50 (1/1, EtOAc/Hex).
- 4) HPLC/MS: (M+H)+ m/z 438.4. Rf=0.40 (1/1, EtOAc/Hex).
- 5) HPLC/MS: (M+H)+ 420.4 m/z. Rf=0.33 (1/1, EtOAc/Hex). 1H NMR (DMSO): δ13.0 (s, 1H), 9.6 (s, 1H), 8.7 (s, 1H), 8.4 (d, J=8.7, 1H), 8.3 (s, 1H), 8.2 (d, J=5.7, 1H), 8.0 (s, 1H), 7.8−7.4 (m, 10H)
- 6) HPLC/MS: (M+H)+ m/z 378.4. Rf=0.62 (1/1, EtOAc/Hex). 1H NMR (DMSO and CH2Cl2): δ12.9 (s, 1H), 9.7 (s, 1H), 8.3-8.4 (m, 3H), 8.0-8.1 (m, 4H), 7.3-7.7 (m, 3H)
- 7) HPLC/MS: (M+H)+ m/z 421.4. Rf=0.24 (1/1, EtOAc/Hex). 1H NMR (CD3OD): δ9.1 (s, 1H), 8.7 (m, 1H), 8.6 (dd, 1H), 8.4-8.5 (d, J=8.1 Hz, 2H), 8.3 (d, J=6.0 Hz, 1H), 8.2 (s, 1H), 8.1 (m, 1H), 8.0 (m, 2H), 7.9 (m, 1H), 7.6-7.7 (m, 2H), 7.6 (d, J=5.1, 1H)
- 8) HPLC/MS: (M+H)+ m/z 438.4. Rf=0.41 (1/1, EtOAc/Hex). 1H NMR (CD3OD): δ8.3-8.4 (..J=8.4 Hz, 2H), 8.3 (d, J=5.4 Hz, 1H), 8.2 (s, 1H), 8.1 (s, 1H), 7.8-7.9 (d, J=8.4 Hz, 2H), 7.6-7.8 (m, 4H), 7.5-7.6 (d, J=5.4, 1H), 7.2-7.3 (m, 2H)
- 9) HPLC/MS: (M+H)+ m/z 454.4. Rf=0.33 (1/1, EtOAc/Hex).
- 10) HPLC/MS: (M+H)+ m/z 454.5. Rf=0.40(1/1, EtOAc/Hex).
- 11) HPLC/MS: (M+H)+ m/z 454.4. Rf=0.42 (1/1, EtOAc/Hex).
- 12) HPLC/MS: (M+H)+ m/z 488.4. Rf=0.43 (1/1, EtOAc/Hex).
- 13) HPLC/MS: (M+H)+ m/z 465.4. Rf=0.36 (1/1, EtOAc/Hex). 1H NMR (CD3OD): δ8.6 (t, J=1.8 Hz, 1H), 8.4 (d, J=8.7, 2H), 8.3 (m, 2H), 8.1-8.2 (m, 3H), 8.0 (d, J=10.5, 2H), 7.7-7.8 (m, 3H), 7.5-7.6 (d, J=5.4 Hz, 1H)
- 14) HPLC/MS: (M+H)+ m/z 468.4. Rf=0.38 (1/1, EtOAc/Hex).
- 15) HPLC/MS: (M+H)+ m/z 480.4. Rf=0.37 (1/1, EtOAc/Hex).
- 16) HPLC/MS: (M+H)+ m/z 480.4. Rf=0.30 (1/1, EtOAc/Hex).
- 17) HPLC/MS: (M+H)+ m/z 470.5. Rf=0.36 (1/1, EtOAc/Hex). 1H NMR (CD3OD): δ8.3-8.4 (m, 2H, 1H), 8.2 (s, 1H), 8.1 (s, 1H), 7.9-8.0 (m, 2H), 7.8-7.9 (m, 1H), 7.7-7.8 (m, 4H), 7.4-7.6 (m, 6H)
- 18) HPLC/MS: (M+H)+ m/z 477.5. Rf=0.13 (1/1, EtOAc/Hex).
- 19) HPLC/MS: (M+H)+ m/z 462.5. Rf=0.33 (1/1, EtOAc/Hex).
- 20) HPLC/MS: (M+H)+ m/z 479.3. Rf=0.39 (1/1, EtOAc/Hex).
- 21) HPLC/MS: (M+H)+ m/z 434.4. Retention time (HPLC): Rt=4.73. 1H NMR (CD3OD): δ8.1-8.4 (m, 6H), 7.4-7.7 (m, 7H1)
- 22) HPLC/MS: (M+H)+ m/z 465.3. Retention time (HPLC, CH3CN/H2O/0.1% TFA): Rt=2.79
- 23) HPLC/MS: (M+H)+ m/z 426.4. Retention time (HPLC): Rt=2.55
- 24) HPLC/MS: (M+H)+ m/z 480.4. Retention time (HPLC): Rt=2.31
- 25) HPLC/MS: (M+H)+ m/z 421.4. Rf=0.13 (1/1, EtOAc/Hex). 1H NMR (CD3OD): δ9.0 (s, 1H), 8.8 (s, 1H), 8.7 (t, J=1.8 Hz, 1H), 8.5-8.6 (m, 1H), 8.4 (m, 1H), 8.3 (d, J=6.0 Hz, 1H), 8.1 (m, 1H), 8.0 (m, 1H), 7.6-7.9 (m, 4H), 7.5-7.6 (d, J=5.7 Hz, 2H)
- 26) Rf=0.33 (CH2Cl2MeOH, 95/5). 1H NMR (CD3OD) δ8.2 (1H, s), 8.2 (1H, s), 8.1 (1H, s), 8.0 (1H, dd, J=1.8, 6.0 Hz), 7.9−7.8 (1H, m), 7.8−7.7 (1H, d, J=9.3 Hz), 7.7−7.6 (2H, m), 7.6−7.5 (1H, m), 7.4 (1H, dd, J=5.4, 2.1 Hz), 7.4−7.3 (1H, m).
- 27) Rf=0.33 (CH2Cl2/MeOH, 95/5). 1H NMR (CD3OD) δ9.1 (1H, d, J=2.4 Hz), 8.6 (1H, dd, J=2.4, 8.7 Hz), 8.1−8.0 (2H, m), 8.0−7.9 (1H, d, J=5.4 Hz), 7.7 (1H, dd, J=2.2, 8.7 Hz), 7.6 (1H, d, J=8.7 Hz), 7.42 (1H, d, J=5.4 Hz), 6.8 (1H, d, J=9.3 Hz).
- 28) Rf=0.47 (Hexane/EtOAc=1/1).1H NMR (CD3OD) δ9.7 (1H, d, J=1.4 Hz), 9.2 (1H, d, J=8.7 Hz), 8.24−8.20 (2H, m), 8.1 (1H, d, J=2.2 Hz), 7.8 (1H, d, J=2.8 Hz), 7.71 (1H, d, J=1.4 Hz), 7.66−7.56 (4H, m), 7.21−7.19 (2H, m), 709−7.07 (1H, m).
- 29) Rf=0.28 (Hexane/EtOAc, 1/2).1H NMR (CD3OD) δ8.60 (2H, d, J=5.7 Hz), 8.53 (2H, dd, J=1.5, 6.9 Hz), 8.15 (1H, d, J=1.0 Hz), 8.10 (1H, d, J=2.2 Hz), 8.01 (1H, d, J=5.4 Hz), 7.88 (2H, dd, J=1.8, 6.6 Hz), 7.79 (2H, dd, J=1.8, 4.5 Hz), 7.74 (1H, dd, J=2.1, 9.0 Hz), 7.76 (1H, d, J=8.7 Hz), 7.48 (1H, d, J=6.5 Hz).
- 30) Rf=0.38 (Hexane/EtOAc, 1/1).1H NMR (DMSO-d6) δ13.08 (1H, s), 9.02 (1H, s), 8.40 (2H, dd, J=2.4, 5.7 Hz), 8.15 (1H, d, J=6.0 Hz), 8.18.−8.09 (2H, m), 7.68 (1H, dd, J=2.1, 9.3 Hz), 7.60 (1H, d, J=9.0 Hz), 7.46 (1H, d, J=5.7 Hz), 7.29 (2H, t, J=7.2 Hz)
- 31)1H NMR (DMSO-d6) δ11.01 (1H, s), 9.34 (1H, s), 8.72 (1H, d. J=5.7 Hz), 8.18 (1H, s), 8.12 (1H, J=6.6 Hz), 7.97−7.90 (4H, m), 7.87 (1H, s), 7.56 (1H, d, J=3.0 Hz), 7.47 (1H, d, J=6.0 Hz), 7.36−7.34 (1H, m)
- 32) Rf=0.42 (Hexane/EtOAc, 1/1). (CD3OD) δ8.91 (1H, d, J=6.3 Hz), 8.37 (1H, d, J=6.3 Hz), 8.30 (1H, dd, J=1.2, 9.0 Hz), 8.25 (1H, dd, J=1.5, 6.3 Hz), 8.20 (1H, d, J=0.60 Hz), 8.12 (1H, d, J=1.0 Hz), 7.86 (1H, t, J=6.2 Hz), 7.80 (1H, s), 7.80−7.78 (1H, m), 7.76 (1H, d, J=1.8 Hz), 7.71 (1H, d, J=6.0 Hz), 7.65−7.62 (1H, m), 7.54−7.46 (2H, m).
- 33) HPLC/MS: (M+H) m/z 462, Rf=0.28 (EtOAc/Hexanes 10:90).
- 34) Purified by silica gel column chromatography (gradient, EtOAc in hexanes from 20% to 70%); Rf=0.22 (EtOAc/hexanes, 1/1); (3.18 g, 68% yield); LCMS m/z 374 (M+H)+; 1H NMR (DMSO-d6) δ13.0 (s, 1H), 9.67 (s, 1H), 8.3 (d, 2H), 8.1 (m, 3H), 7.62 (d, 1H), 7.55 (d, 1H), 7.4 (d, 1H), 6.94 (d, 2H), 3.78 (s, 3H).
- 35) Purified by silica gel column chromatography (gradient, EtOAc in hexanes from 20% to 70%) (2.8 g, 70% yield); LCMS m/z 344 (M+H)+; Rf=0.24 (EtOAc/hexanes, 1/1); 1H NMR (300 MHz, CD3OD) δ8.35 (d, 2H), 8.15 (s, 1H), 8.05 (s, 1H), 7.95 (d, 1H), 7.7 (d, 1H), 7.55 (d, 1H), 7.46 (s, 4H).
- 36) Purified by silica gel column chromatography (gradient, EtOAc in hexanes from 10% to 70%); Rf=0.19 (EtOAc/hexanes, 3/2); (55 mg, 15% yield); LCMS m/z 429 (M+H)+; 1H NMR (DMSO-d6) δ13.07 (s, 1H), 9.65 (s, 1H), 8.24 (d, 2H), 8.1 (m, 2H), 7.66 (d, 1H), 7.56 (d, 1H), 7.4 (d, 1H), 3.73 (s, 4H), 3.21 (4H).
- 37) Purified by silica gel column chromatography (gradient, EtOAc in hexanes from 10% to 50%); Rf=0.3 (EtOAc/hexanes, 1/1); (194 mg, 70% yield); LCMS m/z 420 (M+H)+; 1H NMR (DMSO-d6) δ13.1 (s, 1H), 9.8 (s, 1H), 8.44 (d, 2H), 8.15 (m, 3H), 7.8 (m, 5H), 7.6 (d, 1H), 7.47 (m, 3H), 7.36 (m, 1H).
- 38) Crude 7e was purified by filtration and washed with methanol; Rf=0.16 (MeOH/CH2Cl2, 5/95); (0.36 g, 61% yield); LCMS m/z 401 (M+H)+; 1H NMR (DMSO-d6) δ13.09 (s, 1H), 9.97 (s, 1H), 9.17 (s, 1H), 8.42 (d, 1H), 8.3 (s, 1H), 8.18 (m, 2H), 8.14 (s, 1H), 8.06 (d, 1H), 7.73 (d, 1H), 7.62 (d, 1H), 7.49 (d, 1H).
- 39) N-BOC protected boronic acid used in step 3; BOC group was removed by TFA in CH2CL2 at rt. Purified by silica gel column chromatography (gradient, EtOAc in hexanes from 10% to 75%); (45 mg, 19% yield); LCMS m/z 528 (M+M)+).
- 40) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 428.2. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=3.27.
- 44) The residue was purified by column chromatograpny (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 380.1. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=3.26
- 42) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 388.2. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.52.
- 43) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 362.1. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.69.
- 44) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 374.1. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.43.
- 45) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 358.2. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.46.
- 46) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 358.2. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.50.
- 47) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 372.2. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.61.
- 48) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 370.2. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.67.
- 49) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 400.2. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.81.
- 50) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 386.2. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.73.
- 51) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 386.2. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.79.
- 52) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 374.2. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.06.
- 53) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 374.3. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=2.17.
- 54) The residue was purified by column chromatography (dry mount, gradient from 20% to 75% EtOAc/Hex) to afford product. HPLC/MS: (M+H)+ m/z 412.1. Retention time (HPLC/MS, CH3CN/H2O/0.1% TFA): Rt=3.28. HPLC/MS: (M+H)+ 412.1 m/z. 1H NMR (DMSO-d6): 13.12(s, 1H, NH); 9.95 (s, 1H, NH); 8.71(s, 1H); 8.66(d, 1H); 8.21(d, 1H); 8.16(s, 1H); 8.07 (s, 1H); 7.85(s, 1H); 7.74(t, 1H); 7.65(d, 1H); 7.60(s, 1H); 7.55(d, 1H).
- 55) The residue was purified by column chromatography (gradient from 35-50% EtoAc/Hexane) to afford the pure product. HPLC/MS: (M+H)+ 427. Rf=0.64 (EtOAc/Hexanes, 80/20). 1H-NMR (300 MHz, CD3OD) δ=8.23 (d, 2H), 8.16−8.14 (m, 1H), 8.08 (s, 1H), 7.95 (d, 1H), 7.73 (dd, 1H), 7.61 (d, 1H), 7.40 (d, 1H), 7.01 (d, 2H), 3.32−3.23 (m, 4H), 1.72−1.60 (m, 6H).
- 56) HPLC/MS: (M+H)+ m/z 426.4, Retention time (HPLC): Rt=2.55, Rf=0.68 in (EtOAc/Hex, 80/20). 1H-NMR (300 MHz, DMSO d6) δ=8.17−7.43 (m, 13H).
- 57) HPLC/MS: (M+H)+ m/z 421.4, Rf=0.46 in (MeOH/EtOAc, 07/93). 1H-NMR (300 MHz, CD3OD) δ=7.5−6.25 (m, 14H).
-
- To a slurry of (N-5-aminoindazole)-2-(4-methoxyphenyl)thieno[3,2-d]-pyrimidine (Example 35, 0.86 g, 2.3 mmol) in anhyd CH2Cl2 was added BBr3 at −78° C. The mixture was stirred overnight and warmed to room temperature. The reaction was cooled to 78° C. and treated with aqueous NH4Cl slowly to form precipitate. The solvent was concentrated by rotary evaporation and co-evaporated with toluene. The residue was treated with mixed solvent of MeOH and CH2Cl2, and then filtered. The filtrate was added to 6 g of silica gel and the solvent was removed by rotary evaporation. The residue was poured onto a silica gel column and eluted with a gradient mobile phase containing EtOAc and hexane to afford the product (0.42 g, 1.17 mmol, 51% yield). LC/MS m/z 360 (M+H)+, 1H NMR (DMSO-d6): δ13.15 (s, 1H), 9.8 (s, 1H), 9.7 (s, 1H), 8.2 (d, 2H), 8.1 (d, 3H), 7.7 (dd, 1H), 7.6 (dd, 1H), 7.4 (d, 1H), 6.8 (d, 2H); mp 297-299° C.
-
- To a mixture of (Example 56, 62 mg, 0.17 g), CsCO3 (100 mg, 0.3 mmol) in acetone (3 mL) was added N-(2-bromoethylene)-morpholine (34 mg in 1 mL of acetone). The solution was stirred at room temperature for 4 h and was filtered. The filtrate was added to 0.4 g of silica gel and the solvent was removed by rotary evaporation. The residue was poured onto a silica gel column and eluted with a gradient of EtOAc in hexane (from 50% to 100%) to afford a white precipitate (30 mg, 37% yield). Rf=0.18 (MeOH/CH2Cl2, 5/95). HPLC/MS: m/z 473 (M+H)+; 1H NMR (DMSO-d6): δ13.07 (s, 1IH), 9.71 (s, 1H), 8.30 (d, 2H), 8.09 (m, 3H), 7.70 (d, 1H), 7.57 (d, 1H), 7.43 (d, 1H), 7.02 (d, 2H), 4.14 (t, 2H), 3.57 (t, 4H), 2.68 (t, 2H), 2.46 (t, 4H).
-
-
- A mixture of 4-formylphenylboronic acid (1 g, 6.67 mmol) and 2-pyridinylamine (2.51 g, 26.7 mmol) in dichloroethane (25 mL) was stirred under argon at room temperature. To this mixture was added NaB(OAc)3 (1.84 g, 8.67 mmol). The reaction mixture was quenched with H2O after 3 h. The solvent was removed under reduced pressure and the residue was dissolved in EtOAc and washed with water. The organic layer was then dried and concentrated in vacuo. The crude product was then purified by column chromatography (gradient from 20% to 80% EtOAc/hexane) to give product as colorless liquid (0.39 g, 30%). HPLC/MS: (M+H)+ 229.1 m/z. Retention time (LC−MS)=4.54 min. 1H NMR (CD3OD): 7.90 (1H, d); 7.59 (2H, s); 7.43 (1H, m); 7.30(2H, d); 6.55 (2H, m); 4.47 (2H
-
- To a mixture of N-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N-(1H-indazol-5-yl)amine (50 mg, 0.16 mmol), Na2CO3(aq) (2 M, 1.0 mL) in butanol/toluene (1:1, 4 mL) a stream of argon was bubbled through for 15 min. To the mixture was added 4-[(2-pyridinylamino)methyl]phenylboronic acid (0.15 g, 0.66 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.06 g, 0.08 mmol) in a single portion. The resulting reaction mixture was heated to reflux for 24 h. On cooling, the solution was concentrated, taken up in EtOAc and washed with water. The organic layers were dried over anhyd sodium sulfate and concentrated in vacuo. The crude product was purified by silica gel column chromatography (gradient from 20% to 80% EtOAc/hexane) to give the product (25 mg). HPLC/MS: (M+H)+ 450.1 m/z. Retention time (LC−MS)=min. 1H NMR (CD3OD): 8.31 (2H, d); 8.11 (1H, s); 8.05 (1H, s); 7.96(1H, d); 7.91 (1H, d); 7.71(1H, d); 7.58 (1H, d); 7.47(4H, m); 6.61(2H, m); 4.55 (2H, s).
-
-
- To a solution of methyl 3-amino-2-thiophenecarboxylate (0.82 g, 5.2 mmol) and 2-quinoxalinecarbonyl chloride at 0° C. was added pyridine (1 mL) dropwise. The resulting solution was stirred at room temperature overnight. The solvent was removed under reduced pressure and the residue was dissolved in EtOAc, washed with saturated NH4Cl, and NaHCO3. The organic layer was the dried and concentrated in vacuo. The crude product was used directly in the next step without further purification.
-
- Methyl 3-[(2-quinoxalinylcarbonyl)amino]-2-thiophenecarboxylate (0.5 g, 1.6 mmol) was dissolved in CH2Cl2 (100 mL) at 0° C. and BBr3 (4.8 mL, 1M solution in CH2Cl2) was added dropwise. The solution was stirred at room temperature overnight. The reaction was quenched with NH4Cl at 0° C. The organic layer was washed with NaHCO3 and separated. The resulting organic layer was treated slowly with dil HCl until the solution became acidic. The mixture was concentrated and redissolved in EtOAc. This solution was washed with water, The solvent was removed under reduced pressure and the crude product was re-crystallized from methanol to give the desired product (0.2 g, 42%). HPLC/MS: (M+H)+ 300.1 m/z. Retention time (LC−MS)=2.65 min. 1H NMR (DMSO-D6): 13.75 (s, 1H, broad); 12.43(s, 1H); 9.61(s, 1H); 8.26(m, 2H); 8.17(m, 1H); 8.07(m, 2H); 7.99(d, 1H).
-
- A mixture of 3-[(2-quinoxalinylcarbonyl)amino]-2-thiophenecarboxylic acid (0.70 g, 2.3 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC, 2.24 g, 11.5 mmol), and 4-(dimethylamino)pyridine (DMAP, 1.43 g, 11.5 mmol) in CH2Cl2 (100 mL) was stirred at room temperature for 2 h. To the reaction mixture was added aqueous ammonia (40%, 5 mL), and the stirring continued for another 12 h. The solvent was evaporated to dryness and the resulting solid was washed with satd NH4Cl solution (3×), NaHCO3 solution and H2O. The organic phase was evaporated to dryness resulting in a white powder (0.32 g, 46%).
- HPLC/MS: (M+H)+ 299.4 m/z
- Retention time (LC−MS)=2.74 min.
-
- To a solution of N-[2-(aminocarbonyl)-3-thienyl]-2-quinoxalinecarboxamide (0.24 g, 0.8 mmol) in ethanol (15 mL) was added aqueous NaOH (1.0 M, 2.4 mL). The resulting mixture was stirred at reflux temperature overnight. The mixture cooled to rt and the solvent was removed under reduced pressure. The residue was dissolved in water and acidified with HCl. The white precipitate was filtered and washed thoroughly with water to give product as yellow powder (0.17 g, 77%). HPLC/MS: (M+H)+ 281.1 m/z
- Retention time (LC−MS)=2.78 min.1H NMR (DMSO-D6): 12.65 (s, 1H, broad); 9.77(s, 1H); 8.32(d, 1H); 8.28(m, 1H); 8.23(m, 1H); 8.01(m, 2H); 7.63 (d, 1H).
-
- A solution of 2-(2-quinoxalinyl)thieno[3,2-d]pyrimidin-4-ol (150 mg, 0.54 mmol) in POCl3 (5 mL) was heated to reflux and maintained at reflux overnight. After cooling to rt, excess POCl3 was removed under reduced pressure to give the crude product which was used in the next step without further purification.
-
- Bg9 procedure similar to Example 1, step 2, 2-(4-chlorothieno[3,2-d]pyrimidin-2-yl)quinoxaline and 5-aminoindoazole were allowed to react in THF. After the removal of the solvent, the crude product was purified through column (gradient from 20% to 80% EtOAc/hexane) to afford the product. HPLC/MS: (M+H)+ 396.1 m/z. Retention time (LC−MS)=2.42 min.
-
-
-
- To a mixture of malonontrile (0.96 g, 14.6 mmol), acetol (1.08 g, 14.6 mmol) in methanol (10 mL) at 0° C. was added, dropwise, triethylamine (2.0 mL). The reaction mixture was stirred at room temperature overnight. After removal of solvent under reduced pressure the crude solid was washed with cold isopropanol to give product as white powder (0.54 g, 30%). HPLC/MS: (M+H)+ 123.3 m/z. Retention time (LC−MS)=1.81 min. 1H NMR (CD3OD): 6.58(s, 1H,); 1.95 (s, 3H).
-
- The Vilsmeier Reagent was prepared by stirring of 3-methoxy-N,N-dimethylbenzamide (1.17 g, 7.9 mmol) and POCl3 (3.0 g, 19.7 mmol) at 0° C. for 30 minutes. To this reagent was added 2-amino-4-methyl-3-furonitrile (1.0 g, 6.6 mmol) and dry dichloroethane (5.0 ml). The reaction mixture was heated to 40° C. and stirred at this temperature for 18 h. The mixture was then poured into ice water. After adjusting the pH of the solution to 9 via treatment with NaHCO3 solution, the solution was extracted with dichloromethane. The organic layer was then dried and concentrated. The crude product was purified by silica gel column chromatography (10/90, ethyl acetate/hexane). HPLC/MS: (M+H)+ 275.1 m/z. Retention time (LC−MS)=3.99 min. 1H NMR (DMSO-D6): 8.10 (s, 1H,); 7.98(d, 1H); 7.86 (m, 1H); 7.49 (t, 1H); 7.15 (m, 1H); 3.85 (s, 3H).
-
- A mixture of 4-chloro-2-(3-methoxyphenyl)-5-methylfuro[2,3-d]pyrimidine and 5-Aminoindazole in butanol (2.0 ml) was heated to 100° C. overnight. After the removal of the solvent, the crude product was purified through column (gradient from 20% to 80% ethyl acetate/hexane) to give product Bay 59-8843 (15.2 mg).
- HPLC/MS: (M+H)+ 372.4 m/z. Retention time (LC−MS)=2.53 min. 1H NMR (DMSO-D6): 13.10(s, 1H, NH); 8.70(s, 1H, NH); 8.11(s, 2H); 7.90(m, 2H); 7.75(m, 2H); 7.63(d, 1H); 7.41(t, 1H); 7.05(m, 1H); 3.80 (s, 3H).
- Utilizing a similar procedure to that described above and substituting the appropriate 4-chloro-2-substituted phenyl 5-methylfluro[2,3 mL] pyrimidine, the following compounds were prepared.
TABLE 3 RT (min) Example (from LC-) Mass Spec No R1 R2 MS) [electrospray] 67 5-Me H 3.31 MH+ 342.1 68 5-Me 4-OMe 3.42 MH+ 372.2 69 5.6-Di-Me H 3.65 MH+ 356.3 70 5.6-Di-Me 3-OCH3 3.49 MH+ 386.1 -
- To a solution of N-(1H-indazol-5-yl)-2-(3-methoxyphenyl)-5-methylfuro[2,3-d]pyrimidin-4-amine (50.0 mg, 0.13 mmol) in CH2Cl2 (20 mL) cooled to −78° C. was added BBr3 (0.7 mL, 2.83 mmol, 1M solution in CH2Cl2) drop-wise. The mixture warmed to rt and was stirred overnight. The reaction was quenched with water and the organic and aqueous phases were separated. The organic layer was dried and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (gradient from 20% to 80% EtOAc/hexane) to afford are product (8.4 mg, 17.5%). HPLC/MS: (M+H)+ 358.1 m/z. Retention time (LC−MS)=3.01 min. 1H NMR (DMSO-D6): 8.54(s, NH); 8.11(d, 1H); 8.07(s, 1H); 7.75(m, 3H); 7.60(d, 1H); 7.47(d, 1H); 7.20(t, 1H); 6.83(m, 1H).
-
-
- 2-Chloro-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine (10 mmol, 1 equivalent) was suspended in dimethyl ethylene glycol (60 mL) and Na2CO3 solution (2M, 10 mL) and flushed with argon for 20 min. To this suspension 3-aminophenyl boronic acid (25 mmol, 2.5 eq) and Pd(PPh3)4(2.5 mmol, 0.25 eq) were added. The reaction mixture was refluxed under AR at 100° C. for 48 h. The solvent was evaporated off in vacuo. The residue was taken into THF (100 mL) plus EtOAc/water. (100 mL, 1:1). The organic layer was evaporated to dryness. The residue was separated by silica gel column chromatography (0-5% MeOH in CH2Cl2). The product was obtained as yellow powder (2.04 g, 57%). (M+H)+=359, RT (LC−MS)=1.93.
-
- To a cold solution of the product of step 1 (3.35 mmol, 1 eq) in dry pyridine (50 mL) was added isonicotonic anhydride (6.7 mmol, 2 eq) in two portions. A precipitate formed shortly after the addition. The reaction mixture was stirred at room temperature for 4 h and poured into ice and was stirred continued. The solid was collected by filtration and washed with water. This crude product was further purified by silica gel column chromatography (0-4% MeOH/CH2Cl2) to afford a pale yellow solid (0.8 g, 50%). (M+H)+=464, RT (LC−MS)=2.12.
-
- Preparation of N-(1H-indazol-5-yl)-N-[2-(2-naphthylamino)thieno[3,2-d]pyrimidin-4-yl]amine
- To a solution of 2-chloro-N-(1-H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine (0.166 mmol) in n-BuOH (1.5 mL) was added 2-aminonaphthylene (0.5 mmol, 3 equivalent) and was stirred at 100° C. for two days. The resulted solid was collected on funnel, washed with isopropanol and ether to give a pale gray crystalline product (74%). (M+H)+=409, RT (LC−MS)=2.56.
- Utilizing this method and substituting the appropriate starting materials, the compounds shown in Table 5 were also prepared.
TABLE 5 Mass LC-MS Spec Ex. No Ar RT (min) (source) 73 3-aminophenyl 1.93 359 74 3- 2.12 464 isonicotinamid o-phenyl 75 5-(1H- 2.34 398 indolyl)amino 76 4- 2.78 451 phenoxyanilino -
-
- A solution of 2-fluoro-5-nitroacetophenone (1.57 g, 8.6 mmol) in ethylene glycol (50 mL) was added hydrazine (0.29 g, 9.0 mmol) was stirred for 2 h at room temperature and then heated at 165° C. for 24 h. The reaction mixture was cooled to room temperature, poured over EtOAc (100 mL), and extracted with H2O (2×100 mL). The organic layers was dried over Na2SO4 and the solvent was removed in vacuo. The crude product was purified by silica gel chromatography to afford a light yellow solid (0.8 g, 53%) Rf=0.2 (EtOAc/hexane, 1/3). 1H NMR CDCl3 δ8.63 (s, 1H), 8.23 (d, 2H, J=3 Hz), 7.46 (d, 1H, J=3 Hz), 2.60 (s, 3H).
-
- To a stirred solution of the compound prepared in step 1 (0.8 g, 4 mmol) in methanol was added Pd/C catalyst (0.1 g) The resulting reaction mixture was stirred under a hydrogen atmosphere (1 atm) at room temperature overnight. The mixture was filtered and the filtrate was concentrated in vacuo to afford crude product (0.7 g) as light yellow solid that was not further purified. Rf=0.50 (EtOAc/hexane, 1/1).
-
-
- A mixture of the compound in step 2 (0.7 g, 4.8 mmol), Example 1, step 1, (0.98 g, 4.8 mmol) and potassium acetate (0.66 g, 6.7 mmol) in THF/H2O (75 mL, 2/1) was stirred at room temperature for 16 h. The mixture was extracted with EtOAc, washed with brine, and dried over NaSO4. The solvent was filtered and evaporated to dryness. The residue was purified by silica gel column chromatography to afford a yellow solid (1.2 g, 80% yield). Rf=0.3 (EtOAc/hexane, 1/1). 1H NMR (Methanol-d4) δ7.95−7.80 (m, 2H), 7.63−7.50 (m, 2H), 7.19 (d, 1H, J=3 Hz), 2.40 (s, 3H).
-
- A procedure analogous for that of Example 1, step 3 was followed. A mixture of the step 3 product (0.4 g, 1.3 mmol), 3-phenylphenylboronic acid, (0.3 g, 1.5 mmol) and sodium bicarbonate (0.33 g, 3.9 mmol) in DME/H2O (3/1, 56 mL) was flushed with Ar for 1 h, and Pd(dppf)Cl2 was added. The solution was heated to reflux for 48 h at 100° C. After removal of solvent in vacuo, the crude product was purified by silica gel chromatography to afford a white solid (0.35 g, 65%). R =0.2 (EtOAc/hexane, 1/1). 1H NMR (Methanol-d4) δ8.69 (s, 1H), 8.35 (d, 1H, J=3 Hz), 8.25 (s, 1H), 8.00 (d, 1H, J=3 Hz), 7.70−7.60 (m, 4H), 7.51−7.31 (m, 6H), 2.42 (s, 3H).
-
-
- To a solution of 2-aminonicotinic acid (91.1 g, 8.0 mmol), triethylamine (2.7 mL, 19.1 mmol) and acetone/H2O (3:1, 100 mL) was added 1-benzothiophene-2-carbonyl chloride (2.04 g, 10.4 mmol) at 0° C. The resulting solution was allowed to warm to rt and stir overnight. The volatile solvent was removed under reduced pressure and the aqueous solution was acidified with HCl (conc.). The resulting precipitate was filtered and then washed with EtOAc and dried under reduced pressure to afford the product. (1.2 g, 52%). NMR (DMSO): 11.7(1H, broad), 8.60(1H, m); 8.36(1H, s); 8.25(1H, d); 8.07(1H, d); 8.02(1H, d); 7.51(2H, m); 7.36(1H, m).
-
- A mixture of 2-[(1-benzothien-2-ylcarbonyl)amino]nicotinic acid (1.2 g, 4.0 mmol), EDC (2.3 g, 12.0 mmol) and DMAP (1.46 g, 12.0 mmol) in anhyd dichloromethane (50 mL) was stirred at room temperature for 2 h. To this mixture was added 40% aqueous ammonia (4.0 mL), and the resulting solution stirred at room temperature overnight. The solvent was removed in vacuo and the resulting solid was washed with satd NH4Cl solution, NaHCO3 solution, and water. The solid was dried to give product as white powder (0.92 g, 77%). HPLC/MS: (M+H)+ 298.15 m/z Retention time (LC−MS)=2.44 min. 1H NMR (DMSO-D6): 12.25 (1H, s); 8.54(1H, m); 8.21(1H, s); 8.18(1H, d); 8.07(2H, m); 7.52(2H, m); 7.32(1H, m).
-
- To a solution of 2-[(1-benzothien-2-ylcarbonyl)amino]nicotinamide (0.3 g, 1.0 mmol) in ethanol (20 mL) was added NaOH (10 N, 0.3 mL, 3.0 mmol). The resulting solution was heated to reflux overnight. On cooling to rt the solvent was removed under reduced pressure. The residue was dissolved in excess of water and acidified with HCl. The resulting precipitate was filtered and washed with water to afford the product as yellow powder (0.16 g, 57%). HPLC/MS: (M+H)+ 280.0 m/z; Retention time (LC−MS)=2.66 min; 1H NMR (DMSO-D6): 13.17 (1H, s); 8.94(1H, m); 8.61(1H, s); 8.50(1H, d); 8.08(1H, d); 7.97(1H, d); 7.52(3H, m).
-
- To a suspension of 2-(1-benzothien-2-yl)pyrido[2,3-d]pyrimidin-4-ol_(150 mg, 0.54 mmol) in chloroform (10 mL) was added thionyl chloride (0.47 mL, 6.4 mmol) and a catalytic amount of DMF. The reaction was heated to reflux for 4 h and allowed to cool to rt. The solvent was removed under reduced pressure and the resultant product was (18.2 mg, 12%) used directly in the next step without further purification. HPLC/MS: (M+H)+ 298.2 m/z; Retention time (LC−MS)=3.76 min;
-
-
- A mixture of 2-(1-benzothien-2-yl)-4-chloropyrido[2,3-d]pyrimidine (18.2 mg, 0.06 mmol), 5-aminoindazole (40 mg, 0.3 mmol) and potassium carbonate (83 mg, 0.6 mmol) in dioxane (20 mL) was heated to 100° C. and continued for 24 h. After removal of the solvent, the crude product was purified by silica gel column chromatography (gradient from 20% to 80% EtOAc/hexane) to give the product (1.0 mg, 4.0%); HPLC/MS: (M+H)+ 395.2 m/z; Retention time (LC−MS)=2.75 min.
- The following compounds are prepared analogously:
MS Example No. Structure (Exact Mass) MW (calcd) 79 372.12 372.45 80 406.08 406.90 81 386.13 386.48 82 386.13 386.48 83 416.14 416.51 84 386.13 386.48 85 420.09 420.93 86 390.11 390.44 87 390.11 390.44 88 390.11 390.44 89 408.10 408.43 90 404.12 404.47 91 440.10 440.45 92 386.13 386.48 93 400.15 400.51 94 428.18 428.56 95 432.14 432.51 96 390.11 390.44 97 465.14 465.54 98 452.12 452.50 99 467.10 467.58 100 467.10 467.58 101 435.13 435.51 102 465.14 465.54 103 467.10 467.58 104 412.12 412.48 105 429.08 429.53 106 433.05 433.88 107 438.14 438.52 108 442.08 442.53 109 470.14 470.53 110 492.98 494.40 111 409.11 409.47 112 409.11 409.47 113 418.10 418.44 114 425.11 425.47 115 457.17 457.56 116 441.17 441.56 117 463.14 463.59 118 471.18 471.59 119 483.11 483.48 120 492.11 492.49 121 443.19 443.58 122 463.13 463.99 123 443.15 443.53 124 373.11 373.44 125 373.11 373.44 126 373.11 373.44 127 387.13 387.47 128 402.13 402.48 129 392.06 392.87 130 417.10 417.45 131 417.10 417.45 132 440.10 440.45 133 456.10 456.45 134 408.10 408.43 135 408.10 408.43 136 458.09 458.44 137 425.12 425.48 138 398.11 398.45 139 362.09 362.41 140 395.15 395.49 141 386.13 386.48 142 506.20 506.64 143 484.09 484.97 144 378.16 378.50 145 359.10 359.41 146 373.11 373.44 147 393.06 393.86 148 409.11 409.47 149 409.11 409.47 150 409.11 409.47 151 392.06 392.87 152 388.11 388.45 153 402.09 402.44 154 372.12 372.45 155 386.13 386.48 156 383.10 383.44 157 372.12 372.45 158 402.13 402.48 159 402.13 402.48 160 418.12 418.48 161 404.11 404.45 162 380.14 380.47 163 401.14 401.50 164 442.08 442.42 165 336.12 336.42 166 409.17 409.52 167 376.09 376.42 168 326.09 326.38 169 322.10 322.39 170 380.11 380.43 171 350.13 350.45 172 378.16 378.50 173 365.14 365.46 174 364.15 364.47 175 366.13 366.45 176 455.19 455.59 177 414.16 414.53 178 361.11 361.43 179 402.13 402.48 180 445.08 445.53 181 436.01 437.33 182 398.13 398.49 183 433.06 433.49 184 475.04 475.98 185 379.07 379.47 186 418.17 418.53 187 434.03 434.43 188 402.14 402.48 189 450.13 450.52 190 467.10 467.58 191 388.11 388.45 192 386.13 386.48 193 386.13 386.48 194 408.12 408.49 195 389.11 389.44 196 426.09 426.42 197 402.13 402.48 198 426.09 426.42 199 388.11 388.45 200 422.13 422.51 201 378.07 378.48 202 440.04 441.34 203 448.15 448.55 204 416.14 416.51 205 359.10 359.41 206 398.13 398.49 207 412.15 412.52 208 456.18 456.58 209 437.01 438.32 210 450.03 451.35 211 443.13 443.51 212 404.18 404.54 213 409.11 409.47 214 436.12 436.50 215 441.14 441.52 216 444.09 444.54 217 445.07 446.51 218 446.11 446.56 219 451.05 451.48 220 453.14 453.53 221 466.13 466.53 222 477.11 477.98 223 484.10 484.57 224 465.14 465.54 225 404.08 404.41 226 393.06 393.86 227 434.13 434.52 228 423.13 423.50 229 393.17 393.52 230 451.09 451.53 231 398.13 398.49 232 462.03 463.37 233 399.09 399.44 234 433.20 433.58 235 426.16 426.55 236 427.16 427.53 237 467.16 467.56 238 457.17 457.56 - Intermediates
- Intermediate A
-
-
- To 3-thiophenecarboxaldehyde (8.75 mL) cooled to 0° C. was added aminoacetaldehyde dimethylacetal (14.2 mL). The clear solution was stirred at room temperature for 60 h. The solution was diluted with ethanol and hydrogenated at 56 psi in the presence of 10% Pd/C (5 g) overnight. The catalyst was filtered off and washed with MeOH. The solvent was removed by rotary evaporation and co-evaporated with toluene to afford an oil (19 g, 94% yield).
-
- To a solution of the compound prepared in step 1, (19 g, 95 mmol) in EtOAc (50 mL) at 15° C. was added triethylamine (12 mL, 85.5 mmol), followed by p-toluenesulfonyl chloride (16.3 g, 85.5 mmol). After the addition was complete, the solution was stirred at rt overnight. The reaction mixture was diluted with EtOAc and washed with water three times, HCl (1.0 M), and with satd Na2CO3 The solution was dried over MgSO4, filtered, and concentrated to give a precipitate (31 g, 87 mmol, 91% yield). Rf=0.16 (EtOAc/hexane, 1/9).
-
- To a solution of the compound from step 2 (31 g, 0.087 mol) in dioxane (80 mL) was added conc HCl (45 mL). The solution was heated to reflux temperature overnight. The mixture was cooled to rt and washed with CH2Cl2. The aqueous phase was basified with aqueous NH4OH while cooling with ice and extracted with CH2Cl2. The organic washings were combined and evaporated to dryness. The residue was purified by silica gel column chromatography (25% EtOAc in hexanes) to afford a white precipitate. The precipitate was dissolved with CH2Cl2, dried over MgSO4, filtered, and concentrated to give 5.97 g of white precipitate (50% yield).
-
- To a solution of (0.3 g) in THF (15 mL) was added n-BuLi (1.4 mL, 1.6 M in hexane) at −78° C. The solution was stirred at −78° C. for 70 min and triisopropyl borate (0.52 mL, 2.27 mmol) was added. The solution was stirred for an additional 30 min at −78° C., and then at room temperature for 30 min. The solvent was concentrated under reduced pressure and the crude product was used without purification.
- Intermediate B
-
-
- A solution of 1-bromo-4-iodobenzene (5.0 g, 18 mmol), morpholine (1.85 mL, 21 mmol), sodium tert-butoxide (2.4 g, 25 mmol), 18-crown-6 (6.6 g, 25 mmol) in THF (150 mL)was purged with Ar for 20 min, then BINAP (0.11 g, 0.18 mmol) and Pd2(dba)3(0.16 g, 0.18 mmol) was added. The mixture turned dark after stirring at room temperature overnight. The solvent was concentrated under reduced pressure and the residue was dissolved in diethyl ether and washed with water. The organic phase was mixed with silica gel, and the solvent was evaporated to dryness. The residue was purified by silica gel column chromatography (EtOAc in hexanes 5%) to of white precipitate (250 mg, 5% yield). 1H NMR (CDCl3): 7.3 (d, 2H), 6.85 (d, 4H), 3.1 (d, 4H).
-
- To a solution of the compound prepared in step 1 (0.3 g) in THF (15 mL) was added n-BuLi (0.74 mL, 2 M in pentane) at −78° C. After 1 h triisopropyl borate (0.86 mL) was added at −78° C. The solution was warmed up slowly from −78° C. to room temperature and was stirred overnight. The solution was added to aqueous NH4Cl, a white precipitate formed, and EtOAc was added. The organic solution was separated, concentrated and co-evaporated with toluene. The residue was washed twice with THF and filtered. The filtrate was concentrated and dried under high vacuum to give 0.25 g of light yellow precipitate. LC/MS m/z 208 (M+H)+.
- The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
Claims (19)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/339,393 US20040014755A1 (en) | 2002-01-10 | 2003-01-10 | Rho-kinase inhibitors |
US11/733,045 US7648986B2 (en) | 2002-01-10 | 2007-04-09 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors |
US12/688,428 US20100216789A1 (en) | 2002-01-10 | 2010-01-15 | Rho-kinase inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34662802P | 2002-01-10 | 2002-01-10 | |
US10/339,393 US20040014755A1 (en) | 2002-01-10 | 2003-01-10 | Rho-kinase inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/733,045 Continuation US7648986B2 (en) | 2002-01-10 | 2007-04-09 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040014755A1 true US20040014755A1 (en) | 2004-01-22 |
Family
ID=23360296
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/339,393 Abandoned US20040014755A1 (en) | 2002-01-10 | 2003-01-10 | Rho-kinase inhibitors |
US11/733,045 Expired - Fee Related US7648986B2 (en) | 2002-01-10 | 2007-04-09 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors |
US12/688,428 Abandoned US20100216789A1 (en) | 2002-01-10 | 2010-01-15 | Rho-kinase inhibitors |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/733,045 Expired - Fee Related US7648986B2 (en) | 2002-01-10 | 2007-04-09 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors |
US12/688,428 Abandoned US20100216789A1 (en) | 2002-01-10 | 2010-01-15 | Rho-kinase inhibitors |
Country Status (8)
Country | Link |
---|---|
US (3) | US20040014755A1 (en) |
EP (1) | EP1465900B1 (en) |
JP (1) | JP4505228B2 (en) |
AU (1) | AU2003202263A1 (en) |
CA (1) | CA2472619A1 (en) |
DE (1) | DE60320933D1 (en) |
ES (1) | ES2305435T3 (en) |
WO (1) | WO2003059913A1 (en) |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060142314A1 (en) * | 2001-03-23 | 2006-06-29 | Dhanapalan Nagarathnam | Rho-kinase inhibitors |
US20060142313A1 (en) * | 2001-03-23 | 2006-06-29 | Dhanaphalan Nagarathnam | Rho-kinase inhibitors |
US20070259896A1 (en) * | 2004-12-23 | 2007-11-08 | Ruiping Liu | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
US20080139595A1 (en) * | 2004-04-08 | 2008-06-12 | Bayer Healthcare Ag | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors |
US20080176871A1 (en) * | 2006-11-09 | 2008-07-24 | Ardea Biosciences, Inc. | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
US20080249105A1 (en) * | 2003-12-09 | 2008-10-09 | Bayer Healthcare Ag | Pyrrolopyridine-Substituted Benzol Derivatives for Treating Cardiovascular Diseases |
US20100204240A1 (en) * | 2007-09-21 | 2010-08-12 | Array Biopharma Inc. | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus |
WO2010124142A2 (en) | 2009-04-22 | 2010-10-28 | Cythera, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
WO2011047300A1 (en) | 2009-10-16 | 2011-04-21 | The Scripps Research Institute | Induction of pluripotent cells |
WO2011159684A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
WO2012135621A2 (en) | 2011-03-30 | 2012-10-04 | Cellular Dynamics International. Inc | Priming of pluripotent stem cells for neural differentiation |
WO2013009825A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
WO2013137491A1 (en) | 2012-03-15 | 2013-09-19 | 国立大学法人京都大学 | Method for producing cardiac and vascular cell mixture from artificial pluripotent stem cells |
WO2013151186A1 (en) | 2012-04-06 | 2013-10-10 | 国立大学法人京都大学 | Method for inducing erythropoietin-producing cell |
WO2014160413A1 (en) | 2013-03-14 | 2014-10-02 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells |
WO2014165663A1 (en) | 2013-04-03 | 2014-10-09 | Cellular Dynamics International, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
WO2014168264A1 (en) | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | Method for inducing alveolar epithelium progenitor cells |
WO2014200115A1 (en) | 2013-06-11 | 2014-12-18 | 国立大学法人京都大学 | Method for producing renal precursor cells, and drug containing renal precursor cells |
WO2015020113A1 (en) | 2013-08-07 | 2015-02-12 | 国立大学法人京都大学 | Method for producing pancreatic hormone-producing cell |
WO2015034012A1 (en) | 2013-09-05 | 2015-03-12 | 国立大学法人京都大学 | New method for inducing dopamine-producing neural precursor cells |
US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
WO2017075389A1 (en) | 2015-10-30 | 2017-05-04 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
WO2017183736A1 (en) | 2016-04-22 | 2017-10-26 | 国立大学法人京都大学 | Method for producing dopamine-producing neural precursor cells |
EP3255142A1 (en) | 2009-10-19 | 2017-12-13 | Cellular Dynamics International, Inc. | Cardiomyocyte production |
WO2018035214A1 (en) | 2016-08-16 | 2018-02-22 | Cellular Dynamics International., Inc. | Methods for differentiating pluripotent cells |
WO2018216743A1 (en) | 2017-05-25 | 2018-11-29 | 国立大学法人京都大学 | Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell |
WO2019092939A1 (en) | 2017-11-10 | 2019-05-16 | 株式会社リジェネシスサイエンス | Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease |
WO2019131940A1 (en) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | Pluripotent stem cell aggregation inhibitor |
WO2019131941A1 (en) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | Cell aggregation inhibitor |
WO2019131942A1 (en) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | Cell aggregation promoting agent |
WO2019160148A1 (en) | 2018-02-19 | 2019-08-22 | 大日本住友製薬株式会社 | Cell aggregate, mixture of cell aggregates, and method for preparing same |
US10472610B2 (en) | 2014-05-21 | 2019-11-12 | Kyoto University | Method for generating pancreatic bud cells and therapeutic agent for pancreatic disease containing pancreatic bud cells |
WO2020022261A1 (en) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same |
WO2020130147A1 (en) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage |
US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
WO2020193802A1 (en) | 2019-03-28 | 2020-10-01 | Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe | Polymeric conjugates and uses thereof |
WO2020203538A1 (en) | 2019-03-29 | 2020-10-08 | 株式会社カネカ | Cell population including pluripotent stem cells and production method thereof |
WO2020230832A1 (en) | 2019-05-15 | 2020-11-19 | 味の素株式会社 | Method for purifying neural crest cells or corneal epithelial cells |
US11268069B2 (en) | 2014-03-04 | 2022-03-08 | Fate Therapeutics, Inc. | Reprogramming methods and cell culture platforms |
WO2022149616A1 (en) | 2021-01-08 | 2022-07-14 | 国立大学法人京都大学 | Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids |
US11441126B2 (en) | 2015-10-16 | 2022-09-13 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
WO2022216911A1 (en) | 2021-04-07 | 2022-10-13 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
WO2022259721A1 (en) | 2021-06-10 | 2022-12-15 | 味の素株式会社 | Method for producing mesenchymal stem cells |
WO2023017848A1 (en) | 2021-08-11 | 2023-02-16 | 国立大学法人京都大学 | Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells |
WO2023039588A1 (en) | 2021-09-13 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7557112B2 (en) * | 2004-10-08 | 2009-07-07 | Astellas Pharma Inc. | Aromatic-ring-fused pyrimidine derivative |
WO2007076360A1 (en) | 2005-12-22 | 2007-07-05 | Alcon Research, Ltd. | (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions |
DK1869037T3 (en) | 2005-03-25 | 2011-10-24 | Tibotec Pharm Ltd | Heterobicyclic inhibitors of HVC |
TW200716631A (en) | 2005-05-12 | 2007-05-01 | Tibotec Pharm Ltd | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof |
AR056347A1 (en) | 2005-05-12 | 2007-10-03 | Tibotec Pharm Ltd | USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS |
US8629161B2 (en) | 2005-06-21 | 2014-01-14 | Kowa Co., Ltd. | Preventive or remedy for glaucoma |
WO2007008926A1 (en) * | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
WO2007008942A2 (en) * | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases |
US8193193B2 (en) | 2005-07-12 | 2012-06-05 | Kowa Co., Ltd. | Agent for prevention or treatment of glaucoma |
ES2378473T3 (en) * | 2005-12-21 | 2012-04-12 | Abbott Laboratories | Antiviral compounds |
ES2395386T3 (en) | 2005-12-21 | 2013-02-12 | Abbott Laboratories | Antiviral compounds |
US7867999B1 (en) | 2005-12-22 | 2011-01-11 | Alcon Research, Ltd. | Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions |
EP1999135A2 (en) * | 2006-03-30 | 2008-12-10 | Takeda San Diego, Inc. | Kinase inhibitors |
EP1847543A1 (en) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidines for the treatment of inflammatory diseases |
MX2007012313A (en) | 2006-04-19 | 2007-11-21 | Boehringer Ingelheim Int | Dihydrothienopyrimidines for the treatment of inflammatory diseases. |
EP2526948A1 (en) | 2006-09-20 | 2012-11-28 | Aerie Pharmaceuticals, Inc. | RHO kinase inhibitors |
UA100846C2 (en) | 2006-12-08 | 2013-02-11 | Айерем Елелсі | Compounds and compositions as protein kinase inhibitors |
CA2671744C (en) * | 2006-12-08 | 2012-08-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2008133753A2 (en) | 2006-12-20 | 2008-11-06 | Abbott Laboratories | Anti-viral compounds |
AR064420A1 (en) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS THAT INCLUDE AN EFFECTIVE AMOUNT OF ANALOGS OF 6-AMINOIMIDAZO [1,2B] PIRIDAZINAS, USEFUL FOR THE TREATMENT OF GLAUCOMA AND / OR CONTROL THE NORMAL OR ELEVATED INTRAOCULAR PRESSURE (IOP). |
US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US7981903B2 (en) * | 2007-08-08 | 2011-07-19 | Glaxosmithkline Llc | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer |
KR20220151013A (en) | 2007-08-29 | 2022-11-11 | 센주 세이야꾸 가부시키가이샤 | Agent for promoting corneal endothelial cell adhesion |
NZ585348A (en) | 2007-10-19 | 2012-02-24 | Boehringer Ingelheim Int | Heterocycle-substituted piperazino-dihydrothienopyrimidines |
WO2009050248A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Substituted piperidino-dihydrothienopyrimidines |
JP5563466B2 (en) | 2007-10-19 | 2014-07-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel piperazino-dihydrothienopyrimidine derivatives |
JP5489235B2 (en) | 2007-11-15 | 2014-05-14 | ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド | N-containing heterocyclic compound |
US8455514B2 (en) * | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
AR070317A1 (en) | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | FURO (3,2-C) PIRIDINE AND HAVING (3,2-C) PIRIDINES |
US8450344B2 (en) * | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
EP2424842B1 (en) | 2009-05-01 | 2015-10-28 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
SG10201501272SA (en) * | 2009-10-22 | 2015-04-29 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
US20120309773A1 (en) * | 2009-12-23 | 2012-12-06 | Babu Yarlagadda S | Heterocyclic compounds as janus kinase inhibitors |
AR079814A1 (en) | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | HETEROCICLICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USES |
US8759363B2 (en) | 2010-01-28 | 2014-06-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Quinazoline-based T cell proliferation inhibitors |
UY33659A (en) * | 2010-10-08 | 2012-04-30 | Abbott Lab | FURO COMPOUNDS [3,2-D] PYRIMIDINE |
CA2817712C (en) | 2010-11-12 | 2020-03-24 | Georgetown University | Immortalization of epithelial cells and methods of use |
AU2011329486A1 (en) * | 2010-11-18 | 2013-04-18 | Glaxo Group Limited | Compounds |
EP2502924A1 (en) | 2011-03-24 | 2012-09-26 | Chemilia AB | Novel pyrimidine derivatives |
BR112013024378A2 (en) | 2011-03-24 | 2016-12-13 | Chemilia Ab | new pyrimidine derivatives |
JP6121658B2 (en) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | Therapeutic compounds and related methods of use |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
EP3517604A1 (en) | 2011-12-06 | 2019-07-31 | Astellas Institute for Regenerative Medicine | Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof |
EP3553169B1 (en) | 2011-12-28 | 2021-11-03 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
EP2711365A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
WO2014105958A2 (en) | 2012-12-26 | 2014-07-03 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
WO2014144781A1 (en) | 2013-03-15 | 2014-09-18 | Aerie Pharmaceuticals, Inc. | Combination therapy |
JP6548576B2 (en) | 2013-07-30 | 2019-07-24 | 京都府公立大学法人 | Corneal endothelial cell marker |
EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
CN104903312B (en) * | 2013-10-07 | 2019-01-29 | 卡德门企业有限公司 | RHO kinase inhibitor |
JPWO2015064768A1 (en) | 2013-10-31 | 2017-03-09 | 京都府公立大学法人 | Drugs for diseases related to endoplasmic reticulum cell death in corneal endothelium |
TW201605867A (en) * | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | Thienopyrimidines |
US11624053B2 (en) | 2013-11-27 | 2023-04-11 | Kyoto Prefectural Public University Corporation | Application of laminin to corneal endothelial cell culture |
EP2905024A1 (en) | 2014-02-07 | 2015-08-12 | Institut Quimic De Sarriá Cets, Fundació Privada | Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae |
EP3119881B1 (en) | 2014-03-21 | 2023-03-01 | FUJIFILM Cellular Dynamics, Inc. | Production of midbrain dopaminergic neurons and methods for the use thereof |
JP2017522016A (en) | 2014-06-27 | 2017-08-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Cultured mammalian limbal stem cells, production method thereof and use thereof |
CN104530078B (en) * | 2015-01-27 | 2017-03-22 | 山东大学 | Thieno [3, 2-d] pyrimidine derivative and preparation method and application thereof |
US10100285B2 (en) | 2015-04-03 | 2018-10-16 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
CN107636149A (en) | 2015-04-03 | 2018-01-26 | 普罗帕格尼克斯公司 | The vitro proliferation of epithelial cell |
US10729691B2 (en) | 2015-06-26 | 2020-08-04 | Kadmon Corporation, Llc | Treatment of infectious diseases with glucose uptake inhibitors |
WO2016210330A1 (en) | 2015-06-26 | 2016-12-29 | Kadmon Corporation, Llc | Glucose uptake inhibitors |
CA2988461A1 (en) * | 2015-06-26 | 2016-12-29 | Dana-Farber Cancer Institute, Inc. | Fused bicyclic pyrimidine derivatives and uses thereof |
US10066201B2 (en) | 2015-09-11 | 2018-09-04 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
CN108601355B (en) | 2015-11-17 | 2021-03-30 | 爱瑞制药公司 | Process for preparing kinase inhibitors and intermediates thereof |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
EP3383401B1 (en) * | 2015-12-03 | 2020-05-20 | Zheijiang Jianfreng-Yien Biotechnology Co., Ltd. | Thieno-pyrimidine derivatives and uses thereof |
US10844074B2 (en) | 2015-12-03 | 2020-11-24 | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. | Heterocycle compounds and uses thereof |
WO2017112777A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
EP4218773A1 (en) | 2016-02-15 | 2023-08-02 | Kyoto Prefectural Public University Corporation | Human functional corneal endothelial cell and application thereof |
CN107652273B (en) * | 2016-07-26 | 2020-05-01 | 沈阳药科大学 | Pyrimidine derivative and preparation method and application thereof |
KR102568082B1 (en) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | ophthalmic composition |
SG11201907139UA (en) | 2017-02-03 | 2019-09-27 | Certa Therapeutics Pty Ltd | Anti-fibrotic compounds |
WO2018183911A1 (en) | 2017-03-31 | 2018-10-04 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
MA49458A (en) | 2017-06-21 | 2020-04-29 | SHY Therapeutics LLC | COMPOUNDS INTERACTING WITH THE RAS SUPERFAMILY FOR USE IN THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES AND FIBROTIC DISEASES |
US10323023B2 (en) | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
JP7311228B2 (en) | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | RHO-related protein kinase inhibitors, pharmaceutical compositions containing same and methods for preparation and use thereof |
US10329282B2 (en) | 2017-06-30 | 2019-06-25 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
EP3675861A4 (en) * | 2017-09-01 | 2021-01-06 | Kadmon Corporation, LLC | Inhibitors of rho associated coiled-coil containing protein kinase |
CA3107502A1 (en) | 2018-08-20 | 2020-02-27 | Chengkang ZHANG | Epithelial cell spheroids |
EP3843845A4 (en) | 2018-08-29 | 2022-05-11 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
US20210207088A1 (en) | 2018-08-31 | 2021-07-08 | The Doshisha | Composition and method for preserving or culturing ocular cells |
AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
EP3862424A4 (en) | 2018-10-02 | 2022-06-29 | The Doshisha | Method and vessel for preserving corneal endothelial cells |
UY38427A (en) | 2018-10-26 | 2020-05-29 | Novartis Ag | METHODS AND COMPOSITIONS FOR EYE CELL THERAPY |
JP2022511457A (en) * | 2018-11-30 | 2022-01-31 | セルラリティ インク. | Aromatic compounds for use in activating hematopoietic stem cells and progenitor cells |
WO2021172554A1 (en) | 2020-02-27 | 2021-09-02 | 京都府公立大学法人 | Functional human corneal endothelial cells and application thereof |
CN115667504A (en) | 2020-04-27 | 2023-01-31 | 诺华股份有限公司 | Methods and compositions for ocular cell therapy |
EP4334437A1 (en) | 2021-05-03 | 2024-03-13 | Astellas Institute for Regenerative Medicine | Methods of generating mature corneal endothelial cells |
WO2023069949A1 (en) | 2021-10-18 | 2023-04-27 | Evia Life Sciences Inc. | Compositions and methods of use thereof for treating liver fibrosis |
WO2023067394A2 (en) | 2021-10-22 | 2023-04-27 | Evia Life Sciences Inc. | Methods for making extracellular vesicles, and compositions and methods of use thereof |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4642347A (en) * | 1985-05-21 | 1987-02-10 | American Home Products Corporation | 3(2-quinolinylalkoxy)phenols |
US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
US5240940A (en) * | 1988-01-29 | 1993-08-31 | Dowelanco | Quinoline and cinnoline fungicide compositions |
US5245036A (en) * | 1992-05-07 | 1993-09-14 | Dowelanco | Process for the preparation of 4-phenoxyquinoline compounds |
US5324839A (en) * | 1991-02-07 | 1994-06-28 | Roussel-Uclaf | Nitrogenous bicyclic derivatives substituted with benzyl |
US5817674A (en) * | 1991-02-07 | 1998-10-06 | Roussel Uclaf | Quinoline compounds |
US5840695A (en) * | 1994-10-07 | 1998-11-24 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
US5885803A (en) * | 1997-06-19 | 1999-03-23 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
US5958944A (en) * | 1994-04-18 | 1999-09-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzamide compounds and pharmaceutical use thereof |
US5972598A (en) * | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
US5977102A (en) * | 1996-03-06 | 1999-11-02 | Dr. Karl Thomae Gmbh | Pyrimido [5, 4-d] pyrimidines, pharmaceuticals containing these compounds, their use and processes for their preparation |
US6004979A (en) * | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
US6153617A (en) * | 1997-07-29 | 2000-11-28 | Warner-Lambert Company | Irreversible bicyclic inhibitors of tyrosine kinases |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6218410B1 (en) * | 1996-08-12 | 2001-04-17 | Yoshitomi Pharmaceutical Industries, Ltd. | Medicines comprising Rho kinase inhibitor |
US20010014679A1 (en) * | 1997-05-02 | 2001-08-16 | Tang Peng C. | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds |
US20010044442A1 (en) * | 1998-08-21 | 2001-11-22 | Parker Hughes Institute | Dimethoxy quinazolines for treating diabetes |
US6326373B1 (en) * | 1999-03-05 | 2001-12-04 | Parker Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
US6391874B1 (en) * | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5245038A (en) * | 1987-11-06 | 1993-09-14 | Baxter Diagnostics Inc. | Fluorescent poly(arylpyridine) rare earth chelates |
DE69531558T2 (en) * | 1995-06-07 | 2004-03-18 | Pfizer Inc. | HETEROCYCLIC CONDENSED PYRIMIDINE DERIVATIVES |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
CA2214841A1 (en) | 1997-10-31 | 1999-04-30 | Lisa Mckerracher | Rho antagonists and their use to block inhibition of neurite outgrowth |
WO1999024440A1 (en) * | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
RS49779B (en) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
PT1087970E (en) * | 1998-06-19 | 2004-06-30 | Pfizer Prod Inc | PYRIMIDINE COMPOUNDS 2,3-D | PYRIMIDINE |
EP1034793B1 (en) | 1998-08-17 | 2005-10-26 | Senju Pharmaceutical Co., Ltd. | Preventives/remedies for glaucoma |
SE515247C2 (en) | 1998-09-04 | 2001-07-02 | Alfa Laval Agri Ab | Animal booth with locking means |
KR20010099890A (en) * | 1998-12-23 | 2001-11-09 | 빌프리더 하이더 | Polycarbonates with a Low Yellowness Index |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
DE19911510A1 (en) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
EP1163910B1 (en) | 1999-03-25 | 2007-09-26 | Mitsubishi Pharma Corporation | Rho kinase inhibitors for the prevention or treatment of interstitial pneumonia and pulmonary fibrosis |
AU3328600A (en) | 1999-03-25 | 2000-10-16 | Santen Pharmaceutical Co. Ltd. | Ocular tension-lowering agents |
EP1174150A4 (en) | 1999-04-22 | 2004-06-16 | Mitsubishi Pharma Corp | Preventives/remedies for angiostenosis |
ES2365692T3 (en) | 1999-04-27 | 2011-10-10 | Mitsubishi Tanabe Pharma Corporation | MEDICINAL FOR THE PREVENTION OR THERAPEUTIC TREATMENT OF HEPATIC DISEASES. |
GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
AU1212501A (en) | 1999-10-21 | 2001-04-30 | Merck & Co., Inc. | Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment |
HUP0302221A3 (en) | 2000-09-20 | 2004-01-28 | Merck Patent Gmbh | 4-amino-quinazolines |
AU9684601A (en) | 2000-10-12 | 2002-04-22 | Univ Rochester | Compositions that inhibit proliferation of cancer cells |
AU2002246924A1 (en) | 2001-01-05 | 2002-07-16 | The Medical College Of Georgia Research Institute, Inc. | Treatment of erectile dysfunction with rho-kinase inhibitors |
ATE325795T1 (en) * | 2001-03-23 | 2006-06-15 | Bayer Corp | RHO KINASE INHIBITORS |
MXPA04007196A (en) * | 2002-01-23 | 2005-06-08 | Bayer Pharmaceuticals Corp | Rho-kinase inhibitors. |
-
2003
- 2003-01-10 AU AU2003202263A patent/AU2003202263A1/en not_active Abandoned
- 2003-01-10 EP EP03701278A patent/EP1465900B1/en not_active Expired - Fee Related
- 2003-01-10 JP JP2003560016A patent/JP4505228B2/en not_active Expired - Fee Related
- 2003-01-10 CA CA002472619A patent/CA2472619A1/en not_active Abandoned
- 2003-01-10 DE DE60320933T patent/DE60320933D1/en not_active Expired - Lifetime
- 2003-01-10 US US10/339,393 patent/US20040014755A1/en not_active Abandoned
- 2003-01-10 ES ES03701278T patent/ES2305435T3/en not_active Expired - Lifetime
- 2003-01-10 WO PCT/US2003/000606 patent/WO2003059913A1/en active Application Filing
-
2007
- 2007-04-09 US US11/733,045 patent/US7648986B2/en not_active Expired - Fee Related
-
2010
- 2010-01-15 US US12/688,428 patent/US20100216789A1/en not_active Abandoned
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4642347A (en) * | 1985-05-21 | 1987-02-10 | American Home Products Corporation | 3(2-quinolinylalkoxy)phenols |
US5240940A (en) * | 1988-01-29 | 1993-08-31 | Dowelanco | Quinoline and cinnoline fungicide compositions |
US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
US5324839A (en) * | 1991-02-07 | 1994-06-28 | Roussel-Uclaf | Nitrogenous bicyclic derivatives substituted with benzyl |
US5478938A (en) * | 1991-02-07 | 1995-12-26 | Roussel Uclaf | Nitrogenous bicyclic derivatives substituted with benzyl |
US5817674A (en) * | 1991-02-07 | 1998-10-06 | Roussel Uclaf | Quinoline compounds |
US6004979A (en) * | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
US5245036A (en) * | 1992-05-07 | 1993-09-14 | Dowelanco | Process for the preparation of 4-phenoxyquinoline compounds |
US5972598A (en) * | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
US5958944A (en) * | 1994-04-18 | 1999-09-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzamide compounds and pharmaceutical use thereof |
US5932470A (en) * | 1994-10-07 | 1999-08-03 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
US5840695A (en) * | 1994-10-07 | 1998-11-24 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
US5977102A (en) * | 1996-03-06 | 1999-11-02 | Dr. Karl Thomae Gmbh | Pyrimido [5, 4-d] pyrimidines, pharmaceuticals containing these compounds, their use and processes for their preparation |
US6391874B1 (en) * | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
US6218410B1 (en) * | 1996-08-12 | 2001-04-17 | Yoshitomi Pharmaceutical Industries, Ltd. | Medicines comprising Rho kinase inhibitor |
US20010014679A1 (en) * | 1997-05-02 | 2001-08-16 | Tang Peng C. | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds |
US6207148B1 (en) * | 1997-06-19 | 2001-03-27 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
US5885803A (en) * | 1997-06-19 | 1999-03-23 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
US6153617A (en) * | 1997-07-29 | 2000-11-28 | Warner-Lambert Company | Irreversible bicyclic inhibitors of tyrosine kinases |
US20010044442A1 (en) * | 1998-08-21 | 2001-11-22 | Parker Hughes Institute | Dimethoxy quinazolines for treating diabetes |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6277989B1 (en) * | 1998-08-28 | 2001-08-21 | Scios, Inc. | Quinazoline derivatives as medicaments |
US6326373B1 (en) * | 1999-03-05 | 2001-12-04 | Parker Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
US20020055514A1 (en) * | 1999-03-05 | 2002-05-09 | Parker Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
Cited By (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060142313A1 (en) * | 2001-03-23 | 2006-06-29 | Dhanaphalan Nagarathnam | Rho-kinase inhibitors |
US20060142314A1 (en) * | 2001-03-23 | 2006-06-29 | Dhanapalan Nagarathnam | Rho-kinase inhibitors |
US20080249105A1 (en) * | 2003-12-09 | 2008-10-09 | Bayer Healthcare Ag | Pyrrolopyridine-Substituted Benzol Derivatives for Treating Cardiovascular Diseases |
US20080139595A1 (en) * | 2004-04-08 | 2008-06-12 | Bayer Healthcare Ag | Hetaryloxy-Substituted Phenylamino Pyrimidines as Rho Kinase Inhibitors |
US8329716B2 (en) | 2004-04-08 | 2012-12-11 | Bayer Intellectual Property Gmbh | Hetaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors |
US20100010017A1 (en) * | 2004-12-23 | 2010-01-14 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
US20070259896A1 (en) * | 2004-12-23 | 2007-11-08 | Ruiping Liu | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
EP2132211A2 (en) * | 2006-11-09 | 2009-12-16 | Ardea Biosciences, Inc. | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
US20090281124A1 (en) * | 2006-11-09 | 2009-11-12 | Ardea Biosciences | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
US8324223B2 (en) | 2006-11-09 | 2012-12-04 | Ardea Biosciences, Inc. | Substituted thieno [2,3-d] pyrimidines as HIV inhibitors |
US7595324B2 (en) | 2006-11-09 | 2009-09-29 | Ardea Biosciences, Inc. | Substituted thieno[3,2-D]pyrimidines as HIV inhibitors |
WO2008058285A3 (en) * | 2006-11-09 | 2009-04-09 | Ardea Biosciences Inc | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
EP2132211A4 (en) * | 2006-11-09 | 2011-12-07 | Ardea Biosciences Inc | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
US20080176871A1 (en) * | 2006-11-09 | 2008-07-24 | Ardea Biosciences, Inc. | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
US8211898B2 (en) | 2006-11-09 | 2012-07-03 | Ardea Biosciences, Inc. | Substituted thieno[3,2-d]pyrimidines as HIV inhibitors |
US20100204240A1 (en) * | 2007-09-21 | 2010-08-12 | Array Biopharma Inc. | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus |
US9079890B2 (en) | 2007-09-21 | 2015-07-14 | Array Biopharma Inc. | Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives |
US8853409B2 (en) | 2007-09-21 | 2014-10-07 | Array Biopharma Inc. | Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
US8212045B2 (en) | 2007-09-21 | 2012-07-03 | Array Biopharma, Inc. | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
EP3904505A1 (en) | 2009-04-22 | 2021-11-03 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
US9988604B2 (en) | 2009-04-22 | 2018-06-05 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
WO2010124142A2 (en) | 2009-04-22 | 2010-10-28 | Cythera, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
US9982235B2 (en) | 2009-04-22 | 2018-05-29 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
US20100272695A1 (en) * | 2009-04-22 | 2010-10-28 | Alan Agulnick | Cell compositions derived from dedifferentiated reprogrammed cells |
US11905530B2 (en) | 2009-04-22 | 2024-02-20 | Viacyte, Inc. | Cell encapsulation device comprising a pancreatic progenitor cell population |
WO2011047300A1 (en) | 2009-10-16 | 2011-04-21 | The Scripps Research Institute | Induction of pluripotent cells |
EP4206319A1 (en) | 2009-10-16 | 2023-07-05 | The Scripps Research Institute | Induction of pluripotent cells |
EP3235901A1 (en) | 2009-10-16 | 2017-10-25 | The Scripps Research Institute | Induction of pluripotent cells |
EP3255142A1 (en) | 2009-10-19 | 2017-12-13 | Cellular Dynamics International, Inc. | Cardiomyocyte production |
US8691574B2 (en) | 2010-06-15 | 2014-04-08 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
US10260048B2 (en) | 2010-06-15 | 2019-04-16 | FUJIFILM Cellular Dynamics, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
EP3382008A1 (en) | 2010-06-15 | 2018-10-03 | FUJIFILM Cellular Dynamics, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
US9447382B2 (en) | 2010-06-15 | 2016-09-20 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
WO2011159684A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
US10844356B2 (en) | 2010-12-22 | 2020-11-24 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
WO2012135621A2 (en) | 2011-03-30 | 2012-10-04 | Cellular Dynamics International. Inc | Priming of pluripotent stem cells for neural differentiation |
WO2013009825A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
WO2013137491A1 (en) | 2012-03-15 | 2013-09-19 | 国立大学法人京都大学 | Method for producing cardiac and vascular cell mixture from artificial pluripotent stem cells |
WO2013151186A1 (en) | 2012-04-06 | 2013-10-10 | 国立大学法人京都大学 | Method for inducing erythropoietin-producing cell |
US9650610B2 (en) | 2013-03-14 | 2017-05-16 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
US10376545B2 (en) | 2013-03-14 | 2019-08-13 | Viacyte, Inc. | Methods for producing hormone secreting cells in a subject |
WO2014160413A1 (en) | 2013-03-14 | 2014-10-02 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (pec) and endocrine cells |
EP3521418A1 (en) | 2013-03-14 | 2019-08-07 | ViaCyte, Inc | Cell culture |
US11446335B2 (en) | 2013-03-14 | 2022-09-20 | Viacyte, Inc. | Cryopreserved endocrine cells that express chromogranin A |
WO2014165663A1 (en) | 2013-04-03 | 2014-10-09 | Cellular Dynamics International, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
WO2014168264A1 (en) | 2013-04-12 | 2014-10-16 | 国立大学法人京都大学 | Method for inducing alveolar epithelium progenitor cells |
WO2014200115A1 (en) | 2013-06-11 | 2014-12-18 | 国立大学法人京都大学 | Method for producing renal precursor cells, and drug containing renal precursor cells |
WO2015020113A1 (en) | 2013-08-07 | 2015-02-12 | 国立大学法人京都大学 | Method for producing pancreatic hormone-producing cell |
US9796962B2 (en) | 2013-08-07 | 2017-10-24 | Kyoto University | Method for generating pancreatic hormone-producing cells |
WO2015034012A1 (en) | 2013-09-05 | 2015-03-12 | 国立大学法人京都大学 | New method for inducing dopamine-producing neural precursor cells |
US11268069B2 (en) | 2014-03-04 | 2022-03-08 | Fate Therapeutics, Inc. | Reprogramming methods and cell culture platforms |
US10472610B2 (en) | 2014-05-21 | 2019-11-12 | Kyoto University | Method for generating pancreatic bud cells and therapeutic agent for pancreatic disease containing pancreatic bud cells |
US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
US11441126B2 (en) | 2015-10-16 | 2022-09-13 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
WO2017075389A1 (en) | 2015-10-30 | 2017-05-04 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
WO2017183736A1 (en) | 2016-04-22 | 2017-10-26 | 国立大学法人京都大学 | Method for producing dopamine-producing neural precursor cells |
EP4328301A2 (en) | 2016-08-16 | 2024-02-28 | FUJIFILM Cellular Dynamics, Inc. | Methods for differentiating pluripotent cells |
WO2018035214A1 (en) | 2016-08-16 | 2018-02-22 | Cellular Dynamics International., Inc. | Methods for differentiating pluripotent cells |
EP4001403A1 (en) | 2016-08-16 | 2022-05-25 | FUJIFILM Cellular Dynamics, Inc. | Methods for differentiating pluripotent cells |
WO2018216743A1 (en) | 2017-05-25 | 2018-11-29 | 国立大学法人京都大学 | Method for inducing differentiation of intermediate mesodermal cell to renal progenitor cell, and method for inducing differentiation of pluripotent stem cell to renal progenitor cell |
WO2019092939A1 (en) | 2017-11-10 | 2019-05-16 | 株式会社リジェネシスサイエンス | Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease |
WO2019131941A1 (en) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | Cell aggregation inhibitor |
WO2019131940A1 (en) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | Pluripotent stem cell aggregation inhibitor |
WO2019131942A1 (en) | 2017-12-28 | 2019-07-04 | 株式会社カネカ | Cell aggregation promoting agent |
WO2019160148A1 (en) | 2018-02-19 | 2019-08-22 | 大日本住友製薬株式会社 | Cell aggregate, mixture of cell aggregates, and method for preparing same |
WO2020022261A1 (en) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same |
WO2020130147A1 (en) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage |
WO2020193802A1 (en) | 2019-03-28 | 2020-10-01 | Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe | Polymeric conjugates and uses thereof |
WO2020203538A1 (en) | 2019-03-29 | 2020-10-08 | 株式会社カネカ | Cell population including pluripotent stem cells and production method thereof |
WO2020230832A1 (en) | 2019-05-15 | 2020-11-19 | 味の素株式会社 | Method for purifying neural crest cells or corneal epithelial cells |
WO2022149616A1 (en) | 2021-01-08 | 2022-07-14 | 国立大学法人京都大学 | Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids |
WO2022216911A1 (en) | 2021-04-07 | 2022-10-13 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
WO2022259721A1 (en) | 2021-06-10 | 2022-12-15 | 味の素株式会社 | Method for producing mesenchymal stem cells |
WO2023017848A1 (en) | 2021-08-11 | 2023-02-16 | 国立大学法人京都大学 | Method for producing renal interstitial progenitor cells, erythropoietin-producing cells, and method for producing renin-producing cells |
WO2023039588A1 (en) | 2021-09-13 | 2023-03-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
Also Published As
Publication number | Publication date |
---|---|
AU2003202263A1 (en) | 2003-07-30 |
US20070238741A1 (en) | 2007-10-11 |
EP1465900B1 (en) | 2008-05-14 |
US20100216789A1 (en) | 2010-08-26 |
JP4505228B2 (en) | 2010-07-21 |
EP1465900A1 (en) | 2004-10-13 |
JP2005523251A (en) | 2005-08-04 |
US7648986B2 (en) | 2010-01-19 |
WO2003059913A1 (en) | 2003-07-24 |
CA2472619A1 (en) | 2003-07-24 |
DE60320933D1 (en) | 2008-06-26 |
ES2305435T3 (en) | 2008-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1465900B1 (en) | Rho-kinase inhibitors | |
CA2441501C (en) | Rho-kinase inhibitors | |
EP1370553B1 (en) | Rho-kinase inhibitors | |
CA2409743C (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
US7592352B2 (en) | Substituted thieno and furo-pyridines | |
EP1720864B1 (en) | Benzimidazol substituted thiophene derivatives with activity on ikk3 | |
TWI413522B (en) | Benzodiazepine compound and pharmaceutical composition | |
MX2007000631A (en) | Thienopyrimidines useful as aurora kinase inhibitors. | |
KR20020038800A (en) | Chemical Compounds | |
US20040138249A1 (en) | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | |
US20100324041A1 (en) | Pyrrolopyridines as kinase inhibitors | |
US20140221370A1 (en) | Pyrrolopyridines as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAYER CORPORATION, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAGARATHNAM, DHANAPALAN;KHIRE, UDAY;ASGARI, DAVOUD;AND OTHERS;REEL/FRAME:014012/0153;SIGNING DATES FROM 20030402 TO 20030407 |
|
AS | Assignment |
Owner name: BAYER PHARMACEUTICALS CORPORATION, CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER CORPORATION;REEL/FRAME:014125/0545 Effective date: 20030603 |
|
AS | Assignment |
Owner name: BAYER HEALTHCARE AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER CORPORATION;REEL/FRAME:015505/0665 Effective date: 20040614 |
|
AS | Assignment |
Owner name: BAYER HEALTHCARE AG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER PHARMACEUTICALS CORPORATION;REEL/FRAME:016201/0060 Effective date: 20050628 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: BAYER HEALTHCARE LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER PHARMACEUTICALS CORPORATION;REEL/FRAME:023027/0804 Effective date: 20071219 Owner name: BAYER HEALTHCARE LLC,NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER PHARMACEUTICALS CORPORATION;REEL/FRAME:023027/0804 Effective date: 20071219 |
|
AS | Assignment |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:023769/0122 Effective date: 20081204 Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT,GERMANY Free format text: MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:023769/0122 Effective date: 20081204 |